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ABSTRACT 
 
REGULATION OF EGF RECEPTOR DYNAMICS BY 
PROTEIN TYROSINE PHOSPHATASES 
 
Calixte Stillman Monast 
Matthew J. Lazzara 
 
The phosphorylated epidermal growth factor receptor (EGFR) initiates 
intracellular signaling processes that regulate cell growth, survival, and migration, and 
disregulated EGFR-mediated signaling occurs in many cancers.  While the processes that 
lead to EGFR activation and phosphorylation have been studied in detail, quantitative 
aspects of the spatiotemporal regulation of EGFR by protein tyrosines phosphatases 
(PTPs) are not well understood.  To begin to address this, we developed a new 
compartmentalized mechanistic model of EGFR phosphorylation dynamics and used it to 
interpret quantitative biochemical measurements to show that EGFR is dephosphorylated 
at the plasma membrane and in the cell interior with a time scale that is small compared 
to the time scales for EGFR internalization.  By expanding our computational model and 
experimental data set, we went on to demonstrate that EGFR dephosphorylation at the 
plasma membrane surprisingly does not affect phosphorylation-dependent EGFR 
internalization because a separation of phospho-dependent time scales enables EGFR to 
enter clathrin-coated pits prior to being acted upon by PTPs.  This same separation of 
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time scales does, however, allow PTPs to control EGFR association with adapter proteins 
that regulate downstream signaling.  Thus, our model provides new quantitative 
understanding of how EGFR participates in a number of simultaneous processes that 
compete for EGFR C-terminal phosphotyrosines.  We went on to apply this new 
quantitative understanding of EGFR regulation by PTPs by developing predictive models 
to understand how such regulation might differentially impact the efficacy of antibodies 
and kinase inhibitors targeting EGFR.  We also developed new computational models to 
quantitatively predict how receptor dephosphorylation kinetics as rapid as we found for 
EGFR might differentially control signaling initiated by receptor tyrosine kinases that 
dimerize in structurally distinct ways observed naturally among the family of receptor 
tyrosine kinases (RTKs).  Ultimately, the new quantitative understanding of EGFR 
regulation by PTPs developed in this thesis significantly refines our understanding of the 
dynamics of EGFR-mediated signaling, provides a number of additional testable 
predictions related to fundamental aspects of EGFR signaling complex nucleation and 
efficacy of EGFR-targeted therapeutics, and offers a basic quantitative framework for 
exploring the regulation of other receptor tyrosine kinases by PTPs. 
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Chapter 1 : Introduction 
 
1-1  CELL SIGNALING AND PROTEIN PHOSPHORYLATION 
Cell signaling is a biological process in which information is transferred to cells 
via sequential protein-protein interactions and protein modifications (1-3). Of the 
numerous protein modification processes that occur within cells, the most well-studied is 
the process of phosphorylation, during which a protein kinase covalently attaches a 
phosphate group to a tyrosine, serine or threonine on a substrate protein (4). 
Phosphorylation serves multiple purposes. For example, a phosphorylated residue on one 
protein may serve as a docking site for other proteins via interaction with specific protein 
domains such as the phosphotyrosine binding (PTB) or Src-homology 2 (SH2) domains, 
in the case of tyrosine phosphorylation (5). Phosphorylation can also positively or 
negatively regulate a protein’s ability to mediate protein modifications. For example, the 
kinase activity of the protein tyrosine kinase Src is negatively or positively modulated by 
phosphorylation of distinct Src tyrosines (6). These interactions and modifications 
facilitate the sequential transfer of information from one protein to the next and represent 
a fundamental aspect of signaling networks, which are responsible for translating various 
cues into cellular outcomes such as survival, growth, motility, or differentiation (1). 
Cell signaling initiated by extracellular cues commonly involves receptors, which 
are proteins that span the plasma membrane and translate extracellular events into 
intracellular responses (3). Often, cues take the form of receptor-binding ligands, which 
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bind to the extracellular domains of receptors and promote receptor alterations that link 
the receptor to downstream cellular processes. For the receptors on which this thesis 
focuses, ligand-receptor binding promotes receptor oligomerization and activation of a 
cytoplasmic receptor kinase domain that mediates receptor phosphorylation, which links 
the receptor to various adapter proteins involved in initiating signaling processes and 
influencing cellular outcomes (1, 3).  
Considering the receptor phosphorylation requirement for receptor-mediated 
signaling by some receptors, it is not surprising that disregulated growth factor receptor 
phosphorylation is a key alteration in cancer (3), which is characterized by uncontrolled 
cell growth and invasion of surrounding tissue. For example, specific point mutations in 
the epidermal growth factor receptor (EGFR) that promote receptor phosphorylation in 
the absence of EGFR ligands are associated with non-small cell lung carcinoma 
(NSCLC) (7). Similarly, activated fibroblast growth factor receptor mutants, formed 
through chromosomal translocations, have been identified in multiple cancers, including 
lymphomas and chronic myelogenous leukemia (8). Also, activating mutations in the 
receptors KIT and platelet-derived growth factor receptor have been identified in 
gastrointestinal stromal tumors (9). Wild-type receptors can also mediate disregulated 
signaling via receptor overexpression. For example, overexpression of HER2 is 
associated with poor prognosis in breast cancer patients (10), while overexpression of 
wild-type EGFR is associated with some NSCLC patients (11). To interrupt aberrant 
signaling, receptor-targeted therapeutics (e.g., the EGFR kinase inhibitor gefitinib (12)) 
have been developed. These therapeutics generally function by impairing processes 
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required for receptor phosphorylation, leading to reduced receptor phosphorylation and 
downstream signaling. The relatively limited, yet promising, clinical success of some 
receptor-targeted cancer therapies (e.g., gefitinib in some NSCLC patients (13)) has 
inspired rigorous development of therapeutics designed interrupt processes required for 
receptor phosphorylation. 
The processes leading to receptor phosphorylation account for only some of the 
processes that influence receptor phosphorylation. Receptor phosphorylation, and indeed 
protein phosphorylation in general, is negatively regulated by proteins phosphatases, 
which mediate the removal of a phosphate group from a phosphorylated residue in the 
process of dephosphorylation (14). Given that the balance between phosphorylation and 
dephosphorylation dictates net levels of phosphorylated protein, it follows that 
phosphatases may be important regulators of receptor-mediated signaling in the context 
of receptors for which phosphorylation provides linkage to downstream signaling 
processes. Consistent with this, phosphatases have been shown to be altered in the 
context of multiple human cancers (15). Unfortunately, our quantitative understanding of 
the kinetics of dephosphorylation has lagged significantly behind our understanding of 
kinases and phosphorylation. Thus, it is unclear to what extent phosphatases control the 
many processes involved receptor-mediated signaling and to what extent phosphatase 
disregulation might contribute to disregulated receptor-mediated signaling. 
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1-2  EPIDERMAL GROWTH FACTOR RECEPTOR 
The receptor tyrosine kinases (RTKs) are a particularly important receptor super-
family due to their roles in human physiology and disease (3). Signaling mediated by 
these proteins influences a diverse set of cellular outcomes including cell growth, 
survival, motility, and differentiation via activation of many intracellular signaling 
pathways (1). In general, RTK-mediated signaling is initiated through the binding of 
extracellular ligands to the RTK extracellular domain, which promotes receptor 
oligomerization. RTK oligomerization activates the receptor kinase by relieving auto-
inhibition of the cytoplasmic kinase domain, which is a shared feature among all RTKs. 
Once the kinase is activated, it mediates trans-auto-phosphorylation of C-terminal 
receptor tyrosine residues (3, 16). RTK phosphotyrosines generated by this process serve 
as binding sites for SH2 and PTB domain-containing cytoplasmic adapter proteins, which 
link the receptor to a diverse set of downstream processes, including receptor-mediated 
signaling and internalization (3, 17, 18). 
The ErbB family of RTKs is composed of ErbB1 (EGFR), ErbB2 (HER2), ErbB3, 
and ErbB4 (19). The ErbB receptors have been particularly well-studied due to their roles 
in multiple areas of human health, including multiple human cancers (20) and cardiac 
health (21). Of the ErbBs, EGFR has been the focus of particularly intense study due to 
its role in human health and disease. EGFR functions through the binding of any of a 
family of ligands, including epidermal growth factor (EGF) and amphiregulin (AR), 
triggering EGFR-mediated signaling and internalization processes by promoting EGFR 
dimerization and phosphorylation (Figure 1-1) (22, 23). Given the central role of 
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phosphorylation in initiating multiple receptor-mediated processes, mechanistic studies of 
EGFR have generally focused on the ways in which EGFR becomes phosphorylated, 
including in-depth investigation of ligand-EGFR binding, EGFR dimerization, and 
regulation of EGFR kinase activity (e.g., (24-26)). However, EGFR phosphorylation 
levels are also controlled by protein tyrosine phosphatases (PTPs), which act in 
opposition to the EGFR kinase by dephosphorylating EGFR phosphotyrosines (27). 
Despite a potentially important role in controlling EGFR phosphorylation, and by 
extension EGFR-mediated cellular processes, the kinetics of EGFR dephosphorylation 
and how these kinetics might influence EGFR-mediated process have not been well-
studied. 
 
 
Figure 1-1: EGFR phosphorylation and EGFR-mediated signaling. 
Ligand binding to EGFR promotes EGFR dimerization, which activates the EGFR kinase 
(K) permitting trans-auto-phosphorylation of C-terminal tyrosines (Y). Once 
phosphorylated, tyrosines may bind adapter proteins involved in initiating downstream 
signaling cascades, which ultimately influence cellular outcomes by regulating 
transcription. 
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1-3  EGFR INTERNALIZATION 
In addition to downstream cell signaling, EGFR phosphorylation initiates at least 
one EGFR internalization mechanism through the binding of GRB2 (Figure 1-2), an SH2 
domain-containing adapter protein that binds phosphorylated EGFR (28). GRB2 mediates 
EGFR association with the E3 ubiquitin ligase CBL through its SH3 domains (29, 30). 
CBL may also associate with EGFR directly, however GRB2-mediated EGFR-CBL 
association was found to be more important for EGFR internalization (31). As an E3 
ubiquitin ligase, CBL mediates EGFR ubiquitination (32), during which the protein 
ubiquitin is covalently attached to EGFR lysines. Recent studies suggest that EGFR 
ubiquitination is required for EGFR internalization (33-35), however this requirement has 
been debated (36, 37). Presently, it is thought that EGFR ubiquitination promotes EGFR 
association with proteins, such as Epsin1 (33), in a process that is required for efficient 
translocation of EGFR to membrane structures called clathrin-coated pits (CCPs) (18, 
36). Once enough cargo (e.g., receptors) is bound to a particular CCP, the CCP forms a 
vesicles called an endosome, which is actively transported to the cell interior (38). While 
this mechanism is thought to represent the principle internalization mechanism in the 
presence of physiological ligand concentrations (39), other EGFR internalization 
mechanisms exist. For example, the protein MIG6 mediates internalization of EGFR by 
linking the receptor to AP-2 and intersectins (40, 41).  EGFR can also internalize via a 
mechanism dependent upon EGFR ubiquitination and lipid rafts or through basal 
turnover of the plasma membrane (18, 42). Experiments demonstrate that internalization 
of EGFR in absence of ligand is unaltered by deletion of the EGFR cytoplasmic domain 
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and that internalization rates of EGFR lacking the cytoplasmic domain are unaltered by 
EGF addition suggest that basal EGFR turnover does not require receptor 
phosphorylation or even specific intracellular interactions (43). 
During internalization the endosomal lumen becomes acidified, which promotes 
dissociation of ligand from endosome-associated receptors (44, 45). Ultimately, the 
internalization process results in lysosome-mediated degradation or recycling to the cell 
surface of endosome-localized receptors (18). Due to the endosome acidification and 
receptor degradation components, the internalization process has traditionally been 
considered a negative regulator of receptor-mediated signaling. However, multiple 
studies have demonstrated that EGFR internalization can positively regulate EGFR-
mediated signaling (18) through the MAP kinase pathway (46) or AKT pathway (34, 47). 
Furthermore, impaired EGFR internalization may promote cellular sensitivity to EGFR 
kinase inhibitors via sequestration of intracellular EGFR-binding proteins, which impairs 
EGFR-mediated activation of the ERK signaling pathway (48-50).  Thus, EGFR 
internalization, as EGFR-mediated signaling, is an important EGFR phosphorylation-
dependent regulatory process that influences multiple downstream signaling processes 
and cellular phenotypes (18). 
Given the EGFR phosphorylation requirement for its internalization, it is feasible 
that PTPs could regulate EGFR internalization (Figure 1-2). Indeed, one previous study 
suggests that the receptor-like PTP DEP1 may control EGFR internalization rates by 
dephosphorylating EGFR prior to internalization (51). The general notion that PTPs 
could potentially regulate EGFR internalization is supported by numerous mechanistic 
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studies, which almost universally support a role for EGFR phosphorylation in 
internalization (18, 36). For example, deletion of the cytoplasmic domain removed the 
ability of exogenous ligand to induce EGFR internalization (43). Also, mutation of EGFR 
tyrosines that are targets for EGFR autophosphorylation reduced ligand-mediated EGFR 
internalization rates in porcine aortic endothelial (PAE) (28). Finally, pretreatment of 
PAE cells with EGFR kinase inhibitors significantly slowed EGFR internalization (52). 
In the same study, cells treated with EGF at 4°C, which promotes recruitment of EGFR to 
CCPs but very little EGFR internalization, and then treated with EGFR kinase inhibitors 
were characterized by normal EGFR internalization rates upon warming cells to 37°C, 
despite a significant reduction in EGFR phosphorylation following inhibitor treatment 
(52). Thus, EGFR phosphorylation appears to be required for initiation of EGFR 
internalization, but may become dispensable once EGFR is localized to CCPs. Given the 
finding that EGFR ubiquitination is important for EGFR association with coated pits 
(36), one hypothesis is that EGFR ubiquitination replaces EGFR phosphorylation as the 
internalization driving force at some point during the internalization process. If this were 
true, EGFR PTPs could regulate EGFR internalization provided that they 
dephosphorylate EGFR prior to EGFR ubiquitination (Figure 1-2). While the study by 
Tarcic and coworkers (51) suggests that PTPs are capable of regulating EGFR 
internalization, they based their conclusion on a flow cytometry-based measurement of 
the effect of DEP1 knockdown and expression on EGFR surface localization for a single 
time point after EGF stimulation (51). More extensive study is required not only to 
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understand the role of DEP1 in regulating EGFR internalization, but also to understand 
the general role of EGFR dephosphorylation in regulating EGFR internalization. 
 
 
Figure 1-2: EGFR dephosphorylation and EGFR-mediated internalization and 
signaling. 
Ligand-initiated EGFR tyrosine (Y) phosphorylation by the EGFR kinase (K) promotes 
EGFR-mediated signaling and internalization. EGFR internalization is initiated by 
EGFR-GRB2 binding, which mediates EGFR association with CBL. CBL mediates 
EGFR ubiqutination which promotes EGFR interaction with clathrin-coated pit (CCP) 
proteins, which is required for recruitment of EGFR to CCPs. Once enough cargo 
(EGFR) is bound, CCPs form endosomes which are transported to the cell interior in a 
process that influences EGFR-mediated signaling. Ultimately, EGFR localized to 
endosomes is either recycled back to the cell surface or degraded. 
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1-4  EGFR DEPHOSPHORYLATION 
While the kinetics of EGFR dephosphorylation are not well-understood, much is 
known about specific phosphatases that can regulate EGFR (14, 53). The first PTP to be 
purified and characterized was PTP1B in 1988 (54, 55). Since then, over 100 PTPs have 
been identified and classified into four families: Class I Cys-based PTPs, Class II Cys-
based PTPs, Class III Cys-based PTPs, and Asp-based PTPs (53). Many of the specific 
PTPs described here are Class I Cys-based PTPs, which represent the largest PTP family 
with 38 so called “classical” PTPs and 61 “dual-specificity” phosphatases (53). Classical 
PTPs are further subcategorized into transmembrane receptor-like PTPs and non-
transmembrane PTPs (14). 
Several years after its identification, PTP1B was shown to localize to the 
endoplasmic reticulum (ER) (56) and dephosphorylate several RTKs, including EGFR, in 
cells (57), suggesting the hypothesis that EGFR was only regulated by PTPs after 
internalization. This hypothesis gained traction because typical ligand-mediated EGFR 
phosphorylation dynamics (e.g., (58)) involve a decay in EGFR phosphorylation with a 
timescale similar to the time scale measured for EGFR internalization (int ~ 10 min, 
(59)). A more recent study demonstrated that EGFR could only interact with PTP1B after 
EGFR endocytosis (60). Together, these studies and observations have contributed to the 
wide-spread assumption that EGFR dephosphorylation occurs only in the cell interior, 
after EGFR internalization (e.g. (61)). 
In addition to PTP1B, multiple PTPs, with wide-ranging subcellular localizations, 
have been shown to regulate EGFR phosphorylation, including PTPRS (62), PTPRK (51, 
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63), LAR (64, 65), SHP1 (66, 67), TCPTP (68, 69), CDC25A (70), DEP1 (51, 71), LRP 
(64), and PTP-PEST (72). PTPRS, PTPRK, LAR, DEP1, and LRP have extracellular 
domains and transmembrane regions anchoring them to the cell surface (73). SHP1 (74) 
and PTP-PEST (75) are present in the cytoplasm. PTP1B is localized to the ER (56), but 
this localization may not limit the ability of PTP1B to interact with proteins localized to 
the cell surface (76). TCPTP is localized to the nucleus (77), ER (77) and cytoplasm (78). 
And, lastly, CDC25A is present in both the nucleus and the cytoplasm (79). The notion 
that EGFR regulation by PTPs may not be restricted to the cell interior is suggested by 
the identification of multiple cell surface-localized PTPs that are capable of 
dephosphorylating EGFR but is also supported by other studies. Offterdinger and 
coworkers used a FRET construct to visualize EGFR phosphorylation dynamics in living 
MCF7 and COS7 cells and noted that EGFR phosphorylation was reduced to basal levels 
after roughly 2 min of treatment with an EGFR tyrosine kinase inhibitor (TKI) regardless 
of EGFR cellular localization (80). The same study demonstrated that EGFR could 
become phosphorylated at the cell surface in the absence of stimulatory ligand if cells 
were treated with pervanadate (80), a potent and irreversible inhibitor of PTPs (81). 
These data led the authors to hypothesize that EGFR phosphotyrosines are under control 
by PTPs regardless of EGFR cellular localization. In aggregate, these studies support the 
hypothesis that EGFR phosphorylation levels are in fact controlled by PTPs at the cell 
surface, contrary to the classic view of EGFR dephosphorylation. These data also support 
the possibility that PTPs are important controllers of EGFR-mediated signaling and 
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internalization, but only if EGFR dephosphorylation occurs fast enough to disrupt these 
processes.  
In addition to their potential roles as regulators of EGFR-mediated signaling and 
trafficking, PTPs are also integral to the efficacy of EGFR-targeted therapeutics. Some 
EGFR-targeted therapeutics mediate reductions in phosphorylated EGFR levels by 
disrupting at least one process required for EGFR phosphorylation. For example, binding 
of the EGFR-targeted TKI gefitinib to the EGFR kinase domain prevents ATP binding, 
which is required for receptor phosphorylation (12). Gefitinib can also mediate a 
reduction in existing receptor phosphorylation by displacing ATP from EGFR which 
impairs the EGFR phosphorylation process and allows PTPs to reduce existing EGFR 
phosphorylation. The involvement of PTPs in EGFR-targeted therapeutic efficacy is 
supported by a recent study of the receptor-like phosphatase PTPRS in head and neck 
squamous cell carcinoma (HNSCC) (82). This study found that HNSCC tumors with 
PTPRS deletion and endogenous levels of WT EGFR exhibited increased EGFR and 
AKT phosphorylation compared to control. Furthermore, artificially reducing PTPRS 
expression promoted ligand-independent EGFR phosphorylation in HNSCC cells and 
increased resistance of HNSCC and NSCLC cells to treatment with the EGFR TKI 
erlotinib. Finally, reduced PTPRS expression predicted cellular resistance to treatment 
with the EGFR-targeted inhibitory antibody cetuximab in HSNCC cells and poor 
prognosis in lung adenocarcinoma patients with tumors characterized by EGFR-
activating mutations.  
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In aggregate, careful consideration of previous studies supports the hypothesis 
that, contrary to the classical view of regulation of receptor phosphorylation by 
phosphatases, PTPs control EGFR phosphorylation at the cell surface via receptor 
dephosphorylation. What remains unclear is how rapidly this regulation occurs, how it 
extends to downstream receptor-mediated, phosphorylation-dependent processes, and 
how it may impact the cellular response to drugs. 
 
1-5  EGFR COMPUTATIONAL MODELING 
Quantifying the regulation of phosphorylated EGFR and EGFR phosphorylation-
initiated processes by PTPs would require simultaneous consideration of multiple EGFR-
level processes, including EGFR phosphorylation, dephosphorylation, and 
internalization. Due to the complexity of these processes, mechanistic computational 
models are appropriate tools for a study of this nature. Mechanistic models of EGFR-
mediated processes have, in fact, been used extensively to interpret complex 
experimental data (83). For example, Starbuck and Lauffenburger used a mechanistic 
model to quantify the various processes involved in EGFR trafficking (84). Kholodenko 
and coworkers used a mechanistic model of EGFR phosphorylation and adapter protein 
binding trained on experimental data to study the EGFR-level processes that occur tens of 
seconds after stimulation of cells with ligand (85). More complex models have been used 
to quantify the role of ErbB receptors in promoting signaling through various 
downstream pathways (e.g., (86)). Another study used a mechanistic model to quantify 
the effect of HER2 expression on EGFR internalization and sorting (87). Thus, 
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mechanistic models, especially when paired with experimental data, are proven tools for 
quantification and interpretation of receptor-mediated processes. 
Despite an important role for receptor phosphorylation in the processes considered 
in each of the mentioned computational studies, receptor dephosphorylation and 
internalization were treated very differently in each. Schoeberl and coworkers assumed 
EGFR dephosphorylation occurred at the same rate regardless of EGFR localization (86), 
while Kholodenko and coworkers considered dephosphorylation without considering 
EGFR internalization (85). Hendriks and coworkers considered receptor internalization 
but did not explicitly account for receptor phosphorylation and therefore did not include a 
dephosphorylation process (87). Also, in general, the magnitudes of the 
dephosphorylation rate constants used in these models were not determined using data 
that fully reveals the rate at which EGFR is dephosphorylated. One computational study 
directly assessed the compartmentalization of ErbB dephosphorylation following 
stimulation with ErbB ligands (88). This study concluded that ErbB phosphorylation 
dynamics are consistent with dephosphorylation only occurring in the cell interior but did 
so without explicitly including a phosphorylated receptor species in their model and only 
visually compared model results to experimental data (88). Thus, computational studies 
have generally reflected, rather than remedied, the absence of a consensus regarding 
where in the cell EGFR undergoes dephosphorylation and how rapid EGFR 
dephosphorylation occurs. 
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1-6  PROBLEM SUMMARY 
Phosphorylation of EGFR initiates multiple cellular processes, including EGFR-
mediated internalization and signaling, that influence cell growth and survival and the 
cellular response to EGFR-targeted therapeutics. This important role for EGFR 
phosphorylation has prompted significant study of the processes required for EGFR 
phosphorylation. However, a quantitative understanding of how EGFR 
dephosphorylation influences EGFR phosphorylation and EGFR-mediated processes has 
not been undertaken. Thus, there is no clear consensus on: 1. where in the cell EGFR is 
dephosphorylated, 2. how rapidly EGFR dephosphorylation occurs at different sub-
cellular locations, 3. how EGFR dephosphorylation influences downstream EGFR-
mediated and phospho-dependent processes, and 4. how EGFR dephosphorylation plays a 
role in determining EGFR-target therapeutic efficacy. Thus, there are important 
fundamental and quantitative questions that must be addressed in order to more 
completely understand the mechanisms by which EGFR mediates cellular processes and 
improve the design of EGFR-targeted therapeutics. 
 
1-7  THESIS SUMMARY 
In this thesis, we explore the regulation of EGFR by PTPs using quantitative 
biological measurements paired with mechanistic models that include EGFR 
phosphorylation and dephosphorylation. In Chapter 2, we quantify the rates of EGFR 
dephosphorylation at the plasma membrane and in the cell interior by training a 
mechanistic model on quantitative measurements of the EGFR phosphorylation response 
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to exogenous ligand, PTP inhibition, and EGFR inhibitors (89). We find that EGFR is 
dephosphorylated at the plasma membrane multiple times after the addition of 
stimulatory ligand prior to internalization, contrary to the classical view of receptor 
regulation by PTPs, and with a similar rate in the cell interior. Our analysis suggests that 
instead of becoming statically phosphorylated, EGFR cycles between phosphorylated and 
unphosphorylated states more than once each minute in a process that is predicted to 
influence the efficacy of EGFR-target therapeutics. 
In Chapter 3, we explore the implications of relatively rapid EGFR 
dephosphorylation by investigating how a single EGFR phosphotyrosine is able to initiate 
receptor-mediated signaling, initiate receptor internalization and undergo relatively rapid 
dephosphorylation all in the first few minutes after the addition of exogenous ligand to 
cells. We find that differences among the time scales with which each of these processes 
allows them to effectively occur independently. We conclude that PTPs are able to 
control EGFR phosphorylation without slowing EGFR internalization or significantly 
impairing the ability of EGFR to engage multiple adapter proteins.  
In Chapter 4, we explore the receptor-level processes responsible for determining 
EGFR-targeted therapeutic efficacy in the context of two kinetically distinct EGFR 
ligands. We found that receptor dephosphorylation is an important determinant of the 
efficacy of gefitinib, a small-molecule, and cetuximab, an inhibitory antibody. We also 
identified EGFR internalization and sorting processes as important determinants of 
cetuximab efficacy. Overall, our results suggest that multiple receptor-level processes 
contribute to the efficacy of a particular EGFR-targeted therapeutic beyond processes that 
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influence EGFR-therapeutic competitive binding and that EGFR dephosphorylation is 
indeed important in the context of EGFR-targeted therapeutics.  
In Chapter 5, we investigate how receptor dephosphorylation might differentially 
affect receptor phosphorylation generated by receptor dimerization through direct 
receptor-receptor contacts (receptor-mediated dimerization, RMD) or indirect contacts 
via an interposed bivalent ligand (ligand-mediated dimerization, LMD).  Our analysis 
revealed significant differences between LMD and RMD. For example, LMD versus 
RMD was characterized by an increased number of phosphorylated receptors per 
receptor-bound ligand due to the ability of LMD to facilitate a single receptor dimerizing 
with and phosphorylating multiple other receptors. Interestingly, this process was tightly 
controlled by receptor dephosphorylation. We conclude that different receptor 
dimerization mechanisms could significantly affect ligand-initiated receptor 
phosphorylation in cells, which may contribute to the diversity in signaling dynamics 
downstream of different RTKs. 
Lastly, in Chapter 6 we discuss the implications of our findings, which support an 
emerging paradigm involving protein phosphorylation and protein-protein interactions 
persisting with a far smaller time scale than previously assumed. This paradigm has 
significant implications for the mechanisms by which receptors such as EGFR mediate 
cell signaling and initiate cellular process, which suggests multiple avenues for future 
investigation. 
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Chapter 2 : Computational Analysis of the Regulation of 
EGFR by Protein Tyrosine Phosphatases 
 
2-1  ABSTRACT 
The tyrosine phosphorylated epidermal growth factor receptor (EGFR) initiates 
numerous cell signaling pathways.  Although EGFR phosphorylation levels are 
ultimately determined by the balance of receptor kinase and protein tyrosine phosphatase 
(PTP) activities, the kinetics of EGFR dephosphorylation are not well understood.  
Previous models of EGFR signaling have generally neglected PTP activity or computed 
PTP activity by considering data which do not fully reveal the kinetics and 
compartmentalization of EGFR dephosphorylation.  We developed a novel 
compartmentalized, mechanistic model to elucidate the kinetics of EGFR 
dephosphorylation and the coupling of this process to phosphorylation-dependent EGFR 
endocytosis.  Model regression against data from HeLa cells for EGFR phosphorylation 
response to EGFR activation, PTP inhibition, and EGFR kinase inhibition led to the 
conclusion that EGFR dephosphorylation occurs at the plasma membrane and in the cell 
interior with a timescale which is smaller than that for ligand-mediated EGFR 
endocytosis.  The model further predicted that sufficiently rapid dephosphorylation of 
EGFR at the plasma membrane could potentially impede EGFR endocytosis, consistent 
with recent experimental findings.  Overall, our results suggest that PTPs regulate 
multiple receptor-level phenomena via their action at the plasma membrane and cell 
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interior and point to new possibilities for targeting PTPs for modulation of EGFR 
dynamics. 
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2-2   INTRODUCTION 
The binding of SH2- and PTB-domain-containing proteins to phosphorylated C-
terminal tyrosines of the epidermal growth factor receptor (EGFR) links the receptor to 
cell signaling pathways and to receptor trafficking mechanisms (18).  Whereas the 
processes leading to EGFR tyrosine phosphorylation have been studied in detail, 
relatively little is known about quantitative aspects of receptor dephosphorylation by 
protein tyrosine phosphatases (PTP) (27, 90).  Estimates of the rates of EGFR tyrosine 
dephosphorylation are limited (85, 86, 88), and the extent to which individual PTPs 
contribute to the net dephosphorylation kinetics of specific EGFR phosphotyrosines is 
unknown.  The relative rates of EGFR tyrosine dephosphorylation at different cellular 
locations also remain poorly understood. 
Beyond this fundamental knowledge gap, there are additional reasons why a 
quantitative understanding of EGFR tyrosine dephosphorylation is important.  Indeed, 
dephosphorylation rates may influence receptor inhibition by targeted therapeutics (90), 
receptor trafficking (51), and downstream signaling (91).  Tyrosine cycling between 
phosphorylated and unphosphorylated forms may also influence receptor sensitivity to 
noise (92), system responses to changes in ligand concentration (93), and sensitivity to 
changes in PTP and receptor concentrations (94).  Of course, phosphatases play important 
roles in regulating signaling downstream of the receptor as well.  In linear signaling 
cascades such as those associated with MAP kinases, phosphatases have a role in 
regulating signal induction, duration, amplification, and dampening (95). 
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A number of PTPs which regulate EGFR have been identified, including RPTPσ, 
RPTPκ, LAR, SHP-1, PTP1B, TCPTP, CDC25A, DEP-1, and LRP, with some 
information available on PTP localization.  RPTPσ, RPTPκ, LAR, DEP-1, and LRP are 
anchored to the plasma membrane (73), while SHP-1 is present throughout the cytoplasm 
(74).  PTP1B is tethered to the cytoplasmic side of the endoplasmic reticulum (56) and 
may be released into the cytoplasm (77), while TCPTP (77) and CDC25A (79) are 
shuttled between the nucleus and cytoplasm.  Such spatial organization leads to important 
consequences for the dynamics of EGFR phosphotyrosine regulation by specific PTPs.  
For example, PTP1B dephosphorylates EGFR mainly after receptor endocytosis (96).  In 
contrast, DEP-1’s localization to the plasma membrane allows it to dephosphorylate 
EGFR prior to endocytosis in a process which may affect EGFR internalization (51). 
The incomplete understanding of EGFR tyrosine dephosphorylation is reflected 
by the different ways this process has been incorporated in computational models of 
EGFR dynamics.  One recent model simply assumed identical EGFR dephosphorylation 
rate constants for the plasma membrane and cell interior (86), while another included 
PTP effects without incorporating receptor trafficking (85).  In previous models assuming 
that EGFR internalization is driven by ligand occupancy, neither phosphorylated species 
nor receptor dephosphorylation were explicitly included (87, 97).  In previous models of 
EGFR-mediated signaling focused on effects of receptor internalization on downstream 
signaling (98) and network branching (99), dephosphorylation was omitted, presumably 
due to a focus on downstream dynamics.  Another recent computational study concluded 
that ErbB receptors are mainly dephosphorylated in the cell interior (88).  However, that 
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model did not include explicit phosphorylation or dephosphorylation reactions, equated 
dimers with phosphorylated receptors, and assumed that dephosphorylation was 
equivalent to dimer uncoupling. 
Here, we develop a novel mechanistic model to gain quantitative insight into the 
process of EGFR tyrosine dephosphorylation and its impact on other EGFR rate 
processes.  The model consists of a set of coupled ordinary differential equations which 
describe the kinetics of EGFR phosphorylation, dephosphorylation, and trafficking.  The 
model considers the dynamics of a single representative cytoplasmic EGFR tyrosine and 
accounts for the well-established coupling between receptor phosphorylation and 
endocytosis by requiring that receptors be phosphorylated in order for endocytosis to 
occur.  Most parameters were taken from the literature or estimated using established 
methods.  A novel aspect of our approach is fitting the four unknown parameters 
(including rate constants for EGFR tyrosine dephosphorylation at the plasma membrane 
and in the cell interior) to data gathered in HeLa cells for EGFR Y1068 phosphorylation 
response to EGFR activation by EGF, EGFR kinase inhibition, and PTP inhibition.  
These dynamic responses were quantified as percentages of phosphorylated EGFR using 
an immunoprecipitation based method.  Overall, our model results suggest that EGFR 
dephosphorylation occurs rapidly at the plasma membrane and in the cell interior in HeLa 
cells with a timescale which is smaller than that for EGF-mediated EGFR endocytosis.  
These dephosphorylation kinetics are predicted to exert control over EGFR endocytosis, 
EGFR inhibition, and phosphorylation sensitivity to changes in EGFR expression levels. 
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Figure 2-1: Model topology. 
(A) Reversible binding processes include EGFR interactions with itself, EGF, ATP, and 
an EGFR kinase inhibitor (INH). (B) Irreversible processes include phosphorylation, 
dephosphorylation, and receptor trafficking. 
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Table 2-1: Model parameters. 
parameter description value source 
kE,fs (μM
-1
·min
-1
) EGF binding to EGFR, forward, surface 6.3 × 10
1
 (100) 
kE,rs (min
-1
) EGF binding to EGFR, reverse, surface 1.6 × 10
-1
 (100) 
kE,fi (endosome∙min
-1
) EGF binding to EGFR, forward, interior 3.9 × 10
-4
 (100) 
kE,ri (min
-1
) EGF binding to EGF, reverse, interior 6.6 × 10
-1
 (100) 
kA,f (μM
-1
·min
-1
) ATP binding to EGFR, forward 1.0 × 10
5
 see text 
kA,r (min
-1
) ATP binding to EGFR, reverse 1.1 × 10
7
 see text 
ki,f (μM
-1
·min
-1
) inhibitor binding to EGFR, forward 1.0 × 10
5
 see text 
ki,r (min
-1
) inhibitor binding to EGFR, reverse 2.1 × 10
2
 see text 
kd,fs (cell·min
-1
) EGFR dimerization, forward, surface 6.7 × 10
-4
 see text 
kd,fi (endosome·min
-1
) EGFR dimerization, forward, interior 1.1 × 10
-2
 see text 
kd,r (min
-1
) EGFR dimerization, reverse, unoccupied 1.2 × 10
4
 fit 
kdE,r (min
-1
) EGFR dimerization, reverse, EGF-occupied 1.0 × 10
-10
 fit 
kcat (min
-1
) phosphorylation, unoccupied dimer 2.7 × 10
0
 (101) 
kcatE (min
-1
) phosphorylation, EGF-occupied dimer 1.3 × 10
1
 (101) 
kdp,s (min
-1
) dephosphorylation, surface 1.7 × 10
0
 fit 
kdp,i (min
-1
) dephosphorylation, interior 1.5 × 10
0
 fit 
SE (cell
-1
·min
-1
) EGFR synthesis varies see text 
ke,m (min
-1
) phosphorylated EGFR internalization varies see text 
kexE (min
-1
) endosomal exit, EGF-occupied 4.0 × 10
-2
 (97) 
kex (min
-1
) endosomal exit, unoccupied 4.0 × 10
-2
 (97) 
frE recycle fraction, EGF-occupied 0.5 (97) 
fr recycle fraction, unoccupied 0.8 (97) 
ATP (μM) cellular ATP concentration 1.0 × 103 (102) 
EGF (μM) extracellular EGF concentration varies see text 
INH (μM) inhibitor concentration varies see text 
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2-3  MATERIALS AND METHODS 
General model considerations and topology. The model consists of a set of 
coupled ordinary differential equations which describe interactions of EGFR with itself 
(dimerization and phosphorylation), PTPs, EGF, ATP, and the EGFR kinase inhibitor 
gefitinib (Figure 2-1A).  As these processes occur, EGFR is routed from the plasma 
membrane to an endosomal compartment where it is sorted for recycling or degradation 
(Figure 2-1B).  Essential processes and model parameters are summarized in Figure 2-1 
and Table 2-1, respectively.  The model includes 169 reactions, 52 species, and 25 
parameters. 
EGF binding, trafficking, and concentration. EGF binding at the plasma 
membrane and in the endosome was modeled as a reversible process characterized by 
rate constants for binding at pHs characteristic of these locations (100).  EGF 
concentration was assumed to be constant in the extracellular space and time-dependent 
in the endosomal compartment. 
ATP and inhibitor binding. Rate constants for ATP and gefitinib association 
with EGFR were estimated assuming diffusional limitations.  Gefitinib was assumed to 
have a diffusivity of 2.5 × 10
-6
 cm
2
·s
-1
, equal to that of ATP (103), and an interaction 
radius of 1 nm with EGFR (104).  The rate constant for gefitinib dissociation was 
computed using its affinity for the EGFR kinase (12).  The rate constant for ATP 
dissociation was estimated using an equilibrium binding model and assuming that, for an 
ATP concentration of 1 mM (102), half of EGFR is inhibitor-bound at 21 nM gefitinib, 
consistent with experimental measurements (105).   
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EGFR dimerization. Rate constants for receptor dimerization were estimated 
assuming diffusional limitations (104), as in previous models (85, 87).  The diffusivity of 
EGFR was set to 1 × 10
-10
 cm
2
·s
-1
 (85), and the interaction radius was set to 1 nm (104).  
Cells and endosomes were approximated as spheres of radii 10 m and 350 nm (106), 
respectively.  Dimerization constant estimates were sensitive to changes in area but not to 
changes in EGFR levels.  Thus, distinct dimerization rate constants were computed for 
the plasma membrane and endosome assuming 5 × 10
4
 EGFR per compartment.  Because 
EGF binding to EGFR promotes dimer formation (107), we defined dimer uncoupling 
rate constants for ligand-bound (kdE,r) and ligand-free (kd,r) EGFR, as in previous models 
(87, 99).  These constants were included in the parameter fit.  
EGFR phosphorylation. EGFR phosphorylation was modeled as a process 
occurring within ATP-bound EGFR dimers during which both receptors are 
phosphorylated at a representative tyrosine.  These reactions were characterized by rate 
constants for EGFR catalytic activity in the presence or absence of EGF (101).  This 
structure allows for a small amount of EGFR phosphorylation in the absence of ligand, 
which has been observed even in the presence of a ligand-blocking antibody (108).  The 
simplification of modeling EGFR phosphorylation at a single tyrosine residue has been 
used in previous EGFR models [e.g. (85, 98)].  Provided that the tyrosine considered 
plays a critical role in receptor endocytosis, this simplification should be acceptable for 
our purposes.  Since the dynamics with which different EGFR tyrosines become 
phosphorylated (109) and dephosphorylated (105) appear to be roughly equivalent, the 
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kinetics of tyrosine phosphorylation suggested by our model are likely representative of 
most EGFR tyrosines. 
PTP activity. EGFR dephosphorylation was modeled as zeroth order with respect 
to PTPs, which obviates the need to specify PTP concentrations.  To accommodate the 
possibility of different dephosphorylation rates at the plasma membrane and in the cell 
interior, we defined distinct parameters for these locations (kdp,s and kdp,i, respectively), 
which were included in the parameter fit. 
EGFR endocytosis and synthesis. Movement of phosphorylated EGFR from the 
plasma membrane to the cell interior (endocytosis) was modeled as a first-order process 
with a rate constant ke,m.  The specific endocytosis rate constant ke,e has been measured 
using 
125
I-EGF, with ke,e computed as the slope of internalized 
125
I-EGF counts versus the 
integral of surface-bound 
125
I-EGF counts from t = 0 to the time of the measurement, for 
a series of times  (59).  A ke,e computed in this way is not generally interchangeable with 
the ke,m used in model rate equations describing endocytosis of phosphorylated species, 
even though the constants have similar units.  This inconsistency arises because PTP 
activity at the plasma membrane results in at least some of the ligand-bound, membrane-
localized receptors being unphosphorylated.  In the limit of vanishing PTP activity at the 
membrane and rapid dimerization and phosphorylation, ke,m → ke,e.  To ensure that our 
results accurately reflected experimentally determined ke,e values, ke,m was iteratively 
determined for each simulation to achieve agreement between predicted internal and 
plasma membrane EGF dynamics and a ke,e = 0.13 min
-1 
(48).   
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For our best-fit parameters, ke,m was ~1.6-fold larger than ke,e.  Based on the 
discussion above, it is not surprising that the difference depends upon kdp,s (Figure 2-2A), 
with larger kdp,s values increasing the discrepancy between ke,e and ke,m.  The difference 
also depends upon EGFR expression since increased expression promotes dimerization 
and phosphorylation (Figure 2-2B).  In Figure 2-2A and 2B, ke,e plateaus for arbitrarily 
large ke,m values as other processes become rate-limiting.  
 
 
Figure 2-2: Relationship between model (ke,m) and experimental (ke,e) rate constants 
for EGFR endocytosis. 
The relationship between ke,m and ke,e was determined for 10 ng/mL EGF and (A) kdp,s = 
1.7, 17 and 170 min
-1
 and (B) EGFR expression of 5 × 10
3
, 5 × 10
4
 or 5 × 10
5
 cell
-1
.  For 
a given ke,m, SE was computed and ke,e was calculated. 
 
Because our model accounts for a small rate of EGFR degradation even in the 
absence of EGF, we incorporated an EGFR synthesis rate SE to allow for steady initial 
EGFR levels.  SE and ke,m values were determined iteratively prior to model calculations.  
Endosomal exit and sorting. Receptor exit from the endosome was modeled 
using previously published parameters (97).  The sorting of exiting species for 
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degradation and recycling was modeled by assuming that constant fractions were routed 
to these pathways (97).  EGFR sorting fractions were taken from measurements in 
mammary epithelial cells (97). 
Parameter fitting. To determine the four unknown parameters, we first fit the 
model to data gathered from parental HeLa cells, including the phosphorylation response 
of EGFR Y1068 to 1 and 10 ng/mL EGF, 100 μM pervanadate, and EGF-gefitinib pulse-
chase (Figure S2-7).  To refine our fits, we also included pulse-chase data from HeLa 
cells with conditional expression of dominant negative dynamin (HeLa.Dyn
K44A
), which 
inhibits EGFR endocytosis (Figure S2-7).  Measurements in cells with conditional 
expression of wild-type dynamin (HeLa.Dyn
WT
) matched data from parental HeLa cells 
and were not included to avoid biasing the regression.  Time-courses were restricted to t 
≤ 20 min to minimize potential effects of transcriptional regulation.  Because our 
preliminary analysis revealed that data for the fraction of receptor phosphorylated would 
constrain parameter estimates more than data for relative changes in phosphorylation 
alone, we converted our immunoblot data to estimates of the percentage of EGFR 
phosphorylated at Y1068 (%pEGFR) using immunoprecipitation-based measurements 
(Figure S2-8). 
Parameter fitting was accomplished using simulated annealing to minimize the 
total error between model predictions and experimental data.  For most data points, errors 
were computed as the square of the difference between model prediction and the 
experimental value divided by the magnitude of the experimental value.  For pulse-chase 
data points, a similar form was used, except that experimental and model values were 
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normalized to their values at 8 min post EGF.  This emphasized the fold-changes in 
pEGFR signals observed in the pulse-chase experiments.  The error associated with each 
treatment (e.g., 1 ng/mL EGF) was computed as the sum of individual data point errors 
divided by the number of points for that condition, and the total error was computed as 
the sum of these treatment condition errors.  The best-fit results are included in Table 2-1. 
Sensitivity analysis. Model sensitivity to changes in parameters was computed by 
increasing and decreasing the values in Table 2-1 by factors of 2, 10, and 100.  To 
compute raw measures of sensitivity, we summed the integrated differences between the 
base model and the two perturbed outputs over time.  To compare different perturbation 
magnitudes, raw sensitivities for a given perturbation were reported as percentages of the 
maximum. 
Model scope. To aid computational efficiency, our model topology assumed all 
dimer species to be symmetric (e.g., EGF binds both or neither EGFR monomers in a 
dimer).  To test if this simplification significantly affected our conclusions, we expanded 
the model to allow for asymmetric ligand binding.  This increased the number of species 
from 52 to 119 and the number of reactions from 169 to 499, without changing the 
number of parameters.  We refit the unknown parameters and found that kdp,s and kdp,i 
were nearly identical to the values found in the first fit (Table S2-2), although the dimer 
uncoupling constants changed to accommodate the increased number of species.  All 
remaining calculations were based on the more compact model. 
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Representative HeLa cell. Unless otherwise noted, calculations reflect 5 × 10
4
 
EGFR/cell (110) and ke,e = 0.13 min
-1
 (48).  For HeLa.Dyn
K44A
 cells, calculations reflect 
ke,e = 0.01 min
-1
 (48). 
Model implementation. Codes were generated and compiled using the Systems 
Biology Toolbox 2 (SBT2) package for MATLAB (111).  The simulannealbnd function 
in the Global Optimization Toolbox was used to fit the model to experimental data. 
Cell culture. HeLa cells were obtained from the American Type Culture 
Collection and cultured in DMEM supplemented with 10% fetal bovine serum (FBS), 
100 units/mL penicillin, 100 μg/mL streptomycin, and 1 mM L-glutamine.  HeLa cells 
conditionally expressing wild-type or dominant negative dynamin (HeLa.Dyn
WT
 and 
HeLa.Dyn
K44A
, respectively; Dr. Sandra Schmid, Scripps Research Institute, La Jolla, 
CA) were cultured as described previously (48).  Prior to lysis, cells were serum starved 
in media containing 0.1% FBS for 15-20 hrs.  All media components were purchased 
from Invitrogen (Carlsbad, California, USA). 
Western blotting. Cells in aspirated wells were washed with ice-cold PBS prior 
to addition of a standard lysis buffer.  The lysis buffer base (Invitrogen) contained 10 mM 
Tris (pH 7.4), 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM sodium 
pyrophosphate, 2 mM sodium orthovanadate, 1% Triton X-100, 10% glycerol, 0.1% 
SDS, and 0.5% deoxycholate.  This base was supplemented with 1 mM PMSF, additional 
protease inhibitors (Sigma, St. Louis, MO, USA), and phosphatase inhibitors (Sigma).  
Lysates were clarified by centrifugation at 13,200 rpm for 10 min at 4°C and assayed for 
total protein concentration using the micro bicinchoninic acid assay (Thermo Scientific, 
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Waltham, MA, USA).  Proteins were resolved by SDS-PAGE and transferred to 
nitrocellulose membranes, which were blocked in Odyssey Blocking Buffer (LI-COR 
Biosciences, Lincoln, NE, USA) for 1 hr before incubation with primary antibodies at 
4°C overnight.  Membranes were stripped with 0.2 M NaOH as needed.  Blots were 
imaged and analyzed using a LI-COR Odyssey Infrared Imaging System (LI-COR 
Biosciences). 
Immunoprecipitation. For immunoprecipitations (IPs), the lysis buffer base 
(Cell Signaling Technology, Danvers, MA, USA) contained 20 mM Tris hydrochloride 
(pH 7.5), 150 mM NaCl, 1 mM disodium ethylenediaminetetraacetate, 1 mM EGTA, 1% 
Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM sodium 
orthovanadate, and 1 μg/mL leupeptin.  This base was supplemented with 1 mM PMSF, 
other protease inhibitors (Sigma), and phosphatase inhibitors (Sigma).  Lysates were 
clarified and total protein concentrations determined as previously described.  For each 
sample, 200-400 μg of total protein was incubated with 20 μL of resuspended protein A 
agarose beads conjugated to a pEGFR Y1068 antibody at 4°C overnight.  Beads were re-
suspended in LDS sample buffer (Invitrogen, Carlsbad, CA, USA) and boiled for 10 min 
prior to immunoblotting. 
Calculation of percent phosphorylated EGFR. The percentage of total EGFR 
phosphorylated at Y1068 (%pEGFR) was determined using two different methods.  For 1 
ng/mL EGF or pervanadate treatments, the amount of EGFR in a whole cell lysate was 
compared to the amount of EGFR in a pEGFR Y1068 IP by immunoblotting.  To 
compare EGFR signals on an equal basis, IP signal intensities were corrected for capture 
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efficiency (determined by comparison of the pEGFR Y1068 signal in the whole cell 
lysate to the same signal in the capture).  Serial dilutions of whole cell lysate were used to 
establish linearity for the EGFR signal with protein amount and to correct the EGFR 
signal intensity for a non-zero y-intercept (Figure S2-8).  Linearity of the pEGFR Y1068 
signal with protein amount over a range of signal intensities inclusive of those observed 
was independently confirmed for the antibody dilution used to probe all western blots. 
For experiments with 10 ng/mL EGF, immunoprecipitated pEGFR was not 
efficiently recognized by the EGFR antibody we used throughout our studies (or by 
several other EGFR antibodies we tried).  This effect, which was very small for samples 
treated with 1 ng/mL EGF or 100 μM pervanadate, probably resulted from EGFR 
ubiquitination altering the ability of total EGFR antibodies to bind to cognate epitopes, an 
effect for which corrective measures have been previously implemented (37).  
Accordingly, we chose to instead measure the percentage of unphosphorylated EGFR for 
samples treated with 10 ng/mL EGF.  True total EGFR levels in whole cell lysates were 
determined by chasing 10 ng/mL EGF with 4 M gefitinib for 45 min (Figure S2-8B, L1-
L3), which was shown in a separate experiment to allow the EGFR signal to reach a 
higher steady value (data not shown) and which is consistent with previous studies where 
inhibition of the EGFR kinase resulted in EGFR deubiquitination (112).  
Unphosphorylated EGFR was measured by first clearing pEGFR using a pEGFR Y1068 
IP from whole cell lysates collected from cells treated with 10 ng/mL EGF for 4 min and 
quantifying the remaining EGFR levels in the supernatant by western blot (Figure S2-8).  
This approach worked well because the affinity of the EGFR antibody appeared to be 
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unchanged for unphosphorylated EGFR.  The ratio of the unphosphorylated EGFR signal 
in the supernatant to the total EGFR signal in whole cell lysate from cells treated with 4 
M gefitinib for 45 min allowed for estimation of the fraction of unphosphorylated 
EGFR.  Serial dilutions of the whole cell lysate from a single replicate were used to 
establish linearity of EGFR and extracellular regulated kinase 1/2 (ERK) signals with 
protein amount and to correct the appropriate signal intensities for non-zero y-intercepts.  
ERK was used as the loading control for these blots, instead of actin, due to better 
linearity of this signal at the higher total protein amounts needed for this method. 
pEGFR timecourse data for EGF-treated samples. EGF timecourse data were 
corrected for the disruption of EGFR antibody binding by determining pEGFR and EGFR 
dynamics separately.  To determine pEGFR dynamics, cells were treated with EGF, and 
lysates were analyzed by immunoblotting (Figure S2-7).  pEGFR levels were normalized 
to actin and converted to a fold change with respect to a reference time point (4 min for 
10 ng/mL and 20 min for 1 ng/mL).  Corrected EGFR levels were determined via 
immunoblot by treating parallel samples of cells with EGF for the same times and 
chasing EGF at each time point with 4 M gefitinib for 45 min (Figure S2-7).  These 
samples were also analyzed by immunoblotting, and EGFR levels were normalized to 
actin and converted to a fold change with respect to the same reference time point.  Final 
fold changes in pEGFR/EGFR were estimated by dividing the actin-normalized pEGFR 
signal by the corrected, actin-normalized EGFR signal at each time point. 
To correct EGF-gefitinib pulse-chase data, 8-min treatments of 1 or 10 ng/mL 
EGF with or without a 45 min chase of 4 M gefitinib were performed (Figure S2-7).  
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The ratio of EGFR/actin for the unchased and gefitinib-chased conditions was used to 
correct the EGFR levels for t ≥ 8 min in the pulse-chase data.   
We independently verified that the background intensities for both the EGFR and 
actin signals were negligible compared to the average sample intensities, enabling the 
non-background-corrected calculations as described.  For the higher protein 
concentrations used in IPs, data were corrected using calibration curves, as described. 
Reagents. Antibodies for EGFR (NeoMarkers, #MS-400-P0, Fremont, CA, 
USA), pEGFR Y1068 (Epitomics, #1138 (IP) and #1727 (WB), Burlingame, CA, USA), 
ERK (Cell Signaling Technologies, #4695, Beverly, MA, USA) and actin (Millipore, 
#MAB1501, Billerica, MA, USA) were titrated to ensure linearity of signals with protein 
amount on immunoblots.  Infrared dye-conjugated secondary antibodies were purchased 
from Rockland Immunochemicals (Gilbertsville, PA, USA).  Pervanadate was prepared 
by combining equimolar solutions of hydrogen peroxide and sodium orthovanadate at 
room temperature for 15 min and used immediately after preparation.  Gefitinib was 
purchased from LC Laboratories (Woburn, MA, USA), and recombinant human EGF was 
purchased from Peprotech (Rocky Hill, NJ, USA). 
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2-4  RESULTS 
EGFR phosphorylation dynamics in HeLa cells. Experimental measurements 
of %pEGFR for 20 min treatment with 1 ng/mL EGF, 4 min treatment with 10 ng/mL 
EGF, and 20 min treatment with 100 μM pervanadate were 11.6 ± 0.7%, 35.7 ± 6.8%, 
and 13.1 ± 2.7%, respectively.  These measurements were used to convert immunoblot 
data to estimates of %pEGFR for all time points (Figure 2-3). 
 
 
Figure 2-3: Model recapitulation of experimental EGFR phosphorylation 
measurements. 
The percentage of EGFR phosphorylated at Y1068 (%pEGFR) was measured for several 
experimental conditions.  Data are represented as averages ± s.e.m. and were fit to 
determine four parameters, as described in Materials and Methods.  Measurements and 
model calculations were made for: (A) 1 or 10 ng/mL EGF treatment of parental HeLa 
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cells; (B) 100 μM pervanadate (PV) treatment of parental HeLa cells (simulated by 
setting kdp,s = kdp,i = 0 min
-1
); (C) 8 min treatment with 1 or 10 ng/mL EGF followed by 4 
μM gefitinib (pulse-chase) of parental HeLa cells; and, (D) pulse-chase conditions as in 
panel C in HeLa.Dyn
K44A
 cells [ke,e = 0.01 min
-1
 (48)].  Note that in panels C and D t = 0 
min corresponds to the time when the gefitinib chase was added to cells.  Model results 
indicated by dashed lines were generated using parameters from a fit to parental HeLa 
data only (A-C), while results indicated by solid lines were generated using parameters 
from a fit to all data (A-D). Model and experimental results corresponding to 1 ng/mL 
EGF, 10 ng/mL EGF and PV are indicated by grey lines/open circles, black lines/filled 
circles and black lines/open diamonds, respectively. 
 
Treatment of parental HeLa cells with EGF or pervanadate resulted in time-
dependent induction of EGFR Y1068 phosphorylation (Figs. 3A,B and S1), with 
estimated %pEGFR values as high as ~45% for a 20 min treatment with 10 ng/mL EGF.  
In response to pervanadate, %pEGFR levels rose as high as ~15%, an effect which is 
qualitatively consistent with previous results [e.g., (80)].  When parental cells were 
treated for 8 min with 1 or 10 ng/mL EGF and then treated with 4 M gefitinib, pEGFR 
levels returned to baseline levels within ~1 min after gefitinib addition (Figs. 3C and S1).  
Similar trends in EGFR phosphorylation dynamics for such pulse-chase experiments have 
been previously reported [e.g., (80)].  To directly probe EGFR dephosphorylation at the 
plasma membrane, pulse-chase experiments were also performed in HeLa.Dyn
K44A
 cells.  
Even with impaired EGFR endocytosis, EGFR was dephosphorylated within ~1 min after 
gefitinib addition (Figs. 3D and S1).   
38 
 
Model fitting to experimental data. Parameter fitting revealed that data from 
parental HeLa cells only were best recapitulated when kdp,i and kdp,s were of similar 
magnitudes, with kdp,i > kdp,s  (Table S2-3, entry for K44A PC removed).  Even though 
kdp,i was larger than kdp,s, the magnitude of kdp,s suggests significant regulation of EGFR 
by PTPs at the plasma membrane.  The fit results also suggest a difference in kdE,r and kd,r 
which is larger than previously reported (87, 99), which is a consequence of topological 
differences between our model and previous models.  Using these fitted parameters, the 
model recapitulated the EGFR phosphorylation data in parental cells reasonably well 
(Figure 2-3A-C, dashed lines).  Response to pervanadate was well captured by the model, 
and, with the exception of the response to 10 ng/mL EGF at 4 min, recapitulation of data 
for 10 ng/mL EGF (ligand-only and pulse-chase) was also generally good.  The largest 
discrepancies between model and experiment were observed for ligand-only and pulse-
chase kinetics for 1 ng/mL EGF, with the model underestimating the former and 
overestimating the latter.  Thus, the model could not completely reconcile the best-fit 
PTP kinetics with the modest induction of EGFR phosphorylation for 1 ng/mL EGF.   
Using parameters from fitting parental data only, the model predicted that EGFR 
dephosphorylation would occur within ~2 min in pulse-chase experiments in 
HeLa.Dyn
K44A
 cells, which is slower than the rate observed experimentally (Figure 2-
3D).  To refine our parameters, we refit the model to data including the HeLa.Dyn
K44A
 
pulse-chase data.  Doing this, kdp,s increased to a value slightly larger than kdp,i (Table 2-
1) and model agreement with HeLa.Dyn
K44A
 pulse-chase data improved (Figure 2-3D, 
solid black line) without altering recapitulation of data from parental HeLas (Figure 2-
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3A-C, solid lines).  All remaining calculations use the refined model parameters (Table 2-
1).  
Variations in the fit results among replicate fits led to negligible variation in 
model output.  Thus, we reported parameters for the lowest error among fits for given 
conditions. 
Contributions of specific data and topological features to fitting results. We 
further explored the fit results by examining variation in the total model error and errors 
for individual experimental conditions for variations in kdp,s and kdp,i.  The other two fitted 
parameters were left as listed in Table 2-1 since the model was relatively insensitive to 
changes in these (Figure S2-9). 
As expected, added consideration of the HeLa.Dyn
K44A
 pulse-chase data tightened 
the domain in kdp,s/kdp,i parameter space in which the total error was minimized (Figure 2-
4A,B).  Agreement with data for response to EGFR alone was best for a kdp,i which was 
lower than that found by regression against the complete data set (Figure 2-4C), while 
agreement with pulse-chase data was best for a kdp,i which was larger than that found by 
regression against all data (Figure 2-4D).  Not surprisingly, optimal model agreement 
with HeLa.Dyn
K44A
 cell pulse-chase data alone required a kdp,s larger than that found for 
regression against all data (Figure 2-4E).  Interestingly, the HeLa.Dyn
K44A
 cell pulse-
chase data also constrained kdp,i tightly, since this data includes an initial 8 min response 
to EGF alone.  Optimal model agreement with data from pervanadate (Figure 2-4F) was 
achieved for kdp,s ~10
0
 min
-1
 and higher, resulting from a need to explain increased 
receptor phosphorylation when receptors were mainly at the cell surface.  Interestingly, 
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all data considered tended to push kdp,s to non-negligible values.  It may seem somewhat 
surprising, for example, that consideration of the EGF data alone should require a 
substantial kdp,s.  Because our model framework considers phosphorylation in the absence 
of EGF, however, even explanation of data for response to EGF alone requires PTP 
activity at the plasma membrane. 
 
 
Figure 2-4: Effect of variation in surface (kdp,s) and interior (kdp,i) dephosphorylation 
rate constants on model agreement with EGFR phosphorylation measurements. 
Model error was calculated for ranges of kdp,s and kdp,i considering: (A) all data from 
parental HeLa cells, (B) all data from parental and HeLa.Dyn
K44A
 cells, (C) EGF 
treatment in parental HeLa cells only, (D) EGF-gefitinib pulse-chase experiments in 
parental HeLa cells only, (E) EGF-gefitinib pulse-chase experiments in HeLa.Dyn
K44A
 
cells only, and (F) pervanadate treatment in parental HeLa cells only.  For these 
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calculations, kdp,s and kdp,i were set prior to computing ke,e and SE.  Red circles correspond 
to error minima.  To compare different plots on an equal basis, the scale was defined as 
the log of the error divided by the log of the global error minimum. 
 
The impact of different data used for regression was also assessed by refitting 
parameters excluding various data (Table S2-3) or considering the various data 
individually (Table S2-4).  Excluding each type of data (e.g., EGF treatments only) 
individually revealed that no single treatment condition was required for the conclusion 
that dephosphorylation is rapid at the cell surface because each fit resulted in a kdp,s of 
~10
0
 min
-1
 (Table S2-3).  Fitting to data for each treatment condition individually also 
resulted in kdp,s values of at least ~10
0
 min
-1
 for all cases (Table S2-4).  kdp,i varied 
significantly among these fits, indicating that consideration of multiple types of data are 
required to tightly constrain this parameter. 
To probe the impact of the phosphorylation-dependent endocytosis model, we 
substituted the more common modeling assumption that ligand-occupancy governs 
endocytosis.  These fits also resulted in a substantial value of kdp,s, which was greater than 
kdp,i in some cases (Table S2-5).  Only when we eliminated receptor phosphorylation in 
the absence of ligand and fit the model to data for response to ligand alone was kdp,i 
significantly larger than kdp,s (Table S2-6).  To confirm that the ligand-independent 
phosphorylation topology was not the only factor resulting in a kdp,s ≥ kdp,i, we refit the 
parameters with added consideration of pulse-chase data, which resulted in a fitted kdp,s > 
kdp,i. (Table S2-6). 
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Sensitivity analysis.  To identify parameters which exert control over key model 
behaviors, we performed a sensitivity analysis for the simulation of a pulse-chase 
experiment and the calculation of ke,e for 10 ng/mL EGF (Figure S2-9).  Both analyses 
identified parameters for EGF binding (kE,fs and kE,rs), EGFR dimerization at the cell 
surface (kd,fs), phosphorylation in EGF-bound dimers (kcatE), and kdp,s as important model 
parameters, consistent with the key roles played by EGFR phosphorylation (which is 
promoted by ligand binding and dimerization) and dephosphorylation at the membrane.  
Interestingly, the sensitivity of computing ke,e to changes in kdp,s (Figure S2-9A) is 
consistent with the recently reported role of the receptor-like PTP DEP-1 in EGFR 
internalization and degradation in HeLa cells (51).  Pulse-chase dynamics were also 
moderately sensitive to kdp,i (Figure S2-9B).  Sensitivity to kdp,s and kdp,i suggests that 
substantial dephosphorylation occurs before and after endocytosis for these conditions. 
Predicted effects of PTP activity on ligand-mediated EGFR endocytosis.  A 
key model assumption is that only phosphorylated receptor species are endocytosed.  
Since the fit suggested significant EGFR dephosphorylation at the membrane, and since 
ke,e is somewhat sensitive to changes in kdp,s (Figure S2-9A), we used the model to predict 
the effect of PTP activity on the rate of EGFR endocytosis.  For a range of base kdp,s 
values, SE and ke,m were first computed.  The values of kdp,s and kdp,i were then set to 0 
min
-1
, and ke,e was calculated as previously described (59).  For all nominal kdp,s values, 
ke,e increased when PTP activity was eliminated (Figure 2-5A, fold change in ke,e).  The 
predicted effect on ke,e increased as the base value of kdp,s increased because larger ke,m 
values are required to maintain a constant base value of ke,e as the nominal kdp,s increases 
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(Figure 2-5A, ke,m).  For the parameters in Table 2-1, the model predicted a modest 
increase in ke,e from the base value of 0.13 to 0.15 min
-1
 when PTP activity was 
eliminated.   
 
 
Figure 2-5: Predicted effect of dephosphorylation kinetics on EGF-mediated EGFR 
endocytosis and EGFR phosphorylation inhibition. 
(A) The predicted effect of eliminating all PTP activity on ke,e for 10 ng/mL EGF was 
calculated as a function of kdp,s. Data are presented as a fold-change relative to the value 
of ke,e prior to elimination of PTP activity (black line).  Corresponding ke,m values are also 
shown (grey line). (B) The effect of 5 min pretreatment with 10
-3
-10
2
 μM gefitinib on 
EGFR phosphorylation response to a 20 min treatment with 10 ng/mL EGF was 
calculated.  For each curve, model output was normalized to the pEGFR value predicted 
without inhibitor.  Predictions were made for the base model (no change to PTP activity) 
and for elimination of PTP activity (at t = 0) at the plasma membrane, in the cell interior, 
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and in both compartments.  For each curve, ke,m was chosen to be consistent with a ke,e = 
0.13 min
-1
. 
 
Effects of PTP activity on EGFR inhibition.  We also used the model to predict 
the effect of eliminating PTP activity on the inhibition of EGFR phosphorylation by 
gefitinib.  For each scenario, ke,m was consistent with a ke,e = 0.13 min
-1
, and the effects of 
10
-3
-10
2
 μM gefitinib on EGFR phosphorylation response to 10 ng/mL EGF were 
predicted (Figure 2-5B).  The inhibition curves predicted for elimination of internal or 
surface PTP activity were similar, with IC50 shifts from ~0.1 μM for the base case to ~0.3 
μM for PTP elimination.  The effect was slightly larger for surface-compartmentalized 
PTPs at higher gefitinib concentrations because EGFR internalization is impeded by 
gefitinib, resulting in surface-compartmentalized PTPs exerting greater influence.  
Elimination of all PTP activity had a much larger predicted effect (IC50 shift from ~0.1 to 
~2 M) due to a coupling of kinetic phenomena beyond the scope of this discussion.  
Overall, these results suggest that EGFR inhibitor efficacy depends heavily upon the 
magnitude and localization of PTP activity. 
EGFR phosphate cycling.  Our results suggest that EGFR tyrosines cycle 
between phosphorylated and unphosphorylated states more rapidly than is generally 
appreciated.  This is analogous to the well-known example of phosphofructokinase and 
fructose-1,6-bisphosphatase and the so-called futile cycling process they mediate between 
fructose-6-phosphate and fructose-1,6-bisphosphate (113).  The term futile cycling refers 
to a switching between states on a timescale smaller than other important process 
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timescales.  Although this cycling is more rapid than necessary for signal output 
magnitudes achievable with slower cycling, rapid cycling may result in key system 
robustness qualities (92-95).  For EGFR, this cycling may also regulate receptor 
endocytosis and pharmacological inhibition, as will be discussed. 
Using the relevant phosphorylation and dephosphorylation rate constants, rates of 
EGFR phosphate cycling were estimated for ligand-bound and -free EGFR at the 
membrane and in the cell interior (Figure 2-6A).  The estimated rate was highest (~1.5 
cycles/min) for ligand-bound receptors at the cell surface because the kinetics of 
phosphorylation and dephosphorylation are most rapid for that scenario.  We also 
estimated dynamic rates of ATP consumption by EGFR for four EGF concentrations 
(Figure 2-6B) and compared these to an estimate of ATP consumption for cultured cells 
of 4 × 10
8
 ATP·min
-1
·cell
-1
 (114).  We thus estimated that EGFR phosphate cycling for a 
single tyrosine represents ≤ 0.008% of cellular ATP consumption in a cell with 5 × 104 
EGFR. 
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Figure 2-6: Analysis of EGFR tyrosine phosphate cycling. 
(A) Estimates of tyrosine phosphate cycling rates were made for EGF-occupied and -
unoccupied EGFR at the cell surface (S+E and S−E, respectively) and for EGF-occupied 
and -unoccupied EGFR in the cell interior (I+E and I−E, respectively). (B) EGFR 
phosphate flux was calculated by computing the total phosphorylation rate as a function 
of time for treatment with 0 to 100 ng/mL EGF.  (C and D) Steady-state phosphorylated 
(% max pEGFR, solid lines) and unphosphorylated (% max upEGFR, dashed lines) 
EGFR levels, reported as percentages of the maximum steady value for each curve, were 
calculated for ke,m = 0 min
-1
, a range of EGFR levels, 1 ng/mL EGF, and (C) kdp,s = 10
-4
, 
10
-2
, or 10
0
 min
-1
 and (D) kd,fs = 10
-5
, 10
-4
, or 10
-3
 min
-1
. 
 
We also explored analogies of our results with those of the well-known study of 
phosphate cycling by Goldbeter and Koshland (94), who demonstrated that sensitivity to 
changes in reaction velocities depends upon Michaelis-Menten-like constants for 
phosphorylation and dephosphorylation.  While Goldbeter and Koshland analyzed a 
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model where the enzyme and substrate were distinct species, EGFR is both an enzyme 
and a substrate, which introduces an important topological difference.  In addition, PTP 
concentration is not specified in our model, since dephosphorylation is treated as a zeroth 
order process.  To explore model similarities, we varied the analog of their velocity V1 in 
our model by changing EGFR expression and the analog of their dephosphorylation rate 
constant k2 by changing our kdp,s and computed the EGFR phosphorylation response to 1 
ng/mL EGF as a percent of the maximum phosphorylated EGFR level achieved for a 
given parameter set (Figure 2-6C-D).  Consistent with the general behavior described by 
Goldbeter and Koshland, lowering kdp,s increased the sensitivity of steady EGFR 
phosphorylation levels to changes in EGFR level (Figure 2-6C).  Lowering the rate 
constant for EGFR dimerization, an analog for lowering the a1 parameter of Goldbeter 
and Koshland (94), decreased the sensitivity of steady EGFR phosphorylation levels to 
changes in EGFR levels (Figure 2-6D).  EGFR phosphorylation was not sensitive to 
changes in the EGFR phosphorylation rate constant because the phosphorylation step is 
not rate-limiting for the model as described by the parameters in Table 2-1 (Figure S2-
10). 
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2-5  DISCUSSION 
Our results suggest that the EGFR phosphorylation dynamics we observed 
experimentally are consistent with timescales for EGFR dephosphorylation at the plasma 
membrane and in the cell interior which are smaller than the timescale for EGF-mediated 
EGFR endocytosis.  This result stands in stark contrast to the classical view of EGFR 
phosphorylation dynamics wherein receptor phosphorylation occurs at the plasma 
membrane and dephosphorylation occurs after endocytosis.  Of course, the classical view 
is generally consistent with the apparent timescale for receptor dephosphorylation 
suggested by EGFR phosphorylation in response to EGFR ligands alone.  Given that 
most studies of EGFR phosphorylation dynamics probe response to ligands alone, it is 
perhaps not surprising that this classical view of receptor phosphorylation is so pervasive. 
While certain experiments in our study plainly revealed the importance of EGFR 
dephosphorylation at the plasma membrane (e.g., experiments with HeLa.Dyn
K44A
 cells), 
the incorporation of certain novel model topological features revealed the same thing 
when considering other data where the need for PTP activity was less obvious.  For 
example, substantial PTP activity in the membrane compartment is required to maintain 
low basal levels of EGFR phosphorylation in a model which allows receptor 
phosphorylation in the absence of ligand to proceed as rapidly as we observed with 
pervanadate treatment. 
The possibility that EGFR dephosphorylation may occur at different rates at the 
plasma membrane and in the cell interior was explored in a previous computational study 
(88), but the authors of that study concluded that ErbB receptor dephosphorylation 
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occurred primarily in the cell interior for two different ErbB ligands.  That study sought 
to qualitatively reconcile model predictions with receptor phosphorylation response to 
ligands only.  There are also a number of topological differences between that model and 
ours, among them that the previous model did not consider receptor phosphorylation in 
the absence of ligand.  All of these differences together likely explain the very different 
conclusion reached in that study versus the conclusions of our study.     
Our implementation of a phosphorylation-dependent internalization model (which 
has been used in at least one previous study (98)), instead of a ligand occupancy model as 
in other studies (87, 88, 97), is well supported by experimental data, as reviewed by 
Sorkin and Goh (18).  For example, mutation of key EGFR tyrosines reduced EGF-
mediated EGFR internalization rates in mouse fibroblasts, suggesting that tyrosine 
phosphorylation is indeed required for efficient ligand-mediated EGFR endocytosis (18).  
It should also be emphasized, however, that our particular implementation of 
phosphorylation dependent receptor internalization is novel.  Specifically, our iterative 
calculation of ke,m values which lead to optimum model matching of experimentally 
reported ke,e values is an important and unique way in which our model recapitulates 
experimental data.   
Since our studies concluded that substantial EGFR dephosphorylation occurs at 
the plasma membrane, and since we have implemented a phosphorylation dependent 
model for EGFR endocytosis, it was not surprising that the model predicted that PTP 
activity at the plasma membrane may impede EGFR endocytosis (Figure 2-5A).  
Interestingly, this model-predicted increase in ke,e is qualitatively consistent with the 
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apparent effect of knockdown of the receptor-like PTP DEP-1 on EGFR internalization 
observed recently in HeLa cells (51).  We applied our model to estimate that Tarcic and 
coworkers (51) observed a decrease in surface-localized EGFR in response to EGF 
consistent with ke,e = 0.2 min
-1
 in their flow cytometry data for control cells and a three-
fold increase in ke,e with DEP-1 knockdown.  Assuming DEP-1 accounts for all PTP 
activity at the plasma membrane, our model predicts a three-fold increase in ke,e with a 
kdp,s ~3 × 10
1
 min
-1
 (Figure 2-5A), which is significantly larger than the best fit kdp,s 
(Table 2-1).  Of course, our model results represent the predicted effect of instantaneous 
inhibition of PTP activity.  It is possible that knockdown of DEP-1 resulted in an adaptive 
response which amplified the effect of DEP-1 knockdown in the experiments of Tarcic et 
al. (51).  In addition, it is possible that the tendency of at least some EGFR antibodies to 
not efficiently recognize pEGFR (noted in Materials and Methods) resulted in an effect 
on EGFR levels which was more apparent than real in the data of Tarcic et al. (51).  
Our model results regarding PTP activity at the plasma membrane were directly 
tested through comparison of model predictions with pulse-chase experiments in 
HeLa.Dyn
K44A
 cells.  While the model parameters fitted through consideration of parental 
HeLa cell data only did a reasonable job of predicting the rate at which plasma-
membrane-sequestered receptors were dephosphorylated, consideration of the 
HeLa.Dyn
K44A
 cell data in a refitting of the model aided in refining our parameter 
estimates.  In the future, it will be interesting and important to also directly test other 
model predictions (e.g., the effects of PTP inhibition on EGFR pharmacological 
inhibition) and to use such results to refine the model in a similar way.  Another 
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particularly important aspect of the biochemistry we investigated which would be 
important to understand more deeply is the extent to which PTP activity with respect to 
EGFR is time-dependent for the various cell treatment conditions utilized in our study.  
Surprisingly, very little has been reported on this subject.  As far as we are aware, only 
changes in the activity of the cytosolic PTP SHP2 in response to ligands including EGF 
have been studied in any detail (115). 
While our study focuses on receptor-level regulation, phosphatases have been 
considered in some models of signaling processes distal to receptors.  For example, the 
models developed by Rapoport and coworkers (95) for generalized linear signaling 
cascades demonstrated the role of phosphatases in setting the amplitude, duration, and 
amplification of signaling responses to upstream changes in receptor activation.  Our 
model similarly points to a key role for PTPs in determining EGFR phosphorylation 
amplitude and duration.  Importantly, this regulation is revealed by our model to occur on 
a timescale which is smaller than that for other important process timescales, including 
the typical timescale for complete activation of MAP kinase cascades and receptor 
trafficking.  Incorporation of these new receptor-level considerations revealed by our 
study in models including downstream cascades may help to more fully recapitulate 
dynamic signaling data which spans the space from the receptor to key downstream 
signaling intermediates. 
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2-7  SUPPLEMENTAL MATERIAL 
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Figure S2-7: Immunoblot results 
Relative levels of the indicated proteins from parental HeLa and 
HeLa.Dyn
WT
/HeLa.Dyn
K44A
 cell lysates were analyzed by immunoblotting following 
treatment for the indicated times with (A) 1 or 10 ng/mL EGF, (B, F, G) 1 or 10 ng/mL 
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EGF followed by 4 M gefitinib (INH), or (C) 100 μM pervanadate (PV). (D) To correct 
for the disruption of EGFR antibody binding to pEGFR during immunoblotting, cells 
were treated as in (A), but EGF was also chased with 4 M gefitinib for 45 min.  (E, H, I) 
To correct EGF-gefitinib pulse-chase data for the same disruption of EGFR antibody 
binding, parallel samples of cells were treated for 8 min with the indicated concentrations 
of EGF, and EGF was chased for the indicated times with 4 M gefitinib.  Results for 
biological triplicates are shown in panels E, H, and I, while all other panels show singlet 
data representative of n = 3. 
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Figure S2-8: Generating immunoprecipitation-based estimates of EGFR 
phosphorylation percentages. 
The percent of total EGFR phosphorylated at Y1068 was estimated for parental HeLa 
cells treated with (A) 1 ng/mL EGF for 20 min, (B) 10 ng/mL EGF for 4 min, and (C) 100 
μM pervanadate (PV) for 20 min.  Lanes for triplicate samples contained whole cell 
lysates (L1-L3), IP supernatants (S1-S3), or IP captures (C1-C3).  Where provided, ratios 
indicate dilution factors for lysates used to establish linearity of signal with protein 
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amount.  In panel B, IP supernatants (S) and whole cell lysates (L) for a particular 
replicate were not generated from the same whole cell lysate, as IP captures (C) and 
whole cell lysates (L) were in panels A and C. In panel B, whole cell lysates (L) were 
from cells treated with 4 M gefitinib for 45 min to accurately assess total EGFR levels, 
while IP supernatants (S) were generated with whole cell lysates from cells that were not 
treated with gefitinib in order to preserve pEGFR levels and allow for removal of pEGFR 
by IP. 
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Figure S2-9: Parameter sensitivity analysis. 
The sensitivity of model predictions for (A) a ke,e value for 10 ng/mL EGF and (B) EGF-
inhibitor pulse-chase dynamics (8 min pulse with 10 ng/mL EGF with 2 min chase of 4 
μM gefitinib) to changes in 23 model parameters were computed as described in 
Materials and Methods.  
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Figure 2-10: Effect of variation in kcatE on the sensitivity of steady EGFR 
phosphorylation levels to changes in EGFR expression. 
Steady-state phosphorylated (% max pEGFR) and unphosphorylated (% max upEGFR) 
EGFR levels, reported as percentages of the maximum steady value for each curve, were 
calculated for ke,m = 0 min
-1
, a range of EGFR levels, 1 ng/mL EGF, and a range of values 
of the phosphorylation rate constant in the presence of EGF (kcatE).  Solid and dashed 
lines indicate % max pEGFR and % max upEGFR, respectively. 
 
 
Table S2-2: Expanded model fit results. 
parameter value 
kdp,s (min
-1
) 2.2 × 10
0
 
kdp,i (min
-1
) 3.5 × 10
0
 
kd,r (min
-1
) 1.4 × 10
4
 
kdE,r (min
-1
) 5.5 × 10
-4
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Table S2-3: Parameter fit results generated for exclusion of different types of data 
from the data set used for fitting. 
parameter 
EGF 
removed 
pervanadate 
removed 
pulse-chase 
removed 
K44A pulse-chase 
removed 
kdp,s (min
-1
) 1.5 × 10
0
 1.6 × 10
0
 2.0 × 10
0
 1.0 × 10
0
 
kdp,i (min
-1
) 1.8 × 10
1
 1.5 × 10
0
 1.3 × 10
-1
 4.5 × 10
0
 
kd,r (min
-1
) 1.4 × 10
4
 9.5 × 10
3
 1.6 × 10
4
 1.4 × 10
4
 
kdE,r (min
-1
) 1.0 × 10
-10
 1.0 × 10
-10
 1.0 × 10
-10
 1.0 × 10
-10
 
 
 
Table S2-4: Parameter fit results generated by considering different types of data 
exclusively. 
parameter EGF only 
pervanadate 
only 
pulse-chase 
only 
K44A pulse-chase 
only 
kdp,s (min
-1
) 1.0 × 10
0
 1.4 × 10
0
 1.1 × 10
0
 5.7 × 10
2
 
kdp,i (min
-1
) 1.0 × 10
-1
 1.1 × 10
3
 8.3 × 10
0
 8.5 × 10
-1
 
kd,r (min
-1
) 1.0 × 10
4
 1.5 × 10
4
 1.0 × 10
4
 5.1 × 10
3
 
kdE,r (min
-1
) 2.9 × 10
-10
 2.7 × 10
-3
 4.1 × 10
-1
 3.4 × 10
-1
 
 
 
Table S2-5: Parameter fit results for a model of receptor internalization based upon 
ligand occupancy. 
parameter all data 
1 and 10 ng/mL 
EGF only 
1 ng/mL EGF 
only 
10 ng/mL EGF 
only 
kdp,s (min
-1
) 1.6 × 10
0
 5.0 × 10
-1
 3.9 × 10
-1
 6.1 × 10
-1
 
kdp,i (min
-1
) 1.8 × 10
0
 1.0 × 10
-5
 1.0 × 10
-5
 1.2 × 10
0
 
kd,r (min
-1
) 1.4 × 10
4
 9.9 × 10
3
 1.0 × 10
4
 1.0 × 10
4
 
kdE,r (min
-1
) 1.0 × 10
-10
 1.4 × 10
-6
 8.9 × 10
-8
 3.7 × 10
-9
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Table S2-6: Parameter fit results for altered internalization topology. 
parameter 
10 ng/mL  
EGF only 
10 ng/mL 
EGF only 
10 ng/mL EGF 
and pulse-chase 
 
occupancy-based 
internalization 
phosphorylation-based 
internalization 
phosphorylation-based 
internalization 
kdp,s (min
-1
) 2.3 × 10
-1
 6.5 × 10
-2
 5.8 × 10
0
 
kdp,i (min
-1
) 3.5 × 10
0
 3.7 × 10
0
 9.4 × 10
-1
 
kd,r (min
-1
) 9.8 × 10
3
 1.0 × 10
4
 1.0 × 10
4
 
kdE,r (min
-1
) 1.9 × 10
-5
 8.1 × 10
-7
 1.0 × 10
-10
 
 
Fit results were generated with removal of model topological features allowing for 
receptor phosphorylation in the absence of ligand.  With that topological change made, 
fits were generated for different assumptions regarding receptor endocytosis and for 
consideration of different types of data.  
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Chapter 3 : A Separation of Time Scales Enables EGFR 
Multitasking 
 
3-1  ABSTRACT  
In the first few minutes following ligand binding, kinase activation, and initial 
phosphorylation of cytoplasmic tyrosines, receptor tyrosine kinases initiate downstream 
signaling, recruit endocytosis machinery, and are acted upon by protein tyrosine 
phosphatases (PTPs).  How receptor phosphotyrosines participate in all of these 
potentially competitive processes is not fully understood.  Here, through development of 
a novel mechanistic model trained against quantitative experimental measurements, we 
show that for the epidermal growth factor receptor (EGFR) in HeLa cells this 
multitasking is achieved in part through a separation of time scales for phosphotyrosine-
dependent processes.  For example, despite the fact that EGFR is acted upon by PTPs at 
the plasma membrane, PTP activity surprisingly does not regulate phosphorylation-
dependent EGFR endocytosis.  This apparent paradox was reconciled by the model 
through the conclusion that recruitment of phosphorylated EGFR into clathrin-coated pits 
occurs faster than EGFR regulation by PTPs, a result we validated experimentally.  
Interestingly, another separation of time scales enables PTPs to regulate the association 
of EGFR with the intracellular adapter GRB2, but in a way which again does not affect 
ligand-mediated EGFR endocytosis but should regulate downstream signaling.  Our 
model provides a new quantitative framework for understanding how differences in such 
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time scales enable EGFR, and perhaps other receptors, to participate in a number of 
competing phosphorylation-dependent processes, and provides predictive capability for 
understanding how the balance of these time scales may be tipped in a cell-type specific 
manner to alter receptor-mediated processes. 
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3-2  INTRODUCTION 
Intracellular adapter protein binding to C-terminal phosphotyrosines on receptor 
tyrosine kinases (RTKs) links receptors to downstream signaling pathways and receptor 
endocytic trafficking processes.  In many cases, RTKs initiate signaling and trafficking 
over the same general time scale in response to ligand binding.  For example, in HeLa 
cells, epidermal growth factor receptor (EGFR) promotes substantial phosphorylation of 
SHC and PI3K over the same 5-10 min time scale with which it internalizes in response 
to EGF (46).  Similarly, vascular endothelial growth factor (VEGF) and hepatocyte 
growth factor each drive substantial ERK phosphorylation over the same time scales with 
which these ligands drive VEGF receptor and c-Met internalization, respectively (116, 
117).  Recent evidence also suggests that phosphotyrosines on RTKs such as EGFR may 
be dephosphorylated multiple times over the same general time scale with which 
downstream signaling and trafficking are initiated (89).  How receptors can multitask in 
this way is not understood. 
One possible explanation for receptor multitasking ability is that phosphotyrosine-
dependent processes occur sequentially.  For example, receptor phosphotyrosines might 
first initiate signaling from the plasma membrane, then drive endocytic trafficking, and 
finally be dephosphorylated in the cell interior.  Substantial evidence argues against this 
model, including the finding that receptors such as EGFR are readily dephosphorylated at 
the plasma membrane (80, 89).  Alternatively, a division of labor might exist among 
receptor tyrosines such that each regulates a distinct phosphorylation-dependent process.  
However, internalization (28, 118) and downstream signaling (119, 120) can be regulated 
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by the same EGFR and c-MET tyrosines.  These tyrosines are also regulated by protein 
tyrosine phosphatases (PTPs), with EGFR dephosphorylation occurring with a time scale 
that is small compared to that for receptor endocytosis (89, 121).  Steric limitations may 
also preclude multiple adapters from binding to an individual receptor cytoplasmic tail at 
once (122).  While a quantitative picture of how receptor phosphorylation-dependent 
multitasking has yet to be presented, an understanding of how these processes occur 
simultaneously in normal cells may provide important clues as to how they are perturbed 
in disease. 
A clue as to how multitasking might be achieved for receptors such as EGFR is 
offered by growing appreciation that EGFR phosphorylation and phospho-dependent 
processes are more transient than is generally appreciated.  For example, rate constants 
for GRB2-EGFR binding, which links EGFR to pathways such as ERK (119), have been 
measured by analyzing time-lapse fluorescence microscopy (123) and are consistent with 
GRB2-EGFR association occurring less than one second after EGFR phosphorylation 
(for 100 nM GRB2 (85)).  Rate constants suggesting similarly rapid binding and 
unbinding have also been quantified for p85 SH2 domain binding to IRS-1 
phosphopeptides using Biacore (124) and estimated computationally from data gathered 
from A431 cells for EGFR binding to SHC, PLCγ1, STAT5 and GRB2 (122).  Thus, 
even with receptor regulation by PTPs prior to endocytosis (89), the speeds of various 
binding and unbinding processes, and relative differences among those speeds, may be 
key to the ability of RTKs to multitask. 
66 
 
Here, we explore the quantitative basis for receptor multitasking using EGFR as a 
model system.  We developed a novel mechanistic model of EGFR phosphorylation, 
dephosphorylation, adapter association, recruitment to endocytic pits, and internalization, 
based on the topology shown in Figure 3-1.  We used this model to interpret and predict 
quantitative measurements of EGFR endocytosis, EGFR binding to adapter proteins, and 
EGFR phosphorylation, with or without perturbation of PTP activity.  We found that a 
separation of time scales for phospho-dependent processes explains EGFR’s ability to 
participate in several competitive processes in the first few minutes after addition of 
exogenous EGF to HeLa cells.  For example, while EGFR is acted upon by PTPs at the 
plasma membrane, PTPs do not regulate phosphorylation-dependent EGFR endocytosis.  
The model reconciled these observations by finding that receptor recruitment into 
clathrin-coated pits occurs faster than PTP regulation of EGFR, a result we validated 
experimentally.  At the same time, GRB2 binding to EGFR is highly influenced by PTP 
regulation of EGFR, but in a way which does not impact EGFR endocytosis.   Our study 
also finds that EGFR endocytosis regulation is resilient to changes of several-fold in the 
expression of PTPs and SH2 domain-containing proteins which can compete for EGFR 
phosphotyrosines that regulate receptor trafficking. 
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Figure 3-1: Model topology. 
The model topology includes three compartments: 1. cell surface, 2. endocytic pit, and 3. 
endosome.  All receptor processes considered are shown except for degradation and 
recycling.  Within receptor dimers, the EGFR kinase domain (K) mediates 
phosphorylation (P) of a representative tyrosine (Y).  In each compartment, EGFR 
interacts with ligand (EGF), ATP (A), kinase inhibitor (I), protein tyrosine phosphatases 
(PTP), and GRB2.  A complete list of model parameters is given in Table 3-1. 
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Table 3-1: Model parameters. 
parameter description value source 
kE,fs (μM
-1
·min
-1
) EGF-EGFR association, surface 3.1×10
2
 (125) 
kE,rs (min
-1
) EGF-EGFR dissociation, surface 8.0×10
-1
 KD (100) 
kE,fi (endosome∙min
-1
) EGF-EGFR association, interior 3.1×10
-4
 (100) 
kE,ri (min
-1
) EGF-EGFR dissociation, interior 6.6×10
-1
 (100) 
kA,f (μM
-1
·min
-1
) ATP-EGFR association 1.0×10
5
 (89) 
kA,r (min
-1
) ATP-EGFR dissociation 1.1×10
7
 (89) 
ki,f (μM
-1
·min
-1
) inhibitor-EGFR association 1.0×10
5
 (89) 
ki,r (min
-1
) inhibitor-EGFR dissociation 2.1×10
2
 (89) 
kG,f (cell·min
-1
) GRB2-EGFR association 3.3×10
-3
 (123) 
kG,r (min
-1
) GRB2-EGFR dissociation 4.5×10
2
 (123) 
kd,fs (cell·min
-1
) EGFR-EGFR association, surface 6.7×10
-4
 calculated (89) 
kd,fi (endosome·min
-1
) EGFR-EGFR association, interior 2.7×10
-3
 calculated (89) 
kd,r (min
-1
) EGFR-EGFR dissociation, unoccupied 1.0×10
4
 KD (126) 
kdE,r (min
-1
) EGFR-EGFR dissociation, EGF-occupied 1.0×10
-1
 (87) 
kcat (min
-1
) phosphorylation, unoccupied dimer 2.7×10
0
 (101) 
kcatE (min
-1
) phosphorylation, EGF-occupied dimer 1.3×10
1
 (101) 
kdp,s (min
-1
) dephosphorylation, surface 4.9×10
0
 fit 
kdp,i (min
-1
) dephosphorylation, interior 2.2×10
0
 fit 
kpit (min
-1
) pit recruitment 4.4×10
1
 fit 
ke,m (min
-1
) internalization 1.7×10
-1
 calculated (89) 
kex (min
-1
) endosomal exit 4.0×10
-2
 (97) 
frE recycle fraction, EGF-occupied 5.0×10
-1
 (97) 
fr recycle fraction, unoccupied 8.0×10
-1
 (97) 
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RESULTS 
Effects of PTP inhibition or knockdown on EGF-mediated EGFR 
phosphorylation and endocytosis. We previously demonstrated in HeLa cells that 
EGFR Y1068 is dephosphorylated at the plasma membrane with a time scale that is small 
compared to that for EGF-mediated EGFR endocytosis (89).  Since EGFR 
phosphorylation at Y1068 is required for EGFR endocytosis (52), we asked if EGFR 
dephosphorylation might influence EGF-mediated EGFR endocytosis.  HeLa cells were 
treated for ≤ 5 min with EGF, with or without the PTP inhibitor pervanadate.  As 
expected, pervanadate significantly augmented EGFR phosphorylation (Figure 3-2A).  
siRNA-mediated knockdown of the receptor-like PTP DEP1 also promoted EGF-
mediated EGFR phosphorylation (Figure 3-2B), consistent with a previous study (51).  
Despite their effects on EGF-mediated EGFR phosphorylation, neither pervanadate nor 
DEP1 knockdown altered the rate constant for EGF-mediated EGFR endocytosis (ke) 
measured using 10 ng/mL 
125
I-EGF (Figure 3-2C).  To verify the sensitivity of our assay, 
we demonstrated that ke was reduced by lowering temperature or by hydrogen peroxide, 
each of which is known to inhibit EGFR endocytosis (127, 128).  Note that, in addition to 
inhibiting PTPs, hydrogen peroxide also inhibits EGFR ubiquitination (127), which 
presumably explains why it reduces ke.  Pervanadate or DEP1 knockdown also failed to 
promote EGF-mediated loss of EGFR from the cell surface as measured by flow 
cytometry (Figure 3-2D and 2E).  A lack of effect of pervanadate on ke was also observed 
in three other cell lines (Figure S3-8A-C) and by immunofluorescence (Figure S3-8D and 
E). 
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Figure 3-2: Effects of phosphatases on EGFR phosphorylation and internalization. 
(A) HeLa cells were treated with 10 ng/mL EGF with or without 100 μM pervanadate 
(PV) for the indicated times.  Lysates were analyzed by western blotting with antibodies 
against indicated proteins (n=3). (B) HeLa cells transfected with control or DEP1-
targeting siRNA were treated with 10 ng/mL EGF for the indicated times.  Lysates were 
analyzed by western blotting with antibodies against indicated proteins (n=3). (C) The 
rate constant for EGF-mediated EGFR endocytosis (ke) was measured in HeLa cells using 
10 ng/mL 
125
I-EGF and reported as mean ± s.e.m.  This was done for EGF alone at 37ºC, 
with the addition of 100 μM pervanadate, with transfection of non-targeting control 
siRNA, with transfection of DEP1-targeting siRNA, at 4°C, or with the addition of 1 mM 
hydrogen peroxide (n=6 for all, except for 4ºC and hydrogen peroxide results where 
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n=3). (D and E) HeLa cells were treated as in panels (A) or (B), respectively, except that 
treatments were for 10 min.  Relative EGFR levels were quantified by flow cytometry 
(n=3).   
 
It is unlikely that the absence of an effect of PTP inhibition or knockdown on ke 
resulted from saturation of the clathrin-mediated endocytosis pathway, as pervanadate 
also had no effect on ke measured using 1 ng/mL 
125
I-EGF (Figure S3-8F).  Pretreatment 
(as opposed to cotreatment) with pervanadate also failed to alter ke measured using 1 or 
10 ng/mL 
125
I-EGF (Figure S3-8F and S3-8G), as did treatment with sodium 
orthovanadate (Figure S3-8H).  Taken together, these data strongly suggest that PTPs 
regulate EGFR phosphorylation at the cell surface without regulating EGFR endocytosis. 
Model regression to experimental data.  The model treats as unknowns the rate 
constants for EGFR dephosphorylation at the cell surface (kdp,s), EGFR 
dephosphorylation in the cell interior (kdp,i), and translocation of GRB2-bound EGFR to 
the pit compartment (kpit).  These parameters were determined by model regression 
against quantitative measurements including: 1. our previous measurements of EGFR 
phosphorylation response to an 8 min EGF pulse chased with 4 μM of the EGFR kinase 
inhibitor gefitinib in parental HeLa cells (Figure 3-3A) and in HeLa cells expressing 
dominant negative (K44A) dynamin (Figure 3-3B) (89); and 2. new measurements for the 
effect of PTP inhibition on ke (Figure 3-2C).  The best-fit parameters (Table 3-1) resulted 
in good model recapitulation of the regression data (Figure 3-3A and 3-3B), including an 
unchanged ke with PTP inhibition (Figure 3-3C).  The best-fit model also accurately 
predicted our previous data for the EGFR phosphorylation response to EGF (1 or 10 
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ng/mL) or pervanadate (Figure 3-3D) for t < 20 min (89), which were not included in the 
regression. 
 
 
Figure 3-3: Assessment of model regression strategy. 
To determine unknown model parameters, we considered data from our previous study 
(89) in which (A) parental HeLa cells or (B) HeLa cells expressing K44A dynamin were 
treated with the indicated EGF concentrations for 8 min and then chased with 4 μM 
gefitinib.  Times shown correspond to time after gefitinib addition.  Best-fit results are 
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shown as lines. (C) The best-fit parameters also allow the model to recapitulate the lack 
of effect of pervanadate (PV) on ke measured with 10 ng/mL EGF (Figure 3-2C), which 
was included in the regression. (D) Model predictions (lines) were compared to data for 
the effect of EGF or 100 μM PV on EGFR phosphorylation (circles) from our previous 
study (89). These data were not included in the model regression. (E) Model error was 
calculated as a function of kdp,s and kpit with consideration of all regression data or all data 
excluding that for the effect of PV on ke.  Best-fit model parameters are shown as red 
circles. 
   
Model error. Plotting the model error as a function of kdp,s and kpit revealed that 
kdp,s was well constrained by the regression but that only a lower limit of kpit was defined 
by our approach (Figure 3-3E).  Repeating this analysis with omission of data for the 
effect of PTP inhibition on ke revealed that constraint of the lower bound of kpit was due 
to our consideration of this data (Figure 3-3E).  The requirement that the model 
recapitulate a ke = 0.146 min
-1
 also constrained kpit. In fact, unless kpit ≥ 1.5×10
0
 min
-1
, pit 
recruitment becomes rate-limiting and prevents recapitulation of experimentally 
measured ke values.   
Hypothesis for simultaneous EGFR dephosphorylation and internalization. 
To understand the model’s ability to reconcile relatively rapid EGFR dephosphorylation 
at the plasma membrane with a ke unchanged by PTP inhibition, we calculated 
characteristic times for relevant EGFR processes (Figure 3-4A).  The model suggests that 
GRB2 binding, EGFR dephosphorylation, and EGFR pit recruitment all occur with 
relatively small characteristic times (Figure 3-4A), consistent with the relatively short 
residence time for receptors in the cell surface compartment.  However, GRB2 
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association occurs with the highest maximum rate, followed by pit recruitment, and then 
dephosphorylation (Figure 3-4A, inset), due to relatively rapid GRB2-EGFR association 
(123).  Comparison of compartmentalized EGFR dephosphorylation rates revealed that 
nearly all dephosphorylation prior to internalization occurred for pit-localized receptors 
(Figure 3-4B), suggesting that phosphorylated EGFR associates with GRB2 and moves to 
the pit before substantial receptor dephosphorylation occurs.  Because pit-associated 
receptors internalize regardless of phosphorylation status, as demonstrated 
experimentally (52) and as assumed by our model, EGFR dephosphorylation in the pit 
does not influence ke.  Consistent with this, the model predicted that PTP inhibition 
would not significantly alter the characteristic times for EGFR phosphorylation prior to 
pit recruitment, GRB2-EGFR binding prior to pit recruitment, EGFR recruitment to pits, 
or EGFR internalization (Figure 3-4A).  PTP inhibition was predicted to decrease the 
characteristic times for phosphorylation in the pit and endosome because receptor 
residence time in these compartments is sufficiently long for these characteristic times to 
be influenced by phosphorylation/dephosphorylation cycling with normal PTP activity.   
The model also suggests that large changes must be made to overcome the ability 
of GRB2-EGFR binding to outcompete receptor dephosphorylation.  Only when kdp,s is 
increased by a factor ≥ 15 or when GRB2 concentration is reduced by a factor ≥ 10 is 
PTP inhibition predicted to significantly increase  ke (change of ~30% or more) (Figure 3-
4C).  In both scenarios, PTP-mediated control of ke can be eliminated by increasing kpit.   
Model sensitivity analysis revealed that ke is insensitive to perturbations in kdp,s 
and most sensitive to perturbations in ke,m, the model-determined internalization rate 
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constant (Figure 3-4D).  Conversely, model-predicted EGFR phosphorylation kinetics 
during an EGF-inhibitor pulse-chase are sensitive to perturbations in numerous 
parameters, including kdp,s and kdp,i (Figure 3-4E), supporting the notion that PTP activity 
exerts control over EGFR phosphorylation at the plasma membrane without exerting 
control over receptor endocytosis in the model.  
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Figure 3-4: Model-based explanation for lack of effect of PTPs on EGFR 
endocytosis. 
(A) Characteristic times for various receptor processes were estimated from the model as 
the time at which rates of the indicated processes were maximized in response to 10 
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ng/mL EGF with (red) or without (black) simulated pervanadate (PV) treatment.  
Maximum rates of a subset of processes are shown in the insert. (B) Using the model, the 
rate of EGFR dephosphorylation within the indicated compartments was calculated as a 
function of time after simulated addition of 10 ng/mL EGF. (C) The predicted fold 
increase in the rate constant for EGF-mediated EGFR internalization with simulated PV 
treatment (×ke) was calculated for variation in kpit and kdp,s or kpit and GRB2 
concentration.  Best-fit model parameters are shown as red circles. (D and E) The model 
was used to quantify sensitivity of a simulated ke measurement or pulse-chase experiment 
(as described for Figure 3-3A, with 10 ng/mL EGF) to the indicated perturbations in 
model parameters. 
 
Effects of PTP inhibition or knockdown on EGFR association with pit 
proteins. By estimating time scales () for molecular processes based on the model 
parameters, we find that the processes required for EGFR pit recruitment occur on time 
scales (kG,f
-1
GRB2
-1
 = GRB2,on ~1 s and kpit
-1
 = pit ~1 s) that are smaller than the time scale 
for EGFR dephosphorylation (kdp,s
-1 
= dp,s ~12 s).  Thus, a testable model prediction is 
that PTP inhibition affects GRB2-EGFR association for t > dp,s but without promoting 
EGFR pit recruitment.  To test this, we first measured the effect of PTP inhibition on 
GRB2-EGFR association.  Consistent with our predictions, PTP inhibition promoted 
GRB2-EGFR association for times > dp,s (Figure 3-5A and 3-5B).  We next measured 
the effect of pervanadate on EGF-induced EGFR association with α-adaptin, a subunit of 
the AP-2 complex which links EGFR to coated pits (129).  EGF-induced α-adaptin-
EGFR association was unaffected by PTP inhibition, despite a pronounced effect on 
EGFR phosphorylation (Figure 3-5C), in agreement with the model (Figure 3-5D and 3-
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5E).  The model’s inability to quantitatively capture resting α-adaptin-EGFR association 
is probably related to our method of estimation of this quantity (see Materials and 
Methods).  We confirmed specificity of the α-adaptin antibody by siRNA-mediated 
knockdown (Figure S3-9).  
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Figure 3-5: Effect of phosphatases on EGFR phosphorylation, adapter binding, and 
pit recruitment. 
(A) HeLa cells were treated with 10 ng/mL EGF either with or without 100 μM 
pervanadate (PV) prior to lysis, GRB2 immunoprecipitation, and western blotting with 
antibodies against indicated proteins (n=3). (B) Normalized data (circles) from (A) were 
plotted versus model predictions (lines). (C) HeLa cells were treated with 10 ng/mL EGF 
with or without 100 μM PV prior to lysis, EGFR/pEGFR immunoprecipitation, and 
western blotting with antibodies against indicated proteins (n=3). (D and E) Normalized 
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data (circles) from (C) for α-adaptin-EGFR association or EGFR phosphorylation are 
shown with model predictions (lines). (F) HeLa cells transfected with control or DEP1-
targeted siRNA were treated with 10 ng/mL EGF prior to lysis, EGFR/pEGFR 
immunoprecipitation, and western blotting with antibodies against indicated proteins 
(n=4). (G) The model (lines) was fit to normalized data (circles) from (F) to determine a 
new value for kdp,s. (H and I) The new value of kdp,s determined in (G) for DEP1 
knockdown was used to simulate the effect of DEP1 knockdown on α-adaptin-EGFR 
association with a comparison to normalized data (circles) and to predict the effect of 
DEP1 knockdown on the rate constant for EGF-mediated EGFR internalization (ke).  
Throughout the figure, data are normalized to the 5 min time point for EGF+PV or DEP1 
knockdown and are shown as mean ± s.e.m. 
 
We next tested the ability of specific PTPs to regulate EGFR pit recruitment by 
knocking down DEP1 and assessing EGFR phosphorylation (Figure 3-5F), which model 
regression determined was consistent with kdp,s = 2.4 min
-1
 (Figure 3-5G).  For this kdp,s 
versus the base value for control, the model predicted no change in α-adaptin-EGFR 
association and no change in ke with DEP1 knockdown (Figure 3-5H and 3-5I, 
respectively).  We hypothesize that reduced induction of α-adaptin-EGFR association 
compared to treatment with EGF alone was due to the siRNA transfection process. 
Potential effects of PTP over-expression or intracellular competition between 
SH2 domain-containing proteins on EGFR internalization. A previous study 
identified suppressor of T-cell signaling 1 (STS1) as capable of dephosphorylating EGFR 
and slowing EGFR internalizatio333n (130).  To challenge our model, we first expressed 
STS1 in HeLa cells (Figure 3-6A) and determined that the resulting reduction in 
phosphorylation was consistent with kdp,s = 9.1 min
-1
 (Figure 3-6B).  For this kdp,s versus 
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the base value for control, the model predicted no change in ke, consistent with our 
measurements (Figure 3-6C).  Raguz et al. (130) observed more substantial STS1-
mediated reduction in EGFR phosphorylation, which may explain why they observed 
impaired EGFR internalization.  Consistent with this notion, an ~10-fold reduction in 
EGFR phosphorylation is predicted for a kdp,s = 687 min
-1
 (Figure 3-6B), and this kdp,s 
results in a large predicted drop in ke (Figure 3-6C). 
 
 
Figure 3-6: Potential effects of PTP over-expression or intracellular competition for 
EGFR phosphotyrosines binding on EGFR endocytosis. 
(A) Flag-tagged STS1 was stably expressed in HeLa cells. Control and STS1-
overexpressing HeLa cells were treated with 10 ng/mL EGF, and lysates were analyzed 
by western blotting with antibodies against indicated proteins (n=7). (B) The model (red 
line) was fit to data (circles) from (A) normalized to the 3 min time point for control to 
determine a new value for kdp,s with STS1 expression.  pEGFR was also predicted for a 
kdp,s consistent with the data of Raguz et al. (green line) (130). (C) The values of kdp,s 
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determined in (B) for our data (red bars) and the data of Raguz et al. (green bars) were 
used to simulate the effect of STS1 expression on the EGF-mediated EGFR 
internalization rate constant (ke) and compared to measurements of ke with 10 ng/mL 
125
I-
EGF (n=6). (D) The model was used to compute ke as a function of GRB2 expression and 
kpit.  The best-fit parameters are indicated by the red circle. (E) The effects of the 
indicated expression levels of the GRB2-SH2 domain on ke and GRB2-EGFR association 
(1 min after EGF addition) were predicted using the base model parameters for GRB2-
EGFR binding or with 100-fold reductions in the GRB2-EGFR on/off rate constants. 
 
Competition for binding to EGFR phosphotyrosines between intracellular proteins 
(e.g., STAT3 and GRB2 (131)) could also potentially regulate EGFR endocytosis by 
antagonizing EGFR-GRB2 association.  Since our model does not explicitly include a 
GRB2-competitive species, we simulated the effect of one by reducing GRB2’s 
concentration, which reduced ke (Figure 3-6D).  This predicted sensitivity is reduced, 
however, for increased kpit, which is important to consider given that our regression 
constrains only the lower bound for kpit.   
A previous study demonstrated that expression of the GRB2 SH2 domain (GRB2-
SH2) could reduce ke in HeLa cells by ~70% through competition with full-length GRB2 
(28).  According to the model, this would be consistent with a 90% reduction in GRB2-
EGFR association 1 min after EGF treatment.  Even a 10% reduction in ke is predicted to 
require a 40% decrease in GRB2-EGFR association.  Using a simple model of 
competition between GRB2 (2.1×10
5
 cell
-1
) and  GRB2-SH2, we estimated that 
reductions of 40 or 90% in GRB2-EGFR association could be achieved by expression of 
9.8×10
5
 or 1.7×10
7
 GRB2-SH2/cell, respectively (Figure 3-6E).  EGFR internalization is 
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able to remain relatively unchanged even in the presence of 5-fold higher GRB2-SH2 
concentration because GRB2 and GRB2-SH2 on and off binding is so rapid that one of 
the relatively rare endogenous GRB2 molecules binds EGFR within a relatively short 
time after EGF addition and commits the receptor to pit recruitment.  Consistent with 
this, reducing the rate constants for GRB2-EGFR binding/unbinding by 100-fold without 
changing GRB2-EGFR affinity, did not alter the predicted effect of GRB2-SH2 
expression on GRB2-EGFR association, but significantly reduced the model-predicted ke 
(Figure 3-6E).  
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3-3  DISCUSSION 
We sought to understand how EGFR is able to participate in multiple processes 
that compete for the same EGFR phosphotyrosine in the first few minutes after 
exogenous ligand addition.  Our central finding is that EGFR multitasking is possible 
because processes that depend upon the same phosphotyrosine occur with very different 
time scales.  We reached this conclusion by developing a novel computational model of 
EGFR kinetics and using it to interpret our quantitative experimental measurements. 
 Of course, our computational model reflects an abstraction of EGFR biology 
intended to capture the necessary regulatory aspects with sufficient resolution to answer 
the question at hand. To minimize the number of model parameters, we did not explicitly 
consider every process known to regulate EGFR endocytosis.  Rather, the model-
calculated rate of GRB2-bound EGFR pit recruitment encapsulates the known biological 
processes that occur after EGFR-GRB2 binding, including EGFR-CBL association, 
EGFR ubiquitination, and EGFR-pit protein binding (Figure 3-7A).  Assuming one 
process is significantly slower than the others, that slowest process sets the pit 
recruitment rate and determines kpit.  Immunoprecipitation experiments in HeLa cells 
demonstrate constitutive GRB2-CBL association (28), suggesting that GRB2-CBL 
association is not rate-limiting.  To our knowledge, the rate of CBL-mediated EGFR 
ubiquitination has not been measured, but an upper bound time scale is suggested by the 
measured EGFR-GRB2 dissociation rate (123).  Given that GRB2-mediated EGFR 
association with CBL is important for EGFR internalization (31), CBL’s role in EGFR 
internalization, which may be to mediate EGFR ubiquitination (132), must occur before 
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GRB2 dissociates from EGFR.  Thus, CBL-mediated EGFR ubiquitination would have to 
occur on a time scale at least as small as the EGFR-GRB2 unbinding time scale (GRB2,off 
= 0.1 s).  This is significantly smaller than our estimate of the EGFR pit recruitment time 
scale (pit ~1 s), suggesting that CBL-mediated EGFR ubiquitination also does not rate-
limit EGFR pit recruitment.  Thus, of the three biological processes coarse-grained by the 
model pit recruitment step, we conclude that EGFR-pit protein association is rate-limiting 
and that our estimate of kpit depends mainly upon the rate for this process. 
Based on this conclusion and using time scales calculated from the model 
parameters, we propose a timeline of the events that occur after initial tyrosine 
phosphorylation for the average receptor (Figure 3-7B).  Phosphorylated EGFR quickly 
binds GRB2 (GRB2,on ~1 s), becomes ubiquitinated (ub < 0.1 s) and associated with a 
coated pit (pit ~1 s) prior to dephosphorylation (dephos ~12 s).  Once EGFR is 
ubiquitinated, EGFR dephosphorylation affects GRB2-EGFR association, but not pit 
protein-EGFR association, as the latter does not require EGFR phosphorylation (33).  
Based on these characteristic times, and an EGFR plasma membrane residence time of ~6 
min (based on ke,m), a plasma membrane receptor cycles between phosphorylated and 
unphosphorylated states > 18 times and GRB2-associated/unassociated states > 230 times 
prior to internalization.   
The best-fit model can also be used to predict the EGF-mediated compartmental 
redistribution of total and phosphorylated EGFR versus time (Figure 3-7C and 3-7D).  In 
response to EGF, EGFR moves from the cell surface to the pit compartment within ~2 
min, and becomes internalized with a time scale of ~5 min (Figure 3-7C).  For the same 
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simulation and consistent with relatively rapid pit recruitment, phosphorylated EGFR 
levels are higher in the pit compartment than in the cell surface compartment for t < 5 
min, after which phosphorylated EGFR becomes concentrated in the cell interior (Figure 
3-7D).  These predictions are roughly consistent with observations of the distribution of 
total or phosphorylated EGFR between the plasma membrane and the cell interior in 
184A1 mammary epithelial cells (133).  With simulated PTP inhibition, EGFR 
phosphorylation is increased without affecting total EGFR partitioning among 
compartments (Figure 3-7C and 3-7D, respectively).  
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Figure 3-7: Model coarse graining of pit recruitment process and model-based 
inferences for EGFR multitasking. 
(A) In living cells, EGF-EGFR binding promotes receptor dimerization, kinase (K) 
activation, and phosphorylation (P) of cytoplasmic tyrosines (Y).  GRB2 mediates 
EGFR-CBL association, leading to EGFR ubiquitination and association with pit 
proteins.  These processes are coarse-grained in the model such that phosphorylated 
GRB2-bound EGFR translocates to the pit compartment in a process characterized by the 
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rate constant kpit. (B) Using the model parameters, time scales for EGFR phosphorylation, 
EGFR-GRB2 binding, and EGFR ubiquitination were estimated and used to construct an 
approximate timeline of what happens to the typical EGFR after its first phosphorylation 
in response to EGF binding.  Durations of specific states (e.g., phosphorylation) were set 
equal to the time scales for the appropriate reverse process (e.g., dephosphorylation), and 
durations of various “off” states (shown in grey) were set equal to the time scale for the 
appropriate forward process (e.g., phosphorylation). (C and D) The model was used to 
calculate the amount of total EGFR or phospho-EGFR in the indicated cellular 
compartments in response to 10 ng/mL EGF, with or without simulated pervanadate (PV) 
treatment.  
 
We note that our finding that DEP1 knockdown did not promote EGFR 
internalization in HeLa cells conflicts with the findings of Tarcic et al. (51), despite our 
repetition of their experimental method (Figure 3-2E).  We have also previously noted 
that the degree to which DEP1 knockdown appeared to promote EGFR internalization in 
the experiments of Tarcic et al. would be consistent with an unusually large ke (89).  One 
potential explanation for this discrepancy is that the results of Tarcic et al. could have 
been affected by disruption of antibody binding to activated EGFR, an effect for which 
there is documented evidence (89).   
 Overall, our results emphasize the mechanistic importance of the emerging 
paradigm that phosphorylation (and perhaps other post-translational modifications) and 
protein-protein interactions cycle between “on” and “off” states with time scales that are 
smaller than is generally appreciated.  For EGFR, and perhaps other receptors, this 
enables the receptor to multitask by simultaneously initiating downstream signaling, 
89 
 
internalizing, and being regulated by PTPs.  Further study of this aspect of signaling 
regulation would benefit greatly from improved techniques to measure events with 
extremely small time scales. 
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3-4  MATERIALS AND METHODS 
Cell culture. HeLa cells (American Type Culture Collection, Manassas, Virginia, 
USA) and 3T3 cells overexpressing PTP1B (Ben Neel, Ontario Cancer Institute) and 
EGFR were cultured in DMEM.  SKBR3 cells were cultured in RPMI.  Media was 
supplemented with 10% fetal bovine serum, 100 units/mL penicillin, 100 μg/mL 
streptomycin, and 1 mM L-glutamine (Life Technologies, Carlsbad, California, USA).  
Prior to treatment with ligand, cells were serum-starved in media containing 0.1% FBS 
for 15-20 hrs. 
DEP1 knockdown. HeLa cells were transfected with SMARTpools of control or 
DEP1-targetted siRNA (Dharmacon, Lafayette, CO, USA) using DharmaFECT1.  For 
internalization or immunoprecipitation experiments, 5 or 15 nM siRNA was used, 
respectively, with the higher concentration for immunoprecipitation due to increased 
plated cell density.  DEP1 was efficiently knocked down in both cases (Figure S3-10). 
STS1 expression. FLAG-tagged STS1 was amplified from a previously described 
plasmid (Ivan Dikic, Institute of Biochemistry II) and inserted at the BamHI and NotI 
sites of the pCDH vector.  Lentiviral particles were prepared and target cells infected as 
described previously (49).  Cells were selected in 2 g/mL puromycin. 
Radiolabeling and measurement of ke. Recombinant human EGF (Peprotech, 
Rocky Hill, NJ, USA) was labeled with 
125
I (PerkinElmer, Waltham, MA, USA) and used 
to measure EGF-mediated EGFR endocytosis rate constants (ke), as previously described 
(48).   
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Immunofluorescence. Immunofluorescence microscopy was performed as 
described previously (2). 
Flow cytometry for EGFR. Serum-starved cells were treated as indicated in 
figures and removed from plates using cell dissociation buffer (Sigma-Aldrich, St Louis, 
MO, USA), fixed in 2% paraformaldehyde, incubated with EGFR antibody overnight, 
and incubated with Alexa Flour 488 conjugated secondary (Cell Signaling Technologies, 
Danvers, MA, USA) for 30 min prior to analysis on a FACSCalibur cytometer.  Data 
were analyzed using FlowJo. 
Western blotting.  Cell lysates were prepared and analyzed by western blot as 
described previously (89). 
Immunoprecipitation. Immunoprecipitation (IP) of GRB2, EGFR, and pEGFR 
was performed as previously described (89), with minor changes.  For GRB2 IP, 30 μg of 
total protein was used.  For EGFR IP, lysis buffer was supplemented with 20 mM of the 
deubiquitinase inhibitor N-ethylmaleimide to account for the possibility that 
ubiquitination may influence EGFR-pit protein association (132).  100 μg of total protein 
was added to beads that had been separately conjugated to EGFR or pEGFR Y1068 
antibodies and pooled.  
Other reagents. Antibodies were purchased against EGFR (NeoMarkers, #MS-
400-P0 (WB and IP), #MS-311-P0 (flow cytometry), Fremont, CA, USA), pEGFR 
Y1068 (Epitomics, #1138 (IP) and #1727 (WB), Burlingame, CA, USA), ERK (Cell 
Signaling Technologies, #4695 (WB)), DEP1 (R&D Systems, #MAB1934 (WB), 
Minneapolis, MN, USA), α-adaptin1/2 (Santa Cruz Biotechnology, #SC10761) and 
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GRB2 (Santa Cruz Biotechnology, #SC255). Infrared dye-conjugated secondary 
antibodies were purchased from Rockland Immunochemicals (Gilbertsville, PA, USA).  
Pervanadate was prepared as described previously (89).  
Model topology and overview. The model considers three compartments for 
EGFR: cell surface, endocytic pit, and endosome.  In each compartment, reactions are 
included for the binding of ligand, ATP, and kinase inhibitor to the receptor, receptor 
dimerization, receptor phosphorylation, receptor dephosphorylation, and binding of the 
phosphorylated receptor to GRB2 (Figure 3-1).  A complete parameter list is provided in 
Table 3-1.  Differential equations describing the mass action kinetics of these processes 
were solved using the Systems Biology Toolbox 2 (111).   
EGFR dimers. To limit the number of species, we assumed that receptor 
dimerization occurs only between identical monomers (e.g., ATP-bound EGFR only 
dimerizes with ATP-bound EGFR), as we previously assumed (89).  When applied to 
ligand occupancy, this assumption led to irreconcilable differences in EGFR 
phosphorylation between the model and data at early times.  Thus, we included reactions 
for the formation of dimers which were asymmetric in ligand occupancy, consistent with 
recent experimental findings (134). 
EGFR phosphorylation and dephosphorylation. EGFR phosphorylation within 
ATP-bound dimers was assumed to occur at a single representative EGFR tyrosine that 
controls GRB2 recruitment and endocytosis, as in our previous work (89).  EGFR 
dephosphorylation was modeled as a first-order process with respect to phosphorylated 
species not bound with GRB2 within cell surface and pit (kdp,s) and endosome 
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compartments (kdp,i).  Note that EGFR dephosphorylation in coated pits has been 
documented (52).  Pervanadate treatment was simulated by setting kdp,s = kdp,i = 0 min
-1
.  
EGFR trafficking. GRB2-bound EGFR species were modeled as entering the pit 
compartment (28) in a first-order rate process characterized by kpit.  All pit-localized 
EGFR species were treated as capable of internalizing (52) in a first-order rate process 
characterized by ke,m, which was determined iteratively as previously described (89), such 
that the simulated experimentally determined ke = 0.146 min
-1
 (Figure 3-2C, “EGF 
37°C”).  EGFR degradation and recycling were incorporated as previously described 
(97).   
EGFR-adaptin association. To estimate α-adaptin-EGFR association, we 
assumed that each receptor localized to the pit and endosomal compartments was 
associated with an α-adaptin molecule, consistent with previous findings (129). 
Parameter fitting. kdp,s, kdp,i, and kpit were determined using a simulated 
annealing algorithm to minimize model error.  Error at each time point was calculated as 
the square of the difference between model and experimental values divided by the 
experimental value.  This calculation was made for all time points, and the sum was 
normalized by the number of time points. Error associated with EGFR internalization 
data was weighted more heavily than the individual errors associated with pulse-chase 
kinetics because more conditions were explored for the pulse-chase experiments.  The 
model was fit to the data 25 times.  For the 16 fits with the smallest error, there were only 
small variations in kdp,s, kdp,i, and kpit.  We selected the parameter set with the lowest kpit, 
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in recognition of the fact that the model error structure provided only a lower bound for 
kpit (Figure 3-3E). 
Sensitivity. Model sensitivity to perturbations in parameters was computed as 
described previously (89).  
Representative HeLa cell. Simulations assumed 5×10
4
 EGFR/cell (110), 2.1×10
5
 
GRB2/cell (85), and 1 mM ATP (102), unless noted otherwise.  
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3-6  SUPPLEMENTAL MATERIAL 
 
Figure S3-8: Effects of PTP inhibitors on EGF-mediated EGFR internalization. 
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The rate constant for EGF-mediated EGFR endocytosis (ke) was measured using 10 
ng/mL 
125
I-EGF alone or with 100 μM pervanadate (PV) in (A) H3255 cells (n=3), (B) 
SKBR3 cells (n=3), or (C) 3T3 cells (n=3). (D) 3T3 cells were left untreated, treated with 
10 ng/mL EGF for 15 min, or treated with 10 ng/mL EGF and 100 μM PV for 15 min 
before cells were fixed and prepared for immunofluorescence measurements with 
staining against indicated targets. (E) HeLa cells were left untreated, treated with 10 
ng/mL EGF for 20 min, or treated with 10 ng/mL EGF and 100 μM PV for 20 min before 
EGFR and DNA were visualized by immunofluorescence. (F) ke was measured in HeLa 
cells using 1 ng/mL 
125
I-EGF alone, with 100 μM PV, or with 100 μM PV after a 5 min 
100 μM PV pretreatment (n=3). (G) ke was measured in HeLa cells using 10 ng/mL 
125
I-
EGF after a 20 min pretreatment with serum free media (SFM) or using 10 ng/mL 
125
I-
EGF with 100 μM PV after a 20 min pretreatment with 100 μM PV. (H) ke was measured 
using 10 ng/mL 
125
I-EGF with or without 1 mM sodium orthovanadate (SOV).  All ke 
values are shown as mean ± s.e.m. 
 
  
98 
 
 
Figure S3-9: α-adaptin antibody validation. 
HeLa cells were transfected with control or α-adaptin-targeted siRNA, transfected again 
24 hrs later, and then treated 48 hrs after the second transfection with 100 ng/mL EGF for 
15 min before lysis and immunoprecipitation (IP) of EGFR/pEGFR.  Lysates were 
analyzed by western blotting with antibodies against indicated proteins (n=3).  
Knockdown of α-adaptin was verified in whole cell lysates (WCL), EGFR/pEGFR 
immunoprecipitations (IP: EGFR/pEGFR) and immunoprecipitation supernatants (IP 
Sup.). 
 
 
 
Figure S3-10: siRNA-mediated DEP1 knockdown. 
 HeLa cells were transfected with (A) 15 nM or (B) 5 nM of control or DEP1-targeted 
siRNA 48 hrs prior to analysis by western blotting with antibodies against indicated 
proteins (n=3). 
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Chapter 4 : Identification of Determinants of EGFR-Targeted 
Therapeutic Efficacy Using Computational Modeling 
 
4-1  ABSTRACT 
For decades, clinicians have attempted to antagonize aberrant growth factor 
receptor-mediated signaling in cancer using antibodies and small-molecule inhibitors.  
Significant dose-response variability is observed for these drugs among cells and tumors 
even in the absence of receptor mutations, but the basis for this is not fully understood.  
Using the epidermal growth factor receptor (EGFR) as a model system, we implemented 
a computational analysis of EGFR tyrosine phosphorylation dynamics to identify factors 
that determine the efficacy of the EGFR-targeted kinase inhibitor gefitinib and the ligand-
competitive monoclonal antibody cetuximab.  Our results: 1. identify different kinetic 
processes as preferentially controlling the efficacy of  gefitinib versus cetuximab; 2. 
suggest that the efficacy of  gefitinib and cetuximab may be favored by the expression of 
certain naturally expressed EGFR ligands versus others; and 3. suggest new therapeutic 
design principles.  For example, the model predicts that  gefitinib efficacy is 
preferentially sensitive to perturbations in the activity of protein tyrosine phosphatases 
(PTPs) regulating EGFR, but that cetuximab efficacy is preferentially sensitive to 
perturbations in ligand binding kinetics, suggesting that cell-to-cell variation in PTP or 
ligand expression could underlie heterogeneous cellular responses to  gefitinib or 
cetuximab, respectively.  Our results also highlight that kinetic considerations beyond 
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those reflected by equilibrium affinities determine therapeutic efficacy.  For constant 
gefitinib binding affinity, decreasing rates of  gefitinib binding and unbinding is predicted 
to promote efficacy by increasing the time scale for which the receptor must remain 
unphosphorylated.  Conversely, for constant cetuximab binding affinity, decreasing 
antibody binding and unbinding rates impairs efficacy as cetuximab is increasingly out-
competed by ligand.  By integrating these considerations, the model also identifies 
minimum concentrations of  gefitinib and cetuximab that can be combined to maximally 
reduce receptor phosphorylation.  
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4-2  INTRODUCTION 
In many cancers, aberrant signaling initiated by receptor tyrosine kinases (RTKs) 
such as the epidermal growth factor receptor (EGFR) is a key driver of disease.  For 
several decades, oncologists have tried to leverage this knowledge by treating patients 
with small molecule inhibitors or monoclonal antibodies that antagonize RTK 
phosphorylation by interfering with specific mechanistic steps in RTK function or simply 
promote down-regulation of RTK expression.  For EGFR, the well-known kinase 
inhibitors gefitinib and erlotinib compete with ATP for binding to the receptor and are 
approved for the treatment of non-small cell lung carcinoma (NSCLC) and NSCLC and 
pancreatic cancers, respectively (12, 135).  The monoclonal antibody cetuximab, which 
interferes with EGFR’s ability to bind ligands and dimerize, is approved for the treatment 
of head and neck and colorectal cancers (136).  Multiple trials are currently underway for 
combining cetuximab and erlotinib for treating gastrointestinal, head and neck, non-small 
cell lung, and colorectal cancers.  
Substantial evidence from cell culture and patient data suggests that EGFR-
targeted therapeutics are not uniformly effective.  For example, one study demonstrated 
that the amount of gefitinib, erlotinib, or cetuximab required to reduce EGFR 
phosphorylation to basal levels varied by about 10-fold between the wild-type EGFR-
expressing H1819 and H1299 cells (137).  Another study demonstrated that the 
concentration of cetuximab or gefitinib required to reduce phosphorylated EGFR to basal 
levels differed by roughly 5-fold in wild-type EGFR-expressing DiFi and A431 cells 
(138).  Neither study was able to conclude why this variation existed.  Consistent with 
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this, the inhibitor concentration required to reduce EGFR phosphorylation to half-
maximal (IC50) varied between ~2×10
1
 nM in NR6 cells expressing relatively low and 
relatively high amounts of EGFR (105) and ~7×10
1
 nM in NIH3T3 cells over-expressing 
EGFR (139).  A fourth study identified expression of EGFR ligands as a predictor of 
variations of at least roughly 10-fold in the concentrations of gefitinib and cetuximab 
required to half-maximally inhibit cellular proliferation among wild-type EGFR-
expressing NSCLC cells (140).  Similar variations in response to therapeutics are also 
seen in the clinic as indicated by a 17.2% response rate for erlotinib in EGFR mutation 
negative NSCLC patients (11). Thus, experimental studies in general suggest that 
processes other than EGFR mutational status may affect the efficacy of EGFR-targeted 
therapeutics. 
Computational modeling represents a useful approach for identifying processes 
that may account for the differential therapeutic efficacy that can be observed.  In fact, 
multiple studies have employed these approaches to understand the cellular contexts 
where EGFR-targeted therapeutics work and their mechanisms of action.  For example, 
mechanistic models concentrating on signaling processes downstream of EGFR have 
explored the role of EGFR internalization (50), dual inhibition of EGFR and proteins 
such as PLCγ (141), and basal phosphorylated AKT levels (142) in the efficacy of 
EGFR-targeted therapeutics. Other computational studies have focused on processes that 
directly involve EGFR, such as enzyme-inhibitor binding (143), MIG6-mediated 
feedback regulation (144), and phosphorylation of multiple EGFR tyrosines (99), and 
how these processes might influence targeted therapeutic efficacy. None of these studies 
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have sought to quantitatively delineate the processes most important to the ability of a 
therapeutic to mediate a reduction in EGFR phosphorylation. Identification and 
exploration of these processes is paramount because their variation might account for the 
differential effect of EGFR-targeted therapeutics observed in cell lines and in the clinic.  
One candidate process is receptor dephosphorylation, which therapeutics rely upon to 
remove EGFR phosphorylation and which we have shown occurs more rapidly than 
previously assumed (89).  A role for EGFR dephosphorylation in therapeutic efficacy is 
supported by a review that argues for its importance in the context of kinase inhibitors 
(90) and an experimental study which demonstrated that reduced expression of the 
phosphatase PTPRS correlates with increased EGFR phosphorylation and reduced 
EGFR-targeted therapeutic efficacy in head and neck squamous cell carcinoma (HNSCC) 
patients (82).  EGFR internalization also influences the efficacy of EGFR-targeted 
therapeutics (48, 145). Thus, multiple processes that involve EGFR directly have been 
shown to influence therapeutic efficacy, arguing for more focused study of upstream 
processes in the context of targeted therapeutics.  
Here, we used a previously developed model of EGFR phosphorylation, 
dephosphorylation and internalization to predict the efficacy of EGFR-targeted 
therapeutics in mediating a reduction in EGFR phosphorylation.  We then used a 
sensitivity analysis-based approach to quantify the relative contributions of receptor-level 
processes to therapeutic efficacy at steady-state and as a function of time.  We performed 
our analysis for two EGFR-targeted therapeutics (gefitinib and cetuximab) and two 
EGFR ligands (epidermal growth factor (EGF) and amphiregulin (AR)).  We found that 
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the processes that determine EGFR-targeted therapeutic efficacy vary between 
therapeutic/ligand pairs and extend beyond processes involved in the competitive binding 
of therapeutics to EGFR.  For example, increased therapeutic concentrations are required 
to reduce receptor phosphorylation in the context of EGF compared to AR due to the 
slower ligand-receptor dissociation rate for EGF. Our steady-state sensitivity analyses 
revealed that EGFR phosphorylation and dephosphorylation were preferentially 
important determinants of gefitinib efficacy while EGFR trafficking processes were 
preferentially important determinants of cetuximab efficacy. Our dynamic sensitivity 
analyses identified EGFR dephosphorylation as an important process in the context of 
both gefitinib and cetuximab. Lastly, our model predicts that co-treatment with gefitinib 
and cetuximab would additively, but not synergistically, reduce EGFR phosphorylation in 
the context of either EGFR ligand. We conclude that for each therapeutic/ligand pair 
EGFR-targeted therapeutic efficacy is determined by processes in addition to those that 
control competitive therapeutic binding to EGFR. Based on this, we hypothesize that 
variation in the clinical response to cancer therapeutics may be at least partially explained 
by variation in the EGFR-level processes identified by this study. 
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Figure 4-1: Model topology of processes leading to EGFR phosphorylation and 
therapeutic inhibition of this process. 
(A) Ligand (L) and cetuximab (C) compete for binding to the EGFR extracellular domain 
while ATP (A) and gefitinib (G) compete for binding to the EGFR kinase domain (K). 
Ligand binding promotes EGFR dimerization and ATP-dependent phosphorylation of 
cytoplasmic tyrosines (Y) which link the receptor to adapter proteins. EGFR-adapter 
binding permits recruitment of EGFR to coated pits from which EGFR is internalized. 
(B) From a dimerized phosphorylated state, gefitinib and cetuximab mediate reductions 
in EGFR phosphorylation through different mechanisms. Gefitinib competes for binding 
to EGFR with ATP, which interrupts phosphorylation. Conversely, cetuximab cannot 
bind phosphorylated receptors until they uncouple and dissociate from their ligands, at 
which point cetuximab binding prevents ligand binding and dimerization.  
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Table 4-1: Model parameters. 
parameter description value source 
kL,fs (μM
-1
·min
-1
) ligand binding to EGFR, forward, surface/pit 3.1×10
2
 (125) 
kL,rs (min
-1
)* ligand binding to EGFR, reverse, surface/pit 8.0×10
-1
 KD (100) 
kL,fi (endosome∙min
-1
) ligand binding to EGFR, forward, endosome 3.1×10
-4
 (100) 
kL,ri (min
-1
)* ligand binding to EGF, reverse, endosome 6.6×10
-1
 (100) 
kA,f (μM
-1
·min
-1
) ATP binding to EGFR, forward 1.0×10
5
 (89) 
kA,r (min
-1
) ATP binding to EGFR, reverse 1.1×10
7
 (89) 
kg,f (μM
-1
·min
-1
) gefitinib binding to EGFR, forward 1.0×10
5
 (89) 
kg,r (min
-1
) gefitinib binding to EGFR, reverse 2.1×10
2
 (89) 
kc,f (μM
-1
·min
-1
) cetuximab binding to EGFR, forward 1.3×10
1
 (146) 
kc,r (min
-1
) cetuximab binding to EGFR, reverse 6.6×10
-2
 (146) 
kG2,f (cell·min
-1
) GRB2 binding to EGFR, forward 3.8×10
-4
 (123) 
kG2,r (min
-1
) GRB2 binding to EGFR, reverse 4.6×10
2
 (123) 
kd,fs (cell·min
-1
) EGFR dimerization, forward, surface/pit 6.7×10
-4
 calculated (89) 
kd,fi (endosome·min
-1
) EGFR dimerization, forward, endosome 2.7×10
-3
 calculated (89) 
kd,r (min
-1
) EGFR dimerization, reverse, unoccupied 1.0×10
4
 KD (126) 
kd,rL (min
-1
) EGFR dimerization, reverse, ligand-occupied 1.0×10
-1
 (87) 
kp (min
-1
) phosphorylation, unoccupied dimer 2.7×10
0
 (101) 
kp,L (min
-1
) phosphorylation, ligand-occupied dimer 1.3×10
1
 (101) 
kdp,s (min
-1
) dephosphorylation, surface/pit 4.9×10
0
 fit 
kdp,i (min
-1
) dephosphorylation, endosome 2.2×10
0
 fit 
kp (min
-1
) EGFR recruitment to pit compartment 4.4×10
1
 fit 
ki (min
-1
) EGFR internalization varies calculated (89) 
kx (min
-1
) endosomal exit 4.0×10
-2
 (97) 
frE recycle fraction, EGF-occupied 5.0×10
-1
 (97) 
fr recycle fraction, unoccupied 8.0×10
-1
 (97) 
 
*Values for EGF are shown. Dissociation rate constants for AR were equal to these values multiplied by 
100. 
 
 
  
107 
 
4-3  METHODS 
Model topology. The computational model of EGFR phosphorylation, 
dephosphorylation and internalization used in this study was described previously 
(Monast and Lazzara, 2013), with the exception that kinetics for the binding of the 
therapeutic antibody cetuximab to EGFR were added as described below.  The model 
considers three compartments (Figure 4-1A): 1. cell surface, 2. pit, and 3. endosome. In 
each compartment, EGFR is permitted to reversibly bind ligand, ATP, gefitinib, and 
another EGFR monomer (dimerization).  Reversible EGFR-cetuximab binding occurs 
only in the cell surface and pit compartments (discussed below).  Receptor dimers may 
bind and unbind ligand, ATP, and gefitinib.  Dimerized, ATP-bound receptors undergo 
receptor phosphorylation characterized by rate constants kp and kp,L depending on whether 
the receptor dimer is unoccupied or occupied by ligand, respectively.  Phosphorylated 
receptors may be dephosphorylated or bind the adapter protein GRB2, which was 
considered because of its role in initiating both signaling and internalization processes 
(28, 119).  Dephosphorylation occurs with different rate constants for EGFR in the cell 
surface and pit compartments (kdp,s) compared to EGFR in the endosome compartment 
(kdp,i).  Both rate constants take into account our recent finding that EGFR 
dephosphorylation occurs with a time scale of < 1 min regardless of receptor localization 
(89).  GRB2-bound receptors in the cell surface compartment irreversibly translocate to 
the pit compartment and all receptors in the pit compartment irreversibly translocate to 
the endosome compartment regardless of phosphorylation status, consistent with 
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experimental findings (28, 52).  Model parameters describing these processes, and others 
to be described below, are given in Table 1. 
EGF and amphiregulin. EGF-EGFR binding constants were based on 
experimental measurements (100, 147).  Amphiregulin was assumed to have a rate 
constant for ligand dissociation from EGFR that was 100-fold higher than that for EGF 
dissociation from EGFR, consistent with studies suggesting that AR compared to EGF: 1. 
has a higher value of the ligand-receptor dissociation constant (KD) for binding to EGFR 
(148); 2. is 50-300 times less potent in cellular growth assays (149), and 3. is less 
efficient on a molar basis at promoting ligand-mediated EGFR phosphorylation, 
ubiquitination, and association with CBL (150).  The 100-fold increase in the ligand 
dissociation rate constants was applied to ligand-receptor binding in the cell surface/pit 
compartments and in the endosome compartment (kL,rs and kL,ri, respectively). Ligand-
EGFR binding at these different cellular locations is characterized by different binding 
parameters due to differences in pH (44, 45).  
To compare EGF and AR, we considered: 1. a base EGF concentration (1.6 nM or 
10 ng/mL), 2. an equimolar AR concentration (1.6 nM) and 3. an AR concentration 
increased by 100-fold to correct for the assumed difference in ligand-receptor binding KD 
between EGF and AR (160 nM).  Comparison on the basis of equimolar ligand 
concentrations (1.6 nM EGF and AR) ensures similar ligand-EGFR association time 
scales for the two ligands, but allows for receptor occupancy by ligand to vary due to the 
difference in ligand-receptor KD.  Comparison of the same EGF concentration with an 
increased AR concentration corrects for the difference in ligand-receptor KD (1.6 nM 
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EGF and 160 nM AR) between EGF and AR.  However, this approach leads to more 
rapid ligand-EGFR association in the context of AR compared to EGF. 
Gefitinib and cetuximab. Gefitinib was assumed to be cell permeable and was 
permitted to compete with ATP for EGFR binding regardless of EGFR localization. This 
assumption is consistent with our published results demonstrating that gefitinib can 
mediate a reduction in EGFR phosphorylation even after an 8 min, 1.6 nM EGF treatment 
of HeLa cells which results in localization of roughly 50% of cellular EGFR to the cell 
interior (89). In contrast, the monoclonal antibody cetuximab was assumed to bind only 
EGFR monomers that were not ligand-bound and that were localized to the cell surface or 
pit compartments. The assumption that cetuximab binds to EGFR monomers that are not 
ligand-bound is based on a study suggesting that cetuximab binding to EGFR competes 
with EGFR-ligand binding and EGFR dimerization (136). In the model, cetuximab-bound 
species were permitted to internalize. However, cetuximab-EGFR dissociation was not 
permitted in the cell interior due to issues with the ODE solver. Given that the EGFR-
cetuximab dissociation rate constant and the endosomal exit rate constant are similar in 
magnitude (Table 1), this assumption should not significantly affect simulations.  EGFR-
therapeutic binding is summarized in Figure 4-1. 
Comparing therapeutics. For comparisons of gefitinib and cetuximab that 
required a fixed drug concentration, we assumed concentrations of 1 μM for both.  This is 
an appropriate basis for comparison because these concentrations are significantly greater 
than the therapeutic-EGFR binding KD values, which are similar in magnitude (2.1 nM 
for gefitinib, 5.2 nM for cetuximab (12, 146)).  This eliminates the possibility of 
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differential therapeutic-receptor occupancy between cetuximab and gefitinib.  A 
concentration of 1 μM is also consistent with achievable levels for both therapeutics in 
vivo (7, 151, 152). 
Inhibition curves and IC50 calculation. To quantify the ability of a therapeutic 
to mediate a reduction in EGFR phosphorylation at steady-state, inhibition curves were 
simulated by computing steady-state EGFR phosphorylation in the presence of ligand 
over a range of therapeutic concentrations.  EGFR degradation was not permitted in these 
simulations because our model does not consider receptor synthesis and so this alteration 
was necessary to reach a steady-state.  We defined the IC50 as the therapeutic 
concentration at which steady EGFR phosphorylation was reduced to 50% of its value at 
the lowest therapeutic concentration. Similar approaches have been used in experimental 
studies (105).  Note that there is at least one other definition for IC50. In classical enzyme 
kinetics, IC50 is defined as the therapeutic concentration required to reduce the maximal 
enzyme-mediated product formation rate by half (143). 
Pulse-chase curves and t50 calculation. To quantify the ability of a therapeutic to 
mediate a reduction in EGFR phosphorylation as a function of time, we performed 
calculations in which we simulated a 5 min treatment of cells with ligands followed by a 
chase with 1 μM therapeutic. We defined t50 as the time at which receptor 
phosphorylation was reduced to 50% of the observed decrease between the time of 
therapeutic addition and steady-state.  Again, EGFR degradation was not permitted in 
these simulations in order to reach a steady state. 
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Local parameter sensitivity. To quantify the relative contributions of receptor 
level processes to IC50 and t50 values, we computed the sensitivity of IC50 and t50 to 
perturbations in most model parameters. The excess ligand approximation was applied 
for concentrations of extracellular ligand (EGF or AR), therapeutic (cetuximab or 
gefitinib), and ATP.  Thus, these concentrations are constants and so could be included in 
our sensitivity analysis.  However, perturbations in a particular concentration is 
mathematically identical to perturbations in the respective rate constant for association 
with EGFR, so these concentrations were not included separately in the sensitivity 
analysis.  Sensitivity was defined as the absolute value of the difference in the logarithm 
of IC50 or t50 values between the perturbed and base parameter values, summed over all 
perturbations. Perturbations in parameters were 10-fold and 0.1-fold. 
Representative cell. Cells were assumed to express 5×10
4
 EGFR (110), 2.1×10
5
 
GRB2 (85), and to internalize EGFR at a rate consistent with a measured EGFR 
internalization rate constant of 0.146 min
-1
 (Chapter 3).  Consistency with this 
internalization rate was enforced as described previously (89).  The model was brought to 
steady state in the absence of receptor degradation before the simulated addition of ligand 
or therapeutic, as described previously (Chapter 3). 
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4-4  RESULTS  
Model-predicted inhibition of receptor phosphorylation by gefitinib or 
cetuximab. We used the model to predict dose-response relationships for EGFR 
phosphorylation as a function of gefitinib or cetuximab concentration (Figure 4-2).  For 
1.6 nM EGF, which corresponds to the commonly utilized experimental EGF 
concentration of 10 ng/mL, or 1.6 nM AR, we simulated inhibition curves for each 
ligand/drug pair by computing steady-state EGFR phosphorylation for the indicated range 
of therapeutic concentrations (Figure 4-2A).  As shown in Figure 4-2B, for both 
cetuximab and erlotinib, the predicted IC50 in the presence of EGF exceeds that for AR 
by an order of magnitude.  This occurs, in part, because for ligand concentrations of 1.6 
nM the occupancy of receptors by EGF greatly exceeds that by AR due to the large 
difference in KD.  This reduces the driving force for dimerization (which has second-
order dependence on occupied receptors) and therefore reduces the IC50.  For either 
ligand, the predicted IC50 is significantly larger for gefitinib than cetuximab.  This occurs, 
in part, because gefitinib competes with abundant ATP (1 mM (102)), while cetuximab 
competes with a much less abundant ligand.  Additional factors contribute to these IC50 
differences, as will be discussed.  To account for the difference in ligand-receptor 
affinities, we repeated the previous analysis with a 100-fold increase in AR concentration 
and the same EGF concentration (Figure 4-2C).  That reduces, but does not eliminate, the 
IC50 difference predicted for the two ligands.  Thus, additional factors beyond the 
receptor occupancy by ligand explain the IC50 differences observed for EGF versus AR.  
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Figure 4-2: Predicted therapeutic IC50 values. 
(A) The amount of phosphorylated EGFR (pEGFR) was computed and normalized to the 
maximum value for a range of therapeutic concentrations and the indicated 
ligand/therapeutic pairs for 1.6 nM EGF or AR. (B) The drug concentration at which 
steady-state receptor phosphorylation was reduced to half-maximal (IC50) was quantified 
for each ligand/therapeutic pair in (A).  (C and D) The calculations in (A) and (B), 
respectively, were repeated for an 160 nM AR  and compared to results for 1.6 nM EGF. 
 
Effect of ligand and therapeutic binding kinetics on predicted IC50 values for 
gefitinib and cetuximab. Given that differences in receptor occupancy by ligand do not 
fully explain predicted differences in IC50 values of drugs with different ligands, we 
hypothesized an IC50 dependence on kinetic factors beyond those reflected by 
equilibrium binding affinities.  We thus performed an analysis assuming constant binding 
affinities of ligand (based on EGF) and drug (gefitinib or cetuximab) for the receptor, but 
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varying the rate at which ligand and drug cycle on and off the receptor by multiplying the 
rate constants for binding and unbinding by an equal “cycling factor” over a broad range 
(Figure 4-3A and 4-3B).  Faster cycling of ligand on and off the receptor is predicted to 
decrease gefitinib and cetuximab IC50.  For example, an increase in EGF cycling of 10-
fold reduces gefitinib or cetuximab IC50 by ~25% or 40%, respectively.  This occurs 
because of an effective reduction in the driving force for receptor phosphorylation as the 
time scale for receptor occupancy by ligand becomes similar or small compared to the 
time required for a ligand bound receptor to become phosphorylated.  This is reflected in 
the decrease in steady EGFR phosphorylation levels observed in the absence of any drug 
with increasing ligand cycling factor (see the vertical bars at left in each panel in Figure 
4-3).  This allows the process of receptor dephosphorylation to play a more substantial 
role and decreases the concentration of drug required to reduce receptor phosphorylation.  
We note as well that the predicted sensitivity of IC50 to changes in the ligand cycling 
factor is greater for cetuximab than for gefitinib.  This occurs because of a generally 
greater sensitivity of cetuximab’s efficacy to ligand binding kinetics, which will be 
discussed further later.  Note that IC50 values corresponding to 1.6 nM EGF and 160 nM 
AR are shown in Figure 4-3 panels.  160 nM AR is equivalent to 1.6 nM EGF with a 
ligand cycling factor of 10
2
 because AR is modeled as having a dissociation constant 
100-times larger than that of EGF and the 100-fold greater concentration of AR 
compared to EGF leads to a 100-fold increase in AR’s association relative to EGF (since 
both ligands are assumed to associate with EGFR with equally rapid kinetics). 
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Figure 4-3: Effects of the rates of cycling of ligand or therapeutic binding and 
unbinding. 
(A-D) The logarithm of the drug concentration at which steady-state receptor 
phosphorylation was reduced to half-maximal (IC50) was calculated for the indicated 
fold-change in ligand or therapeutic cycling. Cycling was altered by multiplying ligand-
receptor association and dissociation rate constants or drug-receptor association and 
dissociation rate constants by the indicated ligand or therapeutic cycling factors, 
respectively.  These alterations did not affect the values of the appropriate dissociation 
constant (KD).  Ligand cycling rates corresponding to 1.6 nM EGF (filled yellow circle) 
and 160 nM AR (filled white circle) are shown for no change in the therapeutic binding 
parameters. This analysis was performed for (A) gefitinib and (B) cetuximab with the 
base parameters. (C and D) The simulations in (A) and (B) were repeated but with (C) the 
rate constants for phosphorylation within ligand-bound dimers (kp,L) and 
dephosphorylation at the cell surface and in the cell interior (kdp,s and kdp,i, respectively) 
reduced by 10
2
-fold and (D) the rate constants for receptor dimerization at the cell surface 
and in the cell interior (kd,fs and kd,fi, respectively) and uncoupling of ligand-bound 
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receptor dimers (kd,rL) reduced by 10
3
-fold, respectively. For (A-D), the percent of 
phosphorylated EGFR (pEGFR) is shown in the bar to the left of each plot as a function 
of the ligand cycling factor but in the absence of therapeutic. 
 
Figures 4-3A and 4-3B also show predicted effects of changing cycling rates of 
gefitinib or cetuximab, again for constant binding affinities.  Sufficient decreases in 
gefitinib cycling are predicted to augment gefitinib efficacy (Figure 4-3A), which is 
qualitatively consistent with the observation that irreversible EGFR tyrosine kinase 
inhibitors tend to be more effective than gefitinib (153).  This effect arises because the 
receptor is increasingly less likely to rephosphorylate as the time scale with which it 
remains bound by gefitinib increases.  In support of this reasoning, we find that the 
sensitivity of IC50 to gefitinib cycling is reduced as the cycling of EGFR tyrosines 
through phosphorylated and unphosphorylated states decreases (Figure 4-3C).  In contrast 
to gefitinib, the model predicts that cetuximab efficacy can be augmented by increasing 
its cycling for a constant affinity (Figure 4-3B). This is observed because cetuximab-
EGFR binding occurs slowly relative to ligand-EGFR binding and EGFR dimerization. 
Thus, increased rates of cetuximab cycling on and off the receptor allow cetuximab-
EGFR binding to occur before a receptor monomer becomes ligand-bound or dimerized. 
Consistent with this reasoning, reducing the rate of ligand cycling reduces the predicted 
effect of cetuximab cycling rate on cetuximab IC50 (Figure 4-3B).  Furthermore, reducing 
the rate constants for receptor dimerization and receptor uncoupling, which does not alter 
the KD for receptor dimerization, virtually eliminated the ability of faster cetuximab 
cycling to reduce IC50 (Figure 4-3D).  This occurs because relatively slow dimerization 
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and receptor uncoupling reduces the ability of ligand bound monomers to sequester 
monomers that are not occupied by ligand into receptor dimers which are asymmetric in 
the receptor ligand occupancy. Thus, this alteration generates increased unoccupied 
receptor monomers, which are free to bind cetuximab efficiently without any alteration to 
the cetuximab cycling rate.  
 IC50 sensitivity analysis. To identify other processes that determine therapeutic 
efficacy, we repeated our IC50 calculations for a series of perturbations to individual 
model parameters.  This sensitivity analysis suggests that the IC50 for gefitinib in the 
presence of 1.6 nM EGF ( gEIC ,50 ) is most sensitive to perturbations in the parameters for 
ATP binding (kA,f and kA,r), gefitinib binding (kg,f and kg,r), EGFR phosphorylation within 
ligand-bound dimers (kp,L), and EGFR dephosphorylation in the cell interior (kdp,i) (Figure 
4-4A).  Sensitivity to perturbations in ATP and gefitinib binding parameters is anticipated 
because these parameters directly control the competition between ATP and gefitinib.  
Sensitivity to kdp,i and kp,L arises because of the importance of cycles of receptor 
dephosphorylation and rephosphorylation in setting steady receptor phosphorylation 
levels.  The relative insensitivity to perturbations in dephosphorylation of EGFR at the 
cell surface (kdp,s) is observed because at steady-state and in the presence of 1.6 nM EGF 
the model predicts that most phosphorylated EGFR is localized to the cell interior.  
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Figure 4-4: Local sensitivity analysis to identify determinants of IC50 values for 
gefitinib and cetuximab. 
(A and B) Sensitivity of the therapeutic concentration at which steady-state receptor 
phosphorylation is reduced to half-maximal (IC50) to perturbations of 10-fold in each of 
the model parameters was computed for (A) gefitinib or (B) cetuximab.  Sensitivities 
were reported as the absolute value of the difference in the logarithm of the base IC50 and 
the perturbed IC50 values and then normalized to the maximum. This analysis was 
performed for 1.6 nM EGF, 1.6 nM AR, and 160 nM AR. 
 
Repeating our analysis for 1.6 nM AR revealed that the gefitinib IC50 for that case 
( gAIC ,50 ) is predicted to be sensitive to perturbations in the binding constants of ATP and 
gefitinib but relatively insensitive to perturbations in kp,L and kdp,i.  Relative to EGF, AR 
reduces the driving force for dimer formation by reducing receptor occupancy. This 
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impairs phosphate cycling which decreases sensitivity of gAIC ,50  to kp,L and kdp,i.  
Increasing the AR concentration to 160 nM increases sensitivity of gAIC ,50  to perturbations 
in the rate constants for ligand-receptor association and dissociation (kL,f and kL,r, 
respectively), kp,L and kdp,i (Figure 4-4A), because this change increases dimer formation 
by roughly 30-fold. 
 The IC50 for cetuximab in the presence of 1.6 nM EGF (
cEIC ,50 ) is predicted to be 
most sensitive to perturbations in kL,f and kL,r, the rate constants for EGFR-cetuximab 
binding (kc,f and kc,r), and the rate constant for EGFR internalization (ki) (Figure 4-4B).  
Cetuximab competition with ligand for binding to EGFR results in sensitivity to 
cetuximab-EGFR and EGF-EGFR binding parameters.  cEIC ,50  is sensitive to ki because 
this parameter controls EGFR distribution between the cell surface and the cell interior 
and cetuximab may only bind EGFR at the cell surface. Unlike gEIC ,50 , 
cEIC ,50  is not 
sensitive to perturbations in kp,L, kdp,s or kdp,i due to the mechanisms by which gefitinib or 
cetuximab reduce or prevent EGFR phosphorylation.  Gefitinib antagonizes EGFR 
phosphorylation by directly interrupting phosphate cycling within dimers, while 
cetuximab antagonizes EGFR phosphorylation by preventing receptor from even forming 
dimers (Figure 4-1B).  cEIC ,50  is insensitive to kp,L, kdp,s and kdp,i because cetuximab can 
only indirectly disrupt dimer-mediated phosphate cycling by preventing receptor 
monomers from binding ligand and dimerizing. Thus, relatively slow dephosphorylation 
process is sufficient to reduce receptor phosphorylation in this context. 
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For 1.6 nM AR ( cAIC ,50 ), we observe sensitivity only to the cetuximab binding 
parameters (Figure 4-4B).  Relative insensitivity of cAIC ,50  to AR binding parameters is 
because EGFR occupancy by AR is so low that perturbations in AR-receptor binding 
constants cannot promote AR-cetuximab competition for binding to EGFR. Unlike cEIC ,50
, cAIC ,50  is relatively insensitive to perturbations in ki, because impaired occupancy in the 
context of this AR concentration promotes less EGFR internalization compared to EGF.  
Increasing the AR concentration sensitizes cAIC ,50  to ligand binding and trafficking 
parameters, such that the sensitivity profiles for cAIC ,50  and 
cEIC ,50  were nearly identical 
(Figure 4-4B), because this change increases receptor occupancy (which promotes AR-
cetuximab competition) and increases receptor dimer formation and phosphorylation 
(which promotes receptor internalization). 
Kinetics of therapeutic-mediated reduction in EGFR phosphorylation. As is 
suggested by some of the results already discussed (e.g., Figure 4-3C), many of the 
differences in the IC50 determinants between gefitinib and cetuximab arise because the 
kinetics with which phosphorylated receptors become dephosphorylated (and then 
eventually rephosphorylated) in the presence of the drugs directly influences IC50.  At 
least part of these differences are due to the differential abilities of these drugs to 
antagonize the phosphorylation of receptors that have already bound ligand and become 
phosphorylated.  The general dependence on these kinetics arises because of the 
smallness of time scales for the reversible processes considered here relative to other 
process time scales for the receptor (e.g., time scales for trafficking).  Differences in 
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those kinetics, which again give rise to differential IC50 behaviors for the two drugs, can 
be observed in certain calculations of the kinetic response of EGFR phosphorylation to 
specific perturbations.  For example, the relative insensitivity of cetuximab IC50 to the 
rate of dephosphorylation can be further understood by using the model to predict the 
kinetics of receptor dephosphorylation that would be observed if cells were treated with 
gefitinib or cetuximab after an initial pulse of EGFR ligand.   
 
 
Figure 4-5: Predicted dynamics of ligand-therapeutic pulse-chase. 
(A-D) The model was used to predict the percent of phosphorylated EGFR (pEGFR) 
observed in response to a 5 min treatment with (A) 1.6 nM EGF, (B) 1.6 nM EGF, (C) 
1.6 nM AR, or (D) 160 nM AR, followed by a chase with 1 μM gefitinib or cetuximab. 
For (B), the internalization rate constant (ki) was set to zero at t = 0 min for all conditions 
and the rate constants for ligand-receptor association and dissociation (kL,f and kL,r, 
respectively) were increased by 10
2
 for the cetuximab condition at t = 5 min. 
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We thus simulated a 5 min pulse of EGF chased with 1 μM gefitinib or cetuximab 
(Figure 4-5A). Gefitinib produces a much more rapid reduction in EGFR phosphorylation 
than cetuximab as indicated by the time scales for gefitinib- and cetuximab-mediated 
reduction in phosphorylated EGFR (t50), which we calculated to be 0.2 and 11 min, 
respectively.  These differences are explained by the notion that, in the presence of EGF, 
cetuximab functions by locking the receptor into a state that is multiple mechanistic steps 
away from EGFR phosphorylation and is in competition with the relatively slow 
processes of dimer uncoupling and ligand dissociation (Figure 4-1B).  In contrast, 
gefitinib locks the receptor into a state that is fewer mechanistic steps away from 
phosphorylation and is only in competition with the relatively fast process of ATP 
dissociation (Figure 4-1B).  Thus, competition with slower processes that are additional 
mechanistic steps away from phosphorylation results in slower cetuximab-mediated 
reductions in phosphorylated EGFR compared to gefitinib.  Consistent with this, reducing 
EGFR internalization, to ensure access of EGFR to cetuximab, and increasing ligand 
cycling, which also promotes dimer uncoupling, results in nearly identical t50 values 
between gefitinib and cetuximab (Figure 4-5B). 
For equimolar AR compared to EGF, receptor phosphorylation is significantly 
lower prior to simulated addition of therapeutic due to decreased receptor occupancy by 
ligand. However, the time scales for therapeutic-mediated reduction in EGFR 
phosphorylation were similar for both therapeutics because AR cycles more rapidly 
compared to EGF (Figure 4-5C).  To account for differential occupancy, we repeated the 
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pulse-chase simulation with 160 AR which increased receptor phosphorylation prior to 
addition of therapeutic. Interestingly, time scales for therapeutic-mediated reduction in 
EGFR phosphorylation remained similar due to the rapid ligand cycling in the context of 
AR (Figure 4-5D).  The reduction in EGFR phosphorylation is not complete in this 
context because some receptors were internalized, and therefore unable to bind cetuximab 
consistent with the need to impair internalization in order to force similarity in the t50 
values (Figure 4-5B).  
t50 sensitivity analysis.  In some cancer cells, mutated or over-expressed 
oncoproteins may promote both pro- and anti-apoptotic signaling.  According to the 
theory of “oncogenic shock,” treatment of these cells with targeted therapeutics induces 
cell death especially well in cases where apoptotic signaling persists longer than survival 
signaling in response to therapeutic administration (154, 155).  Thus, in addition to an 
ability to reduce receptor phosphorylation at steady state, the functional ability of a 
therapeutic to kill cancer cells may depend upon the time scale with which a therapeutic 
reduces receptor phosphorylation.  To identify the processes that influence this time 
scale, we examined the sensitivity of t50 to perturbations in model parameters (Figure 4-
6). For the sake of simplicity we will not discuss processes that have already been 
discussed in the context of our steady-state sensitivity analysis because these processes 
control dynamics for similar reasons. 
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Figure 4-6: Local sensitivity analysis to identify determinants of the time scale with 
which therapeutics lead to EGFR dephosphorylation. 
(A and B) Sensitivity of the time after simulated therapeutic addition at which receptor 
phosphorylation was reduced to half-maximal (t50) to perturbations of 10-fold in each of 
the model parameters was computed for (A) gefitinib or (B) cetuximab.  Sensitivities 
were reported as the absolute value of the difference in the logarithm of the base t50 and 
the perturbed t50 and then normalized to the maximum. This analysis was performed for 
1.6 nM EGF, 1.6 nM AR, and 160 nM AR. 
 
For 1.6 nM EGF and gefitinib, t50 (
gEt ,50 ) is sensitive to perturbations in kdp,s and 
kdp,i, kp,L, kA,f and kA,r, kg,f and kg,r, ki, and parameters for GRB2-EGFR binding (kG2,f and 
kG2,r) (Figure 4-6A). 
gEt ,50  sensitivity to GRB2 binding and internalization parameters is 
observed because GRB2 binding protects phosphotyrosines from dephosphorylation and 
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the endosome compartment is characterized by different kinetics for processes involved 
in receptor phosphorylation, respectively.  With 1.6 nM AR, gefitinib t50 (
gAt ,50 ) is 
sensitive to kdp,s, kdp,i and kG2,f and kG2,r (Figure 4-6A).  Compared to 
gEt ,50 , 
gAt ,50  is 
insensitive to perturbations in kp,L because of impaired dimer formation.  For 160 nM AR, 
gAt ,50  is sensitive to perturbations to kdp,s, kA,f, kA,r, kg,f, and kg,r (Figure 4-6A).  Even for 
increased AR, dimer formation is impaired compared to EGF due to more rapid EGFR-
AR dissociation. This leads to reduced sensitivity to phosphorylation and 
dephosphorylation processes because these processes are most important in the context of 
phosphate cycling within receptors dimers. 
For cetuximab and 1.6 nM EGF, t50 (
cEt ,50 ) is sensitive to kL,f and kL,r, kdp,s and kdp,i, 
ki, and the rate constant for EGFR exit from the endosome compartment (kx) (Figure 4-
6B).  Unlike cEIC ,50 , 
cEt ,50  is sensitive to perturbations in dephosphorylation parameters 
because this process directly controls the rate at which cetuximab-mediated reduction in 
EGFR phosphorylation occurs.  Thus, in the context of oncogenic shock, kdp,s and kdp,i 
may be important determinants of cetuximab efficacy despite insensitivity of cEIC ,50 to 
perturbations in these parameters.  cEt ,50  is sensitive to perturbations in ki and kx because 
these parameters control EGFR distribution between the cell interior and cell surface, 
where EGFR-cetuximab binding occurs. For 1.6 nM AR, cetuximab t50 (
cAt ,50 ) is sensitive 
to kdp,s kc,f, kg,f, kg,r, the rate constant for EGFR dimerization in the cell interior (kd,fi), and 
kdp,i (Figure 4-6B). Since AR-EGFR dissociation is more rapid than EGF-EGFR, 
dephosphorylation instead of ligand dissociation rate-limits cetuximab-mediated 
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reduction in EGFR phosphorylation. Sensitivity to perturbations in parameters that 
influence unoccupied dimer phosphorylation (kd,fi and kdp,i) is because ligand-mediated 
EGFR phosphorylation accounts for a smaller fraction of total EGFR phosphorylation.  
Increasing the AR concentration to 160 nM leads to sensitivity of cAt ,50  to perturbations in 
ligand-receptor binding parameters, kc,f, GRB2 binding parameters, kd,fi, 
dephosphorylation parameters and ki. Increasing the AR concentration promotes receptor 
internalization, which protects EGFR from cetuximab binding and increases the 
importance of ki and kdp,i. Since 160 nM AR compared to 1.6 nM EGF promotes dimer 
uncoupling, cAt ,50 compared to 
cEt ,50  is more sensitive to kd,fi and kL,fi and kL,ri. 
Predicted effects of gefitinib and cetuximab in combination. Results from the 
IC50 and t50 sensitivity analyses clearly support the notion that gefitinib- and cetuximab-
mediated reductions in EGFR phosphorylation are achieved through different 
mechanisms and controlled by different processes, suggesting that co-treatment might be 
more effective than treatment with either therapeutic alone. To test this, we simulated 
steady EGFR phosphorylation in the presence of varying concentrations of both 
therapeutics. The model predicted that for a particular concentration of cetuximab or 
gefitinib, addition of increasing concentrations of the other therapeutic further decreased 
steady EGFR phosphorylation in the presence of 1.6 nM EGF, 1.6 nM AR, or 160 nM 
AR (Figure 4-7A-C).  
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Figure 4-7: Effects of gefitinib and cetuximab co-treatment. 
(A-C) The model was used to predict the steady-state percent of phosphorylated EGFR 
(pEGFR) as a function of cetuximab and gefitinib concentrations for (A) 1.6 nM EGF, 
(B) 1.6 nM AR, or (C) 160 nM AR. (D-F) Synergy, defined as the reduction in receptor 
phosphorylation resulting from co-treatment minus the reductions in receptor 
phosphorylation following treatment with each therapeutic alone, was calculated as a 
function of cetuximab and gefitinib concentrations for the same ligand concentrations as 
in (A-C). (G-I) To estimate therapeutic efficiency, pEGFR (A-C), synergy (D-F) and the 
logarithm of the sum of the drug concentrations were scaled to each range between 0 and 
1 and then summed for all drug combinations. Based on this definition, therapeutic 
efficiency is highest for low pEGFR, high synergy, and low amount of drug.  
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To explore the possibility that co-treatment could produce synergistic effects, we 
calculated the difference between the reduction in receptor phosphorylation resulting 
from co-treatment and the sum of the reductions in phosphorylation achieved using each 
therapeutic alone (Figure 4-7D-F).  Co-treatment is not predicted to be synergistic, as 
indicated by negative values for each therapeutic concentration combination.  Negative 
values result from at least some receptors being bound by both therapeutics. As expected, 
our estimates of therapeutic synergy were highest for the lowest concentrations of 
therapeutic, where the likelihood that a single EGFR species would be bound by both 
therapeutics is lowest. The optimal co-treatment concentrations of each therapeutic would 
be those that maximize synergy and minimize receptor phosphorylation while using the 
least amount of drug.  We estimated these regimes (Figure 4-7G-I) by scaling pEGFR 
(Figure 4-7A-C), synergy (Figure 4-7D-F) and the logarithm of the total amount of drug 
to range between 0 and 1 and then summing these quantities for each combination of 
therapeutic. Based on this metric, therapeutic efficiency is highest for low phosphorylated 
EGFR, high synergy, and low drug amount. For 1.6 nM EGF, therapeutic efficiency is 
highest for ~10
3
 nM cetuximab and an arbitrarily low concentration of gefitinib because 
cEIC ,50  < 
gEIC ,50  (Figure 4-2A and 4-2B). Treatment with AR compared to EGF results in 
larger maxima in therapeutic efficiency due to lower IC50s in this context (Figure 4-2A 
and 4-2B). For all three ligand conditions, more therapeutic combinations that involve 
higher cetuximab than gefitinib concentrations exhibit high efficiency due to cEIC ,50  < 
gEIC ,50  and 
cAIC ,50  < 
gAIC ,50  (Figure 4-2).  
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4-5  DISCUSSION 
We quantified the receptor-level processes that contribute to the efficacy of the 
EGFR-targeted therapeutics gefitinib and cetuximab in mediating reductions in EGFR 
phosphorylation in the presence of the EGFR ligands EGF and AR.  A key conclusion of 
our study is that the antagonism of EGFR phosphorylation achieved by these therapeutics 
is influenced not only by equilibrium considerations related to the binding affinities of 
EGFR-targeted therapeutics and the molecules with which they compete, but also by 
relative magnitudes of time scales of kinetic processes which compete with one another 
to determine the ability of these therapeutics to reduce EGFR phosphorylation levels. 
Several studies have noted differences among cell lines expressing wild-type 
EGFR in the efficacy of EGFR-targeted therapeutics.  For example, an IC50 based on a 
metabolic assay performed after 3 days of treatment with gefitinib varied nearly 3 orders 
of magnitude among head and neck squamous cell carcinoma (HNSCC) cell lines (156). 
This study goes on to demonstrate that neither variation in the levels of proteins including 
EGFR, AKT, and ERK nor the mutational status of EGFR correlated with variations in 
IC50.  Our results suggest that differential expression of other proteins might account for 
this variation, including phosphatases and/or EGFR ligands.  For IC50 measured in the 
same way (except for a gefitinib treatment of 6 days), another study used microarray data 
to determine a genetic signature for gefitinib sensitivity or resistance using a panel of 11 
EGFR wild-type expressing NSCLC cell lines that varied in IC50 by 2 orders of 
magnitude (157). Many genes were identified in this analysis. Notably, the phosphatase 
PTPRG was upregulated in the context of resistance, which is consistent with our 
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repeated identification of EGFR dephosphorylation as an important determinant of 
gefitinib efficacy.  While, to our knowledge, there has not been a study that examines the 
ability of PTPRG to dephosphorylate EGFR, the general notion that phosphatases are 
perturbed in multiple cancers is supported by numerous studies (15).  Interestingly, 
another study demonstrates that the cell growth response to separate gefitinib and 
cetuximab treatments varied by nearly an order of magnitude among cell lines expressing 
wild-type EGFR in a manner that correlated with expression of AR (140). Consistent 
with this, our analysis of determinants of gefitinib IC50 identified EGFR-AR association 
(Figure 4-4A), which can be modulated by variation in AR concentration.  It should be 
noted that variability in EGFR phosphorylation after drug treatment has also been 
observed among cell lines expressing wild-type EGFR, which is more applicable to our 
simulated IC50s for reduction in EGFR phosphorylation. For example, the amount of 
gefitinib and cetuximab, separately, required to reduce EGFR phosphorylation can vary 
as much as 10-fold between H1819 and H1299 cells (137) and 5-fold in DiFi and A431 
cells (138).  While the processes that account for this variation have not been identified, 
our work provides strong evidence for multiple candidates. 
In addition to the processes already mentioned above, our study suggests that 
variation in therapeutic-receptor binding and EGFR internalization can affect therapeutic 
efficacy. Interestingly, perturbation of these processes in cells has been observed in the 
context of drug resistance. For example, EGFR
T790M
 confers cellular resistance to 
gefitinib treatment and is characterized by decreased gefitinib-receptor binding and 
increased ATP-receptor binding (158). Gefitinib-EGFR binding also could vary among 
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cell lines that express wild-type EGFR via differential action of drug transporters, which 
regulate the intracellular concentration of small-molecule therapeutics (159).  Cetuximab-
EGFR binding can be perturbed via mutation of the EGFR extracellular domain which 
can also confer cetuximab resistance (160). In a previous study, we elucidated a 
resistance mechanism in which cells characterized by increased EGFR internalization 
were also characterized by a roughly 10-fold higher irreversible EGFR kinase inhibitor 
IC50 for reducing EGFR phosphorylation (145). While it is unknown how these two 
observations relate mechanistically, these findings are consistent with our identification 
of EGFR internalization as an important determinant of therapeutic efficacy. Similarly, 
resistance to cetuximab has been shown to correlate with increased EGFR ubiquitination 
(161), which might also be related to an increase in EGFR internalization (36). In 
contrast, another study reported that cetuximab-resistant cells are characterized by 
impaired EGFR internalization which is inconsistent with our model (162). 
Our sensitivity analyses generally identified the kinetics of EGFR 
dephosphorylation as important in determining gefitinib- and cetuximab-mediated 
reduction in EGFR phosphorylation (Figure 4-6).  This finding is consistent with the 
understanding that neither gefitinib nor cetuximab can directly reverse EGFR tyrosine 
phosphorylation. Rather, these therapeutics function by disrupting EGFR phosphorylation 
processes, which tips the balance toward dephosphorylation and a reduction in 
phosphorylated EGFR.  Therapeutic efficacy is predicted to be sensitive to the kinetics of 
this process because these drugs do more than just sequester free, unphosphorylated 
receptor away from the process that leads to receptor phosphorylation.  Due to the 
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reversibility of all steps considered here, an important aspect of how these drugs work is 
to antagonize the phosphorylation of receptors which have already been phosphorylated.  
Interestingly, multiple protein tyrosine phosphatases (PTPs) have been shown to be 
altered in ways that either positively or negatively affect PTP activity in the context of 
different cancers (15). Some of these PTPs have been shown to dephosphorylate EGFR, 
including: LRP (64), LAR (64), DEP1 (71), PTPRK (63), PTPRS (62), PTP1B (57), 
TCPTP (68), SHP1 (66), and PTP-PEST (72). Of particular significance, PTPRS was 
recently shown to be deleted in 26% of tumor samples from a cohort of HNSCC patients 
(82). Tumor samples characterized by PTPRS deletion were also characterized by 
increased EGFR and AKT phosphorylation compared to normal tissue. Furthermore, 
PTPRS knockdown promoted ligand-independent EGFR phosphorylation in HNSCC cell 
lines (MDA-584 and FaDu) and increased the resistance of cells to treatment with the 
EGFR TKI erlotinib in HNSCC and NSCLC cell lines (HCC827 and H3255, 
respectively). Low PTPRS expression was also predictive of poor prognosis in lung 
adenocarcinoma patients with TKI-sensitizing EGFR mutations.  Taken together, these 
results support our finding that EGFR dephosphorylation is an important process in the 
context of EGFR-targeted therapeutics and that perturbation to EGFR dephosphorylation 
can affect EGFR-targeted therapeutic efficacy. Going forward, mechanistic studies 
should address whether the correlations between PTPRS expression and therapeutic 
efficacy are indeed due to reduced EGFR dephosphorylation rates and their effect on 
AKT phosphorylation or PTPRS-mediated dephosphorylation of another protein target.  
To do this, it would be important to first demonstrate that overexpression of PTPRS can 
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reduce EGFR-mediated AKT signaling and increase cellular sensitivity to EGFR-targeted 
therapeutics.  In the same cells, expression of a constitutively active kinase upstream of 
AKT but downstream of EGFR, such as PI3 kinase, should reduce the ability of PTPRS 
expression to affect AKT phosphorylation and cellular sensitivity. 
In general, our findings suggest that the efficacy of cetuximab, more so than 
gefitinib, is a function of the identity and concentration of available ligands since 
cetuximab competes with ligand for EGFR binding.  Interestingly, the relative levels of 
mRNA encoding the EGFR ligands AR, betacellulin, epigen, epiregulin, EGF, heparin-
binding EGF-like growth factor, and transforming growth factor alpha were shown to 
vary within a panel of gastric and colon cancer cell lines (163). This supports the 
possibility that variability in the response to cetuximab among patients could be 
explained by differential expression of EGFR ligands. This hypothesis is generally 
consistent with the observation that overexpression of ErbB ligands correlates with 
cellular resistance to cetuximab (164).  However, this effect was attributed to EGFR 
nuclear localization and not increased competition of cetuximab with EGFR ligands for 
EGFR binding as our simulations suggest. Additional experimental study is needed to 
explore the degree to which different EGFR ligands influence the efficacy of EGFR-
targeted therapeutics. 
We predicted that gefitinib and cetuximab co-treatment could be efficacious 
(Figure 4-7) due to the difference in the mechanism by which these therapeutics reduce 
EGFR phosphorylation (Figure 4-1B).  This finding is consistent with experimental 
results demonstrating that co-treatment of A431 cells with gefitinib and cetuximab 
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further reduces EGFR phosphorylation compared to treatment with either therapeutic 
alone (165).  In addition, cetuximab was found to benefit NSCLC patients for whom 
gefitinib treatment had not been effective (166).  Lastly, an analysis of a panel of NSCLC 
cell lines revealed that some cell lines characterized by sensitivity to gefitinib were not 
sensitive to treatment with cetuximab (152). These experimental findings are consistent 
with our conclusion that different receptor-level processes determine gefitinib and 
cetuximab therapeutic efficacy. Perhaps the most striking difference between gefitinib 
and cetuximab in our simulations is the time scales with which the therapeutics mediate a 
reduction in EGFR phosphorylation in the context of EGF (Figure 4-5A). Thus, one 
explanation for the experimental observation of differential sensitivity to gefitinib and 
cetuximab is that a relatively rapid reduction in EGFR phosphorylation is required to 
induce the imbalance between pro-apoptotic and pro-survival signaling known as 
“oncogenic shock” (155). This would make gefitinib more effective than cetuximab at 
inducing apoptosis in cells dependent upon EGFR signaling. 
In general, our analysis suggests that therapeutic efficacy is determined by a 
variety of receptor-level processes, making it inaccurate to assume that a therapeutic will 
be effective in a cellular context simply because it is characterized by a relatively low KD 
for its protein target. The notion that IC50 values may be determined by different 
processes in the context of different ligand/therapeutic pairs argues for the study of 
EGFR-targeted therapeutics in the context of multiple EGFR ligands, rather than the 
predominantly-used EGF. More broadly, this work suggests that variation in any of the 
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processes identified herein as determinants of IC50 or t50 may account for variation in the 
response of cancer patients to EGFR-targeted therapeutics. 
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Chapter 5 : Diversity in Dimerization Topologies Enables 
Differential Control of Receptor Tyrosine Kinase 
Phosphorylation Dynamics 
 
5-1  ABSTRACT 
Within the receptor tyrosine kinase (RTK) super-family there is natural diversity 
in mechanisms leading to RTK dimerization, but the impact on receptor-mediated 
signaling is not well understood.  Using parameters from studies of epidermal growth 
factor receptor (EGFR) and considering effects of ligand binding, receptor dimerization, 
and receptor phosphorylation and dephosphorylation, we developed computational 
models to compare the effects of dimerization through direct extracellular receptor-
receptor contacts (receptor-mediated dimerization, RMD) or through indirect receptor-
receptor interactions facilitated by an interposed bivalent ligand (ligand-mediated 
dimerization, LMD).  We found that the LMD topology enables different and complex 
regulatory modes of signaling versus RMD, and that this complexity depends upon 
differences in time scales for ligand binding, dimerization, and receptor 
dephosphorylation.  Versus RMD, the LMD topology: 1. enables non-monotonic 
phosphorylation dynamic response to ligand binding; 2. favors an amplification process 
wherein a single receptor-ligand binding event produces more than two phosphorylated 
receptors within the time scale for receptor dephosphorylation; and 3. generates greater 
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phosphorylation sensitivity to changes in receptor expression at sub-saturating ligand 
concentrations and to changes in preformed receptor dimer abundance.  Thus, different 
dimerization mechanisms may allow RTKs to initiate signaling in very different ways, 
and our models provide a framework for exploring this complexity. 
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5-2  INTRODUCTION 
Ligand binding to the extracellular domains of some receptor tyrosine kinases 
(RTKs) promotes RTK oligomerization (3).  Receptors may oligomerize as dimers, as in 
the case of the fibroblast growth factor receptor and epidermal growth factor receptor 
(EGFR), or as higher order complexes, as has been suggested for receptors such as TIE2 
and Eph receptor (25, 167-171).  For TIE2, for example, the multimeric and multivalent 
receptor ligand angiopoietin-1 may promote the formation of tetrameric TIE2 (169, 170).  
Ultimately, these oligomerization processes promote the phosphorylation of cytoplasmic 
receptor tyrosines that bind intracellular adapter proteins and thereby couple receptors to 
intracellular signaling pathways (1).  Structural studies have revealed that RTK 
oligomerization is generally mediated by: direct contacts between receptors; indirect 
receptor-receptor interaction facilitated by interposed multivalent ligands; or a 
combination of these mechanisms (3).  While many aspects of RTK-mediated signaling 
have been studied in detail, the extent to which these different oligomerization 
mechanisms may account for differences in receptor-mediated signaling dynamics among 
RTKs remains unclear. 
 Perhaps the most common form of receptor oligomerization is dimerization.  The 
well-studied RTKs EGFR and tropomyosin-related kinase A (TrkA) exemplify two 
mechanistic extremes of this process (Figure 5-1) (3).  EGFR undergoes a receptor-
mediated dimerization (RMD) process in which direct contacts occur between receptor 
domains that become preferentially accessible after monovalent ligand binding (25, 168).  
Conversely, TrkA undergoes a ligand-mediated dimerization (LMD) process wherein 
139 
 
receptors do not form direct extracellular receptor-receptor contacts but instead dimerize 
around the bivalent ligand nerve growth factor (NGF) (3, 172, 173).  Interestingly, EGFR 
dimers have been identified at the cell surface in the absence of ligand in Ba/F3 (174) and 
NIH3T3 cells (175).  Similarly,  TrkA dimers have been observed in the absence of 
ligand in PC12 cells (176), and pre-formed oligomers containing at least two TrkA  
receptors have been observed in xenopus oocytes (177).  How these dimers arise and 
what role they play in receptor-mediated signaling is unclear. 
Numerous computational models of receptors characterized by RMD have been 
developed to dissect the dynamics of receptor-mediated signaling.  EGFR has been 
particularly well-studied, including focused investigation of the roles of receptor 
dephosphorylation (89), receptor internalization (97), signal-branching (99), and 
activation of downstream pathways (98),  Receptors characterized by LMD have not been 
the focus of similarly extensive computational efforts.  The relatively few available 
computational models for TrkA have focused on downstream signaling (e.g., (178)) 
without considering the mechanistic details of LMD.  Perhaps the model that most 
thoroughly explores the implications of LMD is the general bivalent ligand/monovalent 
receptor model developed by Perelson and coworkers (179), which showed that ligand 
binding promotes receptor dimerization at sub-saturating ligand concentrations but 
reduces the number of receptor dimers at saturating ligand concentrations.  This model 
focuses solely on dimer formation, without consideration of how LMD might exert 
unique control over receptor phosphorylation. 
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To investigate the consequences of RMD versus LMD for receptor 
phosphorylation, we developed two mechanistic models of receptor phosphorylation 
dynamics that differ only in receptor dimerization mechanism and additionally consider 
the effects of ligand binding, receptor dimerization, and receptor phosphorylation and 
dephosphorylation.  The models use identical parameters based on studies of EGFR, 
including our recent model-based quantitation of EGFR tyrosine dephosphorylation, 
which occurs with a time scale of less than one minute (89).  For the LMD model, 
differences among the time scales for ligand binding, receptor dimerization, and receptor 
dephosphorylation allow for a competition between ligand binding and dimerization to 
arise which can antagonize steady receptor phosphorylation and produce non-
monotonicity in dynamic phosphorylation response to ligand binding.  Differences 
among these time scales also preferentially enable the LMD system to amplify the effects 
of a single ligand-receptor binding event to produce more than two phosphorylated 
receptors within the time scale for receptor dephosphorylation.  Furthermore, the LMD 
model demonstrates a greater degree of receptor phosphorylation sensitivity to changes in 
receptor expression at sub-saturating ligand concentrations and greater sensitivity to the 
presence of preformed receptor dimers.  Thus, our study points to the possibility that 
diversity in dimerization mechanisms may generate important differences in signaling 
initiation capacity among different RTKs and provides a basis for developing testable 
predictions to explore this possibility. 
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Figure 5-1: Receptor-mediated dimerization (RMD) and ligand-mediated 
dimerization (LMD) model topologies 
RMD occurs through direct extracellular receptor-receptor interactions that are stabilized 
by the binding of monovalent ligand to receptors.  LMD occurs through indirect receptor-
receptor interactions facilitated by an interposed bivalent ligand, around which the 
receptors dimerize.  In both cases, receptor dimerization promotes phosphorylation (P) of 
a representative tyrosine (Y) present in the cytoplasmic tail of the receptor.  Symbols for 
parameters describing various receptor processes are indicated in the figure and are 
defined in Table 1. 
 
 
Table 5-1: Model parameters. 
parameter  description value reference 
kL,f  ligand association 1×10
2
 μM-1·min-1 (125) 
kL,r  ligand dissociation 1×10
-1
 min
-1
 KD (100) 
kd,f  receptor coupling 1×10
-3
 cell·min
-1
 (89) 
kd,r  receptor uncoupling 1×10
1
 min
-1
 (85) 
kcat  phosphorylation 1×10
1
 min
-1
 (101) 
kdp  dephosphorylation 1×10
0
 min
-1
 (89) 
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5-3  METHODS 
Model topology and scope.  The RMD and LMD models are comprised of sets of 
coupled ordinary differential equations to describe the kinetics of reversible reactions for 
ligand-receptor binding, receptor dimerization, and receptor tyrosine phosphorylation and 
dephosphorylation, based upon mass-action assumptions.  Phosphorylation at a single 
representative tyrosine is assumed to occur within ligand-bound dimers.  
Dephosphorylation is treated as a first order process with respect to phosphorylated 
receptor species that occurs with the kinetics we previously measured for EGFR (89).  
The sole difference between the models is the mechanism for receptor dimerization 
(Figure 5-1).  In the RMD model, two ligand-bound receptors are required to form a 
single receptor dimer via direct receptor-receptor contacts.  In the LMD model, 
dimerization requires one receptor bound to a dimeric ligand and one empty receptor.  
Models were solved using MATLAB with SBToolBox2 (111). 
Simplifying assumptions. To minimize the number of differential equations in 
each model, we assumed that: 1. the soluble ligand concentration was constant; 2. ligand 
could not dissociate from ligand-bound dimers without the dimers first uncoupling; and 
3. all receptor species were ready to participate in a phosphorylation reaction once 
dimerized (i.e., ATP and its binding to receptors was not explicitly considered).  To 
further simplify the models, receptor trafficking and binding of intracellular adapter 
proteins to receptors were not considered. 
Model parameters. Parameters were based on order-of-magnitude estimates from 
previous studies for EGFR, as summarized in Table 1.  The value of the rate constant for 
143 
 
dephosphorylation of EGFR (kdp) is taken from a previous publication in which we 
quantified the rate at which EGFR Y1068 cycles between phosphorylated and 
unphosphorylated states (~1 min
-1
) (89).  Thus, the RMD and LMD models take into 
account experimental evidence for cycling of RTK phosphotyrosines between 
phosphorylated and unphosphorylated states over time scales smaller than commonly 
assumed.  The speed of this process relative to other receptor processes produces some of 
the interesting complexity discussed herein.  The same set of parameters was used for 
both models so that the source of model output differences could only be attributed to 
differences in the dimerization topology.  Unless otherwise noted, receptor expression 
was assumed to be 100,000 cell
-1
. 
Receptor coupling and uncoupling. In the RMD model, receptor coupling 
(dimerization) and uncoupling parameters describe the reversible association between 
two ligand-bound receptors via receptor-receptor contact.  In the LMD model, the same 
receptor coupling and uncoupling parameters describe the reversible association between 
one ligand-bound and one empty receptor with contacts occurring only between receptors 
and the interposed ligand.  Thus, for comparisons using identical parameters, there is an 
inherent assumption that the interaction between a ligand-bound receptor and a free 
receptor in the LMD model occurs with the same kinetics as the interaction between two 
ligand-bound receptors in the RMD model. 
Calculation of R50.  To quantify the sensitivity of steady-state ligand-initiated 
receptor phosphorylation to changes in receptor expression levels, we computed the 
receptor expression level for which 50% of maximum steady-state receptor 
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phosphorylation was achieved for a specific ligand concentration.  This receptor 
expression level is defined as the R50. 
Preformed receptor dimers. In both models, preformed receptor dimers were 
treated as dimeric complexes that could not dissociate into monomers.  As with other 
receptor species, these complexes were permitted to bind ligand reversibly, become 
phosphorylated, and be dephosphorylated. 
Sensitivity analysis. The sensitivity of predicted receptor phosphorylation 
response to ligand addition to changes in model parameters was calculated by computing 
the fold-change in model output for 10-fold perturbations to individual parameter values, 
with summation over 0 ≤ t ≤ 10 min.  Sensitivity was reported as the sum of the fold 
change in model output for a 10-fold increase and a 10-fold decrease in that parameter. 
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5-4  RESULTS 
Dynamics and steady-states of ligand-mediated receptor phosphorylation.  
For calculations shown as a function of time, it is convenient to show results for a limited 
number of ligand concentrations (L).  We will thus define three values of L relative to the 
dissociation constant for ligand binding to the receptor (KD).  “Low,” “medium,” or 
“high” L is defined as L/KD = 10
-2
, L/KD = 10
0
, or L/KD = 10
2
, respectively.  As expected 
for the RMD model and as generally described elsewhere, receptor phosphorylation rates 
and phosphorylation levels increase with L due to increased rate of ligand binding and 
increased receptor occupancy (Figure 5-2A).  For LMD, initial receptor phosphorylation 
rates uniformly increase with increasing L, but at high L a non-monotonic dynamic 
response of receptor phosphorylation to ligand is observed which results in an eventual 
antagonism of receptor phosphorylation versus medium L (Figure 5-2B).  This non-
monotonicity in receptor phosphorylation versus time for LMD does not require an L as 
high as 100-fold in excess of Kd, and the factors that contribute to this effect are 
discussed in detail later.  For now, it suffices to comment that this occurs because 
sufficiently high L antagonizes dimerization in the LMD model.  This notion is 
qualitatively consistent with previous models of receptor complex formation for bivalent 
ligands (179). 
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Figure 5-2: Dynamic and steady-state receptor phosphorylation. 
(A and B) The percent of total receptor that is phosphorylated (pR) was calculated as a 
function of time for the indicated ligand concentrations (L) with the (A) receptor-
mediated dimerization (RMD) and (B) ligand-mediated dimerization (LMD) models. (C) 
The steady-state percentage of total receptor that is phosphorylated (solid lines) or ligand-
bound (dashed lines) was calculated as a function of L.  The value of the dissociation 
constant for ligand binding to the receptor (KD) is shown by the dashed vertical line. 
 
Differences between RMD and LMD can also be explored by comparing steady 
receptor phosphorylation and ligand-occupancy as a function of L.  For RMD, steady-
state levels of phosphorylation and occupancy increase monotonically with L (Figure 5-
2C), as expected.  The percentages of total receptor occupied by ligand or phosphorylated 
are roughly equal until L ≈ KD.  At this point, receptor phosphorylation reaches a plateau, 
and ligand binding continues to occur.  The difference between the two plateaued 
percentages of ligand-bound and phosphorylated receptors is a result of the 
dephosphorylation kinetics considered in our model.  While not easily seen in Figure 5-
2C, the dephosphorylation process maintains an excess of ligand-bound compared to 
phosphorylated receptors of at least ~15% for all L for RMD.  For LMD, the percentage 
of total receptor phosphorylated increases up to L = KD, but decreases beyond that point 
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as occupancy continues to increase (Figure 5-2C).  Interestingly, for LMD, the percent of 
receptor phosphorylated is greater than the percent occupied for low L, for reasons 
discussed later.  As L increases above KD and receptor occupancy exceeds ~80%, 
receptor phosphorylation decreases.  This is because ligand binds receptors uncoupling 
from dimers, which antagonizes dimerization as free receptors become limiting thereby 
slowing the phosphorylation rate.  L = KD represents a maximum in receptor 
phosphorylation because this L results in 50% occupancy of the receptor monomers not 
incorporated into receptor dimers, which maximizes dimer formation rate.  Note that 
receptor occupancy is > 50% for L = KD due to our assumption that ligand only 
dissociates from receptor monomers. 
Amplification of phosphorylation. In Figure 5-2C, we noted that LMD allows 
for the percent of phosphorylated receptor to exceed that for occupied receptor at 
sufficiently low L.  This occurs because of a process of “amplification,” which we define 
as the ability of the minimum number of ligands required to form a dimer (two for RMD, 
one for LMD) to induce steady phosphorylation of more than two receptors.  For LMD, 
this can occur if a single ligand-bound monomer dimerizes with and phosphorylates 
multiple empty receptors within the time scale for dephosphorylation (Figure 5-3A).  For 
RMD, this can occur if a phosphorylated dimer uncouples, ligands dissociate, and 
dissociated ligands bind to and induce the phosphorylation of two other receptors before 
the original receptors are dephosphorylated (Figure 5-3A).  To determine the extent of 
amplification, we computed the amount of phosphorylated receptor (pR) per bound ligand 
(Lb) at steady-state for both models over a range of L (Figure 5-3B).  According to our 
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definition, amplification occurs if pR/Lb > 2 for LMD (two phosphorylated receptors per 
bound ligand) or if pR/Lb > 1 for RMD (two phosphorylated receptors per two bound 
ligands).  For LMD,  amplification is promoted by lower L because the process depends 
upon a relative abundance of free receptors.  For the base model parameters and LMD, 
pR/Lb increases to a maximum of ~7 as L decreases (Figure 5-3B).  We note that the 
degree to which receptor phosphorylation exceeds occupancy in Figure 5-2C may appear 
inconsistent with a pR/Lb as high as ~7.  This apparent discrepancy is explained by 
recalling that an LMD dimer consists of two occupied receptors and one bound ligand.  
Thus, the ratio of phosphorylated receptor to occupied receptor for LMD (which can be 
estimated from data shown in Figure 5-2C) is two-fold lower than pR/Lb for the same 
conditions.  For RMD, amplification does not occur for the base model parameters 
(although it is possible for it to occur), as indicated by a pR/Lb that increases with L but 
does not exceed unity (Figure 5-3B).  Amplification is not observed here because by the 
time ligand dissociates from one uncoupled dimer and induces dimerization and 
phosphorylation of two other receptors, the initially-phosphorylated receptors are 
dephosphorylated. This limitation does not affect amplification in the context of LMD 
because LMD amplification is not dependent upon ligand-receptor unbinding and 
rebinding. 
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Figure 5-3: Phosphorylation amplification. 
(A) For ligand-mediated dimerization (LMD), amplification occurs when a ligand-bound 
receptor dimerizes with and phosphorylates multiple empty receptors within the time 
scale for receptor dephosphorylation.  For receptor-mediated dimerization (RMD), 
amplification occurs when a phosphorylated dimer uncouples, ligands dissociate, and 
dissociated ligands bind to and induce the phosphorylation of two other receptors before 
the original receptors are dephosphorylated. (B) The steady-state ratio of the number of 
phosphorylated receptors to the number of bound ligands (pR/Lb) was calculated as a 
function of ligand concentration (L) for the base model parameters (solid lines) or for a 
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10
5
-fold reduction (relative to the base parameters) in the receptor dimer uncoupling rate 
constant (kd,r) (dashed lines).  (C and D) pR/Lb was calculated with the (C) LMD and (D) 
RMD models as a function of ligand concentration and for the indicated values of the rate 
constant for receptor dephosphorylation (kdp). 
 
Based on the preceding discussion, it is clear that dimer uncoupling and 
dephosphorylation exert control over amplification.  Consistent with this, dramatically 
decreasing the rate constant for dimer uncoupling (kd,r) by a factor of 10
5
 relative to the 
base parameter value in Table 1 eliminates amplification in the LMD model, as indicated 
by  pR/Lb < 2 for all L (Figure 5-3B).  By promoting dimerization, decreased kd,r also 
increases pR/Lb at a lower L with the RMD model compared to the base parameters, but 
the maximum pR/Lb is unchanged.  Also consistent with our discussion, reducing the rate 
constant for receptor dephosphorylation (kdp) increases the extent of amplification 
observed for LMD (Figure 5-3C).  A sufficiently small  kdp also permits amplification 
over a short range of low L in the RMD model, as indicated by  pR/Lb > 1 (Figure 5-3D).  
Even with decreased kdp, amplification disappears with increasing L in the RMD model as 
receptors become saturated and pR/Lb > 1 becomes increasingly difficult to achieve.  We 
note finally that if amplification occurs as described above, a reduced kdp should not 
promote amplification if dimer uncoupling is impaired.  Indeed, reducing kd,r by a factor 
of 10
5
 relative to the base parameters eliminates amplification in both models regardless 
of the value of kdp (Figure S5-8A and S5-8B, respectively). 
Peak formation in receptor phosphorylation dynamics. To explain the 
formation of peaks in receptor phosphorylation versus time with LMD (as observed in 
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Figure 5-2B), we propose the model shown schematically in Figure 5-4A.  Upon ligand 
addition, dimers begin to form and receptor phosphorylation is induced.  As the supply of 
empty monomeric receptors is depleted, dimerization and phosphorylation slow to a point 
where phosphorylation and dephosphorylation occur at the same rate (d(pR)/dt = 0).  
Beyond this point, receptor dephosphorylation becomes the faster overall process as 
dimers break apart and ligand binds the free receptors produced by dimer uncoupling, 
preventing dimers from reforming.  This proposed mechanism requires a number of 
things to be true about the relative time scales for ligand binding, receptor dimerization, 
and receptor phosphorylation and dephosphorylation.  For example, receptors must 
become maximally bound by ligand more slowly than dimerization can occur because 
this difference in time scales enables receptor phosphorylation to temporarily achieve a 
higher level of phosphorylation than is sustainable.  Receptor dephosphorylation must 
also occur more quickly than occupied and free receptors can dimerize once free 
receptors become limiting. 
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Figure 5-4: Transient peak formation in receptor phosphorylation with the ligand-
mediated dimerization (LMD) model. 
(A) A schematic is shown to demonstrate the kinetic processes which lead to the non-
monotonic receptor phosphorylation dynamics predicted by the LMD model.  Ligand 
binding initially promotes receptor phosphorylation by promoting dimer formation and 
receptor phosphorylation that is fast enough to overcome receptor dephosphorylation.  As 
empty receptor monomers become scarce, the rate of phosphorylation slows and is 
balanced by the rate of dephosphorylation, forming a maximum in the percent of total 
receptors that are phosphorylated (pR).  At this point, ligand continues to bind receptors 
that uncouple from receptor dimers, reducing the number of free receptor available to 
participate in dimer formation and allowing dephosphorylation to reduce pR.  (B-D) pR 
was calculated with the LMD model as a function of time after introduction of 10
-1
 μM 
ligand and for specific alterations to parameters relative to the base values (Table 1; 
“base” curve).  In panel (B), curves are shown for: a decrease in the rate constant for 
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ligand-receptor association (kL,f) of 10
2
-fold (blue); an increase of kL,f of 10
5
-fold and 
decrease of the rate constant for ligand-receptor dissociation (kL,r) of 10
5
-fold (red); 
increases of 10
5
-fold for kL,f and kL,r (green).  In panel (C), curves are shown for: an 
increase in the rate constant for receptor dimerization (kd,f) of 10
5
-fold and decrease of the 
rate constant for dimer uncoupling (kd,r) of 10
5
-fold (blue); and decreases in kd,f and kd,r of 
10
2
-fold (red).  In panel (D), curves are shown for: a decrease in the rate constant for 
receptor dephosphorylation (kdp) of 10
2
-fold (blue); and decreases in kdp and the rate 
constant for receptor phosphorylation (kcat) of 10
1
-fold (red). 
 
To test our proposed model, we explored a number of changes to model 
parameters versus the values given in Table 1 for an L well in excess of the base value of 
KD.  As shown in Figure 5-4B, a number of different changes to the kinetics of ligand 
binding can eliminate non-monotonic phosphorylation dynamics.  A sufficient reduction 
in the rate constant for ligand binding to receptor (kL,f) eliminates peak formation for the 
simple reason that free receptors can no longer become limiting (i.e., KD is increased 
above L).  Increasing kL,f and decreasing the rate constant for ligand dissociation (kL,r) 
results in receptors becoming virtually instantaneously and irreversibly bound by ligands, 
which eliminates the ability for phosphorylation to occur at all.  As a final example of 
ligand-associated changes, we note that sufficient increases in both kL,f and kL,r without 
changing KD can also eliminate peak formation because the time scale for receptor 
equilibration with ligand becomes smaller than that for dimerization.  Thus, even with L 
in excess of KD, it is possible for peaks not to arise.  As shown in Figure 5-4C, sufficient 
and similar reductions of kd,f and kd,r (i.e., without changing the affinity of dimerization) 
eliminate peak formation by slowing dimerization relative to ligand binding.  Increasing 
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kd,f and reducing kd,r also results in a high level of phosphorylation with monotonic 
dynamics since this parametric change makes dimer formation less reversible.  Finally, in 
Figure 5-4D, we show that sufficient reduction of kdp, either with or without a similar 
fold-change in kcat, results in monotonic phosphorylation dynamics as the time scale for 
dephosphorylation becomes large compared to that for dimers to reform.  
 Sensitivity of steady-state phosphorylation to changes in receptor expression.  
We next explored the sensitivity of steady receptor phosphorylation to changes in 
receptor expression for the two dimerization topologies.  For calculations at a particular 
L, steady-state receptor phosphorylation was normalized to the maximum receptor 
phosphorylation value, which occurs at the highest receptor expression level and changes 
with L.  For both models, increased receptor expression promotes phosphorylation due to 
the second-order dependence of dimerization rate on receptor monomer concentration 
(Figure 5-5A and 5-5B).  For RMD (Figure 5-5A), increasing L sensitizes receptor 
phosphorylation to increased receptor expression by increasing the fraction of receptors 
bound by ligand.  Sensitivity to changes in L vanishes roughly when L becomes > KD and 
receptors are saturated with ligand.  For LMD (Figure 5-5B), steady receptor 
phosphorylation is also sensitized to increased receptor expression for an increase from 
low to medium L (for the same reason as the RMD model), but is desensitized to 
increased receptor expression by further increases to high L as the limited availability of 
empty receptors antagonizes phosphorylation rates. 
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Figure 5-5: Effect of receptor expression on steady receptor phosphorylation. 
(A and B) Using the (A) receptor-mediated dimerization (RMD) and (B) ligand-mediated 
dimerization (LMD) models, the steady-state percentage of total receptor that is 
phosphorylated (pR) was calculated as a function of receptor expression per cell for the 
indicated ligand concentrations (L) and then normalized to the maximum pR value for a 
particular L.  (C) The number of receptors per cell required to achieve half-maximal 
receptor phosphorylation (R50) was plotted as a function of ligand concentration.  The 
value of the dissociation constant for ligand binding to the receptor (KD) is shown by the 
dashed vertical line. 
 
To quantify the sensitivity of steady phosphorylation to changes in receptor 
expression in a different way, we calculated the number of receptors required to reach 
50% of the maximum receptor phosphorylation (R50) as a function of L (Figure 5-5C).  
R50 is thus a reflection of the sensitivity of steady receptor phosphorylation to changes in 
receptor expression.  For RMD, increasing L decreases R50, but this effect vanishes as L 
becomes larger than KD and receptors are saturated with ligand.  For LMD, R50 decreases 
with increasing L for L < KD and increases with increasing L for L > KD, reflecting a need 
for increased receptor expression to counteract the antagonistic effects of higher L.  
Comparing the models, R50 for RMD exceeds that for LMD at lower L, reflecting that 
receptor phosphorylation is a more efficient process for LMD than RMD when free 
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receptors are not limiting.  We note as well that the magnitude of d(R50)/dL is larger for 
RMD than LMD for lower L.  This is observed because an incrementally larger L 
increases the abundance of both species required for RMD, while the same increase in L 
only increases the abundance of one of the species required for LMD. 
Effects of preformed receptor dimers on dynamic and steady receptor 
phosphorylation. Given experimental evidence for the existence of preformed dimers for 
RTKs including EGFR and TrkA (174-177), we investigated how the presence of 
preformed receptor dimers (PFDs) affects receptor phosphorylation for RMD and LMD.  
Increasing the fraction of receptors present as PFDs leads to a negligible increase in  
phosphorylation for RMD (Figure 5-6A) but has a striking effect for LMD (Figure 5-6B).  
While PFDs promote receptor phosphorylation in both models by stabilizing dimers, they 
also provide protection from the antagonistic effect of excess ligand in the LMD model, 
leading to the substantially larger sensitivity to PFDs for LMD.  Increasing PFDs also 
reduces and eventually eliminates the extent of non-monotonic receptor phosphorylation 
dynamics for LMD. 
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Figure 5-6: Effect of preformed receptor dimers on receptor phosphorylation. 
(A and B) Using the (A) receptor-mediated dimerization (RMD) and (B) ligand-mediated 
dimerization (LMD) models, the percentage of total receptor that is phosphorylated (pR) 
was calculated as a function of time for the indicated percentages of total receptors 
present as preformed receptor dimers (PFDs) and a ligand concentration of 1 μM.  (C and 
D) Using the the (C) RMD and (D) LMD models, steady-state pR was calculated as a 
function of ligand concentration (L) for the indicated percentages of total receptors 
present as PFDs. 
 
To further explore the effect of PFDs, we computed steady receptor 
phosphorylation as a function of L and the fraction of receptors present as PFDs.  As with 
the dynamic simulations, the effect of PFDs on steady phosphorylation is smaller for 
RMD than for LMD (Figs. 4-6C and 4-6D, respectively).  This difference is most 
158 
 
pronounced at high L, where PFDs provide protection against ligand-mediated 
antagonism of phosphorylation.  Interestingly, increasing the abundance of PFDs slightly 
impairs phosphorylation for lower L in the LMD model (Figure 5-6D) because an 
inability of dimers to uncouple there antagonizes the amplification process, which is 
maximized at lower L (Figure 5-3B). 
Model sensitivity analysis. Sensitivity of model-predicted receptor 
phosphorylation response to ligand (low or high L for 10 min) to perturbations of 10-fold 
in the model parameters was assessed with both models (Figure 5-7).  For low L, the 
RMD model is more sensitive than the LMD model to perturbations in nearly all 
parameters (Figure 5-7A).  This is observed because receptor phosphorylation is so 
severely impaired with RMD at low L that even small perturbations can significantly 
affect phosphorylated receptor levels.  The only parameter that was more sensitive in the 
LMD compared to the RMD model was kdp, due to the role dephosphorylation plays in 
the amplification process.  Both RMD and LMD models are most sensitive to changes in 
kL,f, because the availability of ligand-bound monomers limits phosphorylation for both 
models.  While a decrease in kL,r could also promote ligand binding to the receptor, the 
models are less sensitive to this parameter because perturbations to this parameter do not 
affect receptor phosphorylation within the 10 min timeframe of the simulation.   
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Figure 5-7: Sensitivity analysis. 
(A and B) Model-predicted sensitivity of phosphorylated receptor levels over a 10 min 
ligand treatment to perturbations of 10-fold in the indicated model parameters (see Table 
1 for definitions) and the receptor expression level (R0) was calculated for ligand 
concentrations of (A) 10
-5
 μM or (B) 10-1 μM using the receptor-mediated dimerization 
(RMD) and ligand-mediated dimerization (LMD) models. 
 
At high L (Figure 5-7B), ligand saturation of receptors leads to reduced sensitivity 
of the RMD model to changes in ligand binding and dimerization parameters relative to 
what was observed at low L. For high L and RMD, receptor phosphorylation remains 
fairly sensitive to perturbations in kcat and kdp since ligand saturation has no effect on 
these processes, both of which directly influence receptor phosphorylation many times 
within the 10 min time scale of our sensitivity calculations. For LMD, receptor 
phosphorylation is relatively sensitive to perturbations in all parameters, consistent with 
our previous observations that ligand binding, dimerization, phosphorylation and 
dephosphorylation time scales influence peak formation in receptor phosphorylation in 
response to high L in the LMD model. 
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5-5  DISCUSSION 
Receptor dimerization is an important step in the activation of downstream 
signaling processes for RTKs such as EGFR, TrkA, and FGFR (3).  While the structural 
basis for dimerization has been well-studied for some receptors, the implications of 
different topological dimerization schemes for receptor phosphorylation dynamics have 
not been thoroughly explored.  Here, we developed two mechanistic models to explore 
the effects of an RMD versus LMD topology on receptor phosphorylation, motivated by 
EGFR and TrkA as examples of these different mechanisms, respectively.  We find that 
RMD and LMD are generally characterized by very different steady and time-dependent 
phosphorylation profiles in response to ligand, resulting mainly from an intrinsic 
antagonistic effect of ligand at sufficiently high L that free receptors become limiting and 
from altered competition between process time scales that arise for the different 
dimerization topologies.  Our models utilize a common set of parameters, based upon 
studies of EGFR.  Our results thus delineate possibilities for how differences in 
dimerization may enable important differential control over receptor-mediated signaling, 
without any definitive comparative implications for specific RTKs versus EGFR. 
Importantly, both models assume that receptors undergo dephosphorylation with a 
time scale of less than one minute, based upon our previous experimental observations 
and modeling work for EGFR in HeLa cells (89).  While the smallness of this time scale 
is not widely appreciated, it is important to comment on here because its size relative to 
other process time scales is strongly determinative of receptor phosphorylation dynamics 
predicted by our models.  Indeed, both amplification (Figure 5-3) and non-monotonic 
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receptor phosphorylation dynamics for LMD (Figure 5-4) exhibited significant sensitivity 
to perturbations in kdp. Thus, our study also explores the differential role that relatively 
rapid dephosphorylation might play in the context of ligand-initiated phosphorylation of 
RTKs characterized by different dimerization schemes.  Of course, it remains an open 
question whether or not the kinetics we previously determined for EGFR 
dephosphorylation apply to other RTKs, including those that utilize an LMD mechanism 
such as TrkA.  Answering this question for particular RTKs, with either dimerization 
topology, will be an important component of utilizing these models in a predictive 
capacity. 
Our consideration of realistic rates of receptor dephosphorylation also enabled the 
simulation of antagonism of receptor phosphorylation at saturating ligand concentrations 
with the LMD model.  Antagonistic effects of various kinds have been noted in previous 
computational and experimental studies involving bivalent ligands.  For example, the 
binding of bivalent haptens to bivalent IgEs was computationally predicted to produce 
non-monotonic oligomer formation as a function of ligand concentration through 
competition between hapten-IgE binding and hapten-mediated IgE chain formation in a 
process analogous to our predictions with the LMD model (180).  Another study 
demonstrated experimentally that treatment of human basophils with bivalent hapten 
resulted in non-monotonic histamine release consistent with their model, which 
considered ligand-receptor binding and receptor complex formation (180, 181).  These 
findings may provide experimental support for the general notion that saturating 
concentrations of a bivalent ligand could mediate a reduction in an output of receptor 
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activation.  However, it is important to recognize that such results could also be explained 
by a number of other possibilities, including the increased expression or activity of 
negative regulators of histamine release at high hapten concentrations.   
In previous experimental studies, TrkA phosphorylation in PC12 cells was found 
to increase monotonically with ligand concentration for 20 min treatments with  0.5, 5, or 
50 ng/mL NGF (182), which corresponds to 0.02, 0.2, or 2 nM NGF, respectively 
(assuming wild-type dimeric β-NGF with a molecular weight of 26 kDa (183)).  Values 
of KD,NGF from multiple studies range from 10
-10
 - 10
-11
 M (0.1 - 0.01 nM) (183-186).  To 
compare our model to these experimental results, we set kL,f = 5×10
1
 μM-1min-1, 
consistent with measurements of NGF-TrkA binding (187), and kL,r such that KD,NGF = 
10
-10
 M and used the LMD model to calculate receptor phosphorylation as a function of 
time for L = 0.02, 0.2, or 2 nM.  Interestingly, the LMD model predicts that, for these 
parameters, receptor phosphorylation increases monotonically with L for t = 20 min 
(Figure S5-9).  Non-monotonic variation in receptor phosphorylation with L was only 
observed for t > 50 min, which is outside the times for which TrkA phosphorylation was 
reported in the study by Chang et al. (182)  Thus, these published experimental results are 
qualitatively consistent with our model predictions.  However, even with the relatively 
simple accounting of receptor processes in our models, our calculations suggest the 
possibility that this monotonic response to increasing L may not have been observed for 
longer times after ligand addition. 
In another study, ligand-mediated EGFR and TrkA phosphorylation in PC12 cells 
were compared as a function of time for EGF and NGF concentrations ranging from 0.5 - 
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50 ng/mL, which correspond to 0.08 - 8 nM for EGF or 0.02 - 2 nM for NGF (178).  Both 
ligand concentration ranges spanned the KD values for the respective receptors, but peaks 
were formed in both EGFR and TrkA phosphorylation after less than 10 min of treatment 
with L ≥ KD.  Our relatively simple models would predict peak formation for TrkA 
(LMD) with sufficiently high L only, but not for EGFR (RMD).  A potential explanation 
for this inconsistency is that processes not included in our models, but that reduce EGFR 
phosphorylation (and possibly that of TrkA as well), such as ligand-mediated receptor 
internalization (3, 188), receptor degradation (39, 189), or induction of receptor 
phosphatase activity, might significantly influence receptor phosphorylation dynamics.  
Receptor internalization might contribute to peaks in phosphorylation response due to 
translocation of receptors to the endosome, where ligand binding is generally less favored 
due to a more acidic environment (44, 45).  Peaks in EGFR and TrkA phosphorylation 
could also potentially result from ligand-mediated receptor degradation, but the time 
scale for that process for both receptors is probably too large for this effect to account for 
peaks observed less than 10 min after the addition of ligand (39, 189).  Finally, ligand-
mediated induction of phosphatase activity downstream of each receptor would result, in 
the context of our models, in an increased kdp as a function of time, which could also 
clearly contribute to peaks in receptor phosphorylation.  Interestingly, ligand-mediated 
activation of EGFR and TrkA has been shown to induce activity of the phosphatases 
SHP2 and PTP1B, respectively (115, 190).  However, relatively little is known about 
these processes and how they might affect receptor phosphorylation.   
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Overall, our results suggest that differences in dimerization mechanisms among 
RTKs could account for significant diversity in receptor phosphorylation response to 
ligand.  In living cells, the ligand concentration regimes over which the phenomena 
discussed here (e.g., amplification, formation of peaks in receptor phosphorylation as a 
function of time) would be observed would be a function of multiple variables, including 
the rate constants in Table 1.  These are likely to be quite different for different 
receptor/ligand pairs and across different cell types.  These issues notwithstanding, the 
results of our relatively simple models point to the general conclusion that, compared to 
RMD, the LMD topology enables a greater degree of complexity in the regulation of 
receptor phosphorylation in response to ligand binding and a greater degree of sensitivity 
to changes in kinetic parameters. 
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5-7  SUPPLEMENTAL MATERIAL 
 
 
Figure S5-8: Amplification and dimer uncoupling. 
(A and B) The steady-state ratio of the number of phosphorylated receptors to the number 
of bound ligands (pR/Lb) was calculated as a function of ligand concentration (L) for the 
indicated values of the dephosphorylation rate constant (kdp) with the (A) ligand-mediated 
dimerization (LMD) and (B) receptor-mediated dimerization (RMD) models. These 
calculations were made with a receptor dimer uncoupling rate constant 10
5
-fold lower 
than the base value. 
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Figure S5-9: Qualitative comparison of model to published data. 
The percent of total receptor that is phosphorylated (pR) was calculated as a function of 
time for the indicated ligand concentrations (L) with the ligand-mediated dimerization 
(LMD) model. To match the experimental conditions described in the Discussion section, 
we set kL,f = 5×10
1
 μM-1min-1, an experimentally measured value, and kL,r such that 
KD,NGF was equal to the experimentally measured value of 10
-10
 M. The 20 min time point 
from the experiment is indicated by the dashed vertical line. 
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Chapter 6 : Implications and Conclusions   
 
6-1  INTRODUCTION 
One of the most important findings of this thesis is that, at least in some cells, 
EGFR dephosphorylation can occur with a timescale of ~10 s regardless of EGFR 
cellular localization (Chapters 2 and 3).  This dephosphorylation process represents one 
step of a relatively rapid cycling process of regulatory receptor tyrosines between 
phosphorylated and unphosphorylated states (“phosphate cycling”; see Chapter 2). The 
computational and experimental approaches used to measure EGFR phosphate cycling 
also constitute a general framework with which phosphate cycling of other proteins can 
be quantified. Our quantification of dephosphorylation kinetics has significant 
consequences even for processes that were thought to be relatively well understood. For 
example, for protein tyrosine phosphatases (PTPs) to access phosphotyrosines on the 
relatively small time scales we identify, adapter proteins that bind EGFR 
phosphotyrosines, and consequently protect them from dephosphorylation (191), must 
also cycle relatively rapidly between bound and unbound states (“association cycling”; 
see Chapter 3). Importantly, association cycling with a relatively small timescale was 
recently demonstrated for the adapter protein GRB2 binding to phosphorylated EGFR 
(123). The notion of association cycling directly contradicts the common view that 
EGFR-adapter protein complexes formed by interactions between adapter SH2/PTB 
domains and EGFR phosphotyrosines persist for relatively long time scales. Instead, our 
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data are consistent with the hypothesis that protein complexes involving EGFR 
phosphotyrosines are cycling between different conformations with relatively small 
timescales (< 1 s for GRB2; Chapter 3). This update to the textbook understanding of a 
“signaling complex” is supported by another recent study (192), and has significant 
implications (193). Here, we discuss implications of some of our findings and suggest 
directions for future studies. 
 
6-2  POST TRANSLATIONAL MODIFICATION CYCLING 
While our data clearly support the notion of cycling of EGFR phosphotyrosines 
multiple times each minute after the addition of exogenous ligand, the rate to which 
phosphoresidues on other proteins cycle between phosphorylated and unphosphorylated 
states is unknown. Interestingly, a study by Pan and coworkers (194) used a mass 
spectrometry-based phosphoproteomic approach to quantify phosphorylation of proteins 
in mouse hepatoma cells after a 10 min treatment with pervanadate (to reduce PTP 
activity) and calyculin A and deltamethrin (to reduce serine/threonine phosphatase 
activity). The study found that phosphorylation of 70% of tyrosines predicted to be 
phosphorylation sites were increased at least two-fold by treatment with these inhibitors, 
compared to only 41% and 26% of predicted threonine and serine phosphorylation sites, 
respectively. The study by Pan and coworkers supports the hypothesis that 
phosphorylation of most tyrosines is basally suppressed by the action of PTPs. However, 
a phosphorylation site is identified by this analysis only if processes that mediate this 
sites phosphorylation in the presence of the phosphatase inhibitor cocktail are fast enough 
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to promote phosphorylation within the 10 min timeframe of the experiment. Thus, 
phosphorylation sites might only be revealed by this type of analysis in the presence of a 
specific stimulus. Based on this observation, a similar approach involving treatment of 
cells with stimulatory ligand either with or without the phosphatase inhibitor cocktail for 
a relatively short (e.g., 1 min) period of time would be more appropriate for identification 
of proteins that are characterized by relatively rapid ligand-mediated tyrosine phosphate 
cycling. Even for this redesigned approach, careful follow-up experiments should be 
performed to rule out false positives, which would most likely be due to proteins whose 
increased phosphorylation compared to control was due to increased activation of 
upstream kinases by the phosphatase inhibitor treatment.  
The finding by Pan and coworkers that serine and threonine residues become 
phosphorylated in the presence of serine/threonine phosphatase inhibitors may also 
support the hypothesis that a smaller fraction of serine/threonine residues compared to 
tyrosine residues may also undergo relatively rapid phosphate cycling (194). In addition 
to performing a nearly identical study to that described above for tyrosine phosphate 
cycling, we also propose a study very similar to our work in Chapters 2 and 3 to quantify 
serine/threonine phosphate cycling of a candidate protein. For this study, we suggest the 
transforming growth factor beta (TGFβ) receptor as a model system due to its similarities 
to EGFR. For example, TGFβ receptor undergoes ligand-mediated oligomerization that 
results in phosphorylation of intracellular serine residues, linking the receptor to 
downstream signaling (195) and internalization (196).  Also, TGFβ receptor-mediated 
signaling plays an important role in multiple areas of human health through its mediation 
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of the epithelial to mesenchymal transition, which is a differentiation program that plays 
a key role in cancer metastasis (197) and cellular sensitivity to EGFR-targeted therapy 
(198). As with EGFR, pharmacological inhibitors of the TGFβ receptor kinase have been 
developed and characterized (e.g., SB-431542 (199)), which are useful tools for the study 
of receptor phosphate cycling (Chapter 2). Finally, significant study has led to multiple 
estimates of the kinetics for processes involved in TGFβ-mediated signaling (200), 
enabling mechanistic modeling of this system. The study should follow the approaches 
outlined in Chapters 2 and 3 to first quantify the rate of TGFβ receptor dephosphorylation 
in different cellular compartments and then explore how this dephosphorylation affects 
downstream receptor phosphorylation-dependent processes.  
Our findings in Chapters 2 and 3 support a critical role for PTPs in regulating 
some EGFR-mediated processes via dephosphorylation of the receptor. However, 
determining the identities of the PTPs responsible for this regulation remains an 
important area of investigation. Specifically, it is important to identify the PTPs that 
regulate EGFR in the context of EGFR mutations that promote ligand-independent EGFR 
phosphorylation (e.g., EGFR
L858R
). It is unknown if the same subset of PTPs regulate the 
wild-type and mutant receptor. While aberrant EGFR phosphorylation is commonly 
attributed to increased kinase activity in the context of EGFR mutants (201), the 
possibility that disregulated PTP activity contributes in this context has not been directly 
addressed. One possible though technically challenging way to identify the subset of 
PTPs that regulates a given tyrosine substrate would involve first generating a library of 
substrate trapping PTP mutants, which lack intrinsic catalytic activity but retain an ability 
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to bind their substrates (202, 203).  Instead of highly transient, PTP-substrate interactions, 
substrate-trapping PTPs form stable association with their substrates. Using a display 
technique, such as ribosome display (204), to link the DNA to the protein it encodes, 
libraries of substrate-trapping PTPs could be screened for interaction with an 
immobilized substrate of interest, such as a peptide corresponding to an EGFR 
phosphorylation site. A screen performed in this way would suggest candidates for the 
subset of PTPs that dephosphorylate a given substrate. Follow up experiments would then 
determine if the set of candidate PTPs corresponded to the PTPs responsible for 
regulating that substrate in cells. Unfortunately, a library of substrate-trapping PTPs has 
not yet been created, to our knowledge, and generation of such a library would be 
technically intensive. 
While experimental evidence supports the notion of that phosphorylated residues 
cycle between phosphorylated and unphosphorylated states, the rate of cycling of other 
post-translational modifications (PTMs) has not be measured. In the context of EGFR, we 
would argue that the highest priority for a quantitative study of the cycling of a PTM 
other than phosphorylation is ubiquitination due to its importance in regulating EGFR 
internalization (33, 132, 205), which influences receptor-mediated signaling (34, 46, 47) 
and the cellular response to EGFR inhibitors (48-50, 145). If receptor deubiquitination 
were found to occur at the cell surface with a time scale that is small relative to the time 
scale for EGFR internalization, this would suggest that deubiquitinases might exert 
control over receptor internalization. A similar regulatory relationship between a 
modification required for internalization and a negative regulator of that modification 
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was argued for phosphorylation and PTPs (51). However, our study described in Chapter 
3 clearly argues against this finding. Thus, a study that examines ubiquitin cycling and 
control of internalization by deubiquitination should consider the possibility that 
deubiquitinases may not act rapidly enough to slow EGFR internalization, as we found 
for PTPs (Chapter 3). However, some of the protein-protein associations between 
activated EGFR and coated pit proteins are mediated by ubiquitination (e.g., Epsin1 (33)) 
suggesting that ubiquitination, unlike phosphorylation, may remain important for EGFR 
internalization after EGFR becomes recruited to a clathrin-coated pit. This suggests that 
the time scale over which deubiquitination is able to slow EGFR internalization may be 
significantly larger than our estimate of the time scale over which PTPs are able to slow 
EGFR internalization. In general, these observations support a study focused on 
quantifying the rate at which deubiquitinases deubiquitinate a particular substrate, which 
could be determined using a quantitative framework similar to that present in Chapter 3.  
However, it is important to note that assessing the importance of ubiquitination in 
processes such as EGFR internalization has been particularly difficult due to technical 
limitations in detecting ubiquitination (34, 36). 
 
6-3  DYNAMICS OF PROTEIN-PROTEIN ASSOCIATION 
One implication of relatively rapid EGFR phosphate cycling is that association 
between EGFR and proteins that bind EGFR phosphotyrosines (referred to here as 
binding partners) must also cycle between associated and unassociated states relatively 
rapidly for PTPs to access EGFR phosphotyrosines with the necessary time scales. This 
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implication is supported by measurements of the kinetics of EGFR-GRB2 binding (123), 
which suggest that, for a specified GRB2 cellular concentration (85), EGFR cycles 
between GRB2-bound and -unbound states in less than 1 s (Chapter 3). A recent study 
demonstrated that, as a consequence, the time scale with which GRB2 diffuses away 
from membranes containing phosphorylated EGFR is significantly larger than the time 
scale for GRB2-EGFR dissociation (192). This is explained by the finding that once 
GRB2 dissociates from a particular phosphorylated EGFR it then preferentially rebinds to 
an adjacent phosphorylated EGFR ~20 times before diffusing away into the cytosol. 
Thus, phosphorylated receptors may be able to maintain an increased concentration of 
SH2- or PTB-domain containing proteins in a boundary layer near the plasma membrane. 
This hypothesis is generally supported by a study from our lab by Furcht and coworkers 
(49) which demonstrated that impaired internalization of phosphorylated EGFR can 
sequester activated SHP2 at the plasma membrane (49).  
Together, these findings suggest that the relationship between protein diffusion 
and protein rebinding might have important consequences for cellular processes. 
Quantitatively, this relationship can be assessed by evaluating a ratio of the time scales 
for binding partner diffusion and receptor-binding partner association. Considering the 
similarity of this ratio to the well-known dimensionless Damköhler number (a ratio of 
reaction and diffusion rates) we refer to this ratio as Da. For Da << 1, where diffusion 
over a particular length scale is much more rapid than receptor-binding partner 
association, binding partner diffusion is not perturbed by association with a 
phosphorylated receptor. For Da >> 1, where diffusion is slow compared to receptor-
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binding partner association, the binding partner will preferentially associate with a 
receptor instead of diffusing away. Based on this and in cells, Da should increase with 
increasing exogenous ligand concentration or with activating receptor mutations since 
these changes promote receptor phosphorylation which would decrease the receptor-
binding partner time scale. Conversely, increased PTP activity, which would reduce 
phosphorylated receptor and increase the time scale for binding partner-receptor 
association, should decrease Da. 
The findings by Furcht and coworkers (49) raise an interesting question: When a 
receptor translocates, such as during EGFR internalization, do receptor-bound proteins 
also translocate? The answer to this question is related to the relative rates of the involved 
processes. Consider a single phosphorylated receptor and a single protein binding partner 
that interacts with the receptor via a phosphorylated receptor residue. At t = 0, the 
receptor and the binding partner are placed next to one another and the receptor begins 
translocating with constant velocity (vtrans). For this discussion, the relevant time scale 
(ttrans) is the time it takes the translocating receptor to move a distance equal to the 
interaction radius between the receptor and the binding partner (s), such that ttrans = 
s/vtrans. If the receptor is able to move s before the receptor and binding partner associate, 
then the receptor will leave the binding partner behind during translocation. However, if 
the binding partner is able to rebind before the receptor moves s the binding partner 
would be carried, at least briefly, by the translocating receptor. 
Some experimental studies suggest that receptors are indeed able to mediate 
translocation of binding partners. For example, the E3 ubiquitin ligase CBL, which 
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associates with EGFR directly via a PTB domain and indirectly via the adapter protein 
GRB2, was suggested to remain associated with EGFR during the internalization process 
(32). However, these data do not rule out the possibility that instead of remaining 
associated to the same CBL molecule, EGFR may unbind and bind many different CBL 
molecules throughout the trafficking process. Also, the hypothesis presented by Furcht 
and coworkers suggests that EGFR internalization is able to mediate the redistribution of 
activated SHP2 to the cell interior during receptor internalization (49). Lastly, EGFR 
internalization was shown to be required for STAT3 translocation to the nucleus and 
STAT3-mediated gene regulation (206). Assuming that binding partner association with 
the receptor is rapid such that a receptor can indeed mediate phosphorylation-dependent 
translocation of a binding partner, PTPs could potentially regulate this processes. For 
example, sufficiently rapid receptor dephosphorylation kinetics could result in receptor 
dephosphorylation before the binding partner was able to bind, allowing the receptor to 
move s without any association taking place. Thus, increased PTP activity would 
decrease the effective s or decrease the association time scale required for receptor-
mediated binding partner translocation. 
Based on this discussion we suggest two hypotheses: 1. PTPs control the ability of 
phosphorylated receptors to sequester adapter proteins near the plasma membrane, and 2. 
PTPs control the ability of receptor internalization to mediate binding partner 
relocalization.  Testing the first hypothesis could utilize techniques such as those used to 
explore the kinetics of GRB2-EGFR association, specifically total internal reﬂection 
(TIR) microscopy (192).  We would recommend beginning with experiments in which 
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the time a protein spends near the plasma membrane (dwell time (192)) is measured with 
EGF alone, with inhibition of PTPs, or with overexpression of a cytoplasmic EGFR PTP.  
If PTPs control EGFR-mediated binding partner sequestration, we would hypothesize 
that PTP inhibition would increase binding partner dwell time, while PTP overexpression 
would reduce binding partner dwell time. To test the second hypothesis, we would build 
on the study by Bild and coworkers, which demonstrated that EGFR internalization was 
required for appearance of STAT3 in a nuclear fraction prepared from cell lysates (206). 
Repeating this measurement in the presence of PTP inhibitors or overexpression of an 
EGFR PTP would determine if PTPs are capable of regulating receptor-mediated 
translocation of STAT3 to the nucleus. If PTPs control this process, PTP inhibition would 
increase the amount of STAT3 appearing in a nuclear fraction, while inhibition of 
internalization should reduce nuclear STAT3 levels to baseline.  
 
6-4  RECEPTOR-MEDIATED REGULATION OF PTP ACTIVITY 
While our simulations assume that EGFR is regulated by PTP activity that does 
not vary with time, multiple previous studies support the possibility that treatment of cells 
with growth factors may increase the activity of cellular PTPs. For example, total PTP 
activity was found to increase in cells treated with insulin, EGF, or PDGF compared to 
BSA control (207). EGF treatment also resulted in an increase in serine/threonine 
phosphatase activity in cytosolic fractions from A431 cells (208). More recent studies 
have revealed that the activity of the PTPs SHP2 and PTP1B are increased by stimulation 
of cells with EGF and nerve growth factor, respectively (115, 190). Considering the 
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importance of PTP activity in regulating EGFR phosphorylation and therapeutic efficacy 
(Chapters 2-5), it is critical that receptor-mediated regulation of PTP activity be 
quantitatively addressed. A study of this nature could begin by measuring the activity of 
specific PTPs known to interact with EGFR (e.g., DEP1 (51), PTP1B (57) etc.) as a 
function of time after addition of different EGFR ligands. This study could also quantify 
general PTP activity of whole cell lysates, which has been done previously (207, 208). 
Use of multiple EGFR ligands would address the intriguing hypothesis that different 
EGFR ligands might mediate upregulation of PTP activity with different efficiencies. 
Pharmacological inhibitors or knockdown of proteins downstream of EGFR should then 
be used to explore the mechanistic details of the connectivity between EGFR 
phosphorylation and altered PTP activity. Finally, a mechanistic model should be used to 
determine if the growth factor-mediated increase in PTP activity is consistent with EGFR 
phosphorylation dynamics. 
Assuming that PTPs are found to increase in activity downstream of 
phosphorylated EGFR, it would be particularly important to determine if this regulatory 
relationship is intact in the context of EGFR mutants, such as EGFR
L858R
, which are 
characterized by increased receptor phosphorylation in the absence of ligand. Aberrant 
EGFR phosphorylation should lead to increased cellular PTP activity, which should at 
least partially negatively feedback and antagonize EGFR phosphorylation. The fact that 
EGFR
L858R
 is characterized by increased receptor phosphorylation suggests that negative 
feedback involving a receptor-mediated increase in PTP activity is not able to completely 
reduce aberrant EGFR phosphorylation. This might be because: 1. induced PTP activity 
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is not strong enough to oppose aberrant phosphorylation of the EGFR
L858R
 mutant, 2. the 
negative feedback mechanism is disrupted in this context, or 3. ligand binding is 
somehow required for this negative feedback. A relatively simple exploratory study 
would involve measuring PTP activity in whole cell lysates from cells expressing similar 
levels of exogenous WT EGFR or EGFR
L858R
 both in the presence and absence of EGFR 
ligands. The measurement of PTP activity could be done using 
32
P-based (207, 208) or 
absorbance-based (49) assays. An identical cellular background for expression of wild-
type EGFR and EGFR
L858R
 is necessary to control for possible baseline differences in 
PTP expression. If cellular PTP activity is shown to increase with ligand but not with 
expression of EGFR
L858R
 compared to wild-type without ligand, this would suggest that 
this negative feedback mechanism is disrupted in the context of EGFR
L858R
 which may 
contribute to its oncogenic potential. Though purely speculative, one interesting 
hypothesis is that internalization of EGFR, which is impaired in the context of 
EGFR
L858R
, is required for this negative feedback. 
 
6-5  IMMUNODETECTION OF EGFR 
One of the technical issues that hampered the completion of our experimental 
work was the reduced ability of some EGFR antibodies to bind in vitro to EGFR from 
HeLa cells treated with at least 1.6 nM (10 ng/mL) EGF for as little as 4 min (Chapters 2 
and 3). This disruption resulted in a reduced total EGFR signal by western blot for EGF-
treated conditions compared to control. Degradation of EGFR within 4 min of EGF 
treatment is inconsistent with 
35
S-based measurements, which do not rely on EGFR-
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antibody binding, of EGFR degradation in  SUM102 cells (209). Thus, a more likely 
explanation is that EGFR is altered by EGF treatment in a manner that impairs EGFR-
antibody binding. Consistent with this, treatment of cells with 4 μM of the EGFR tyrosine 
kinase inhibitor gefitinib for 45 min after a short EGF stimulation restored EGFR levels 
by western blot (89).  
We used several approaches to explore how exogenous EGF could impair EGFR 
detection by western blotting, leading to multiple findings. First, multiple EGFR 
antibodies, including some directed against extracellular EGFR epitopes, were 
characterized by this issue. Second, treatment of cells with matrix metalloprotease 
inhibitors had no effect on EGF-mediated reductions in EGFR levels, suggesting that 
protease-mediated cleavage of EGFR, which has been described previously (210), was 
not responsible for loss of EGFR signal from western blots. Third, treatment of cells with 
ubiquitin ligase inhibitors (to determine if EGFR ubiquitination disrupted EGFR antibody 
binding) did not reverse this effect. Fourth, treatment of cell lysates with deubiquitinases 
reduced the ubiquitin signal at high molecular weights by western blot but did not restore 
EGFR antibody binding. Thus, the data from our efforts to elucidate the mechanism for 
EGFR non-detection did not suggest a clear hypothesis for its occurrence. 
Despite our lack of success testing this hypothesis, previous work suggests that 
EGFR ubiquitination results in EGFR antibody binding disruption (37). This is consistent 
with our finding that treatment with gefitinib, which promotes EGFR deubiquitination 
(112), reversed this effect. Understanding and correcting this technical issue should be a 
priority due to the false conclusions that could result. For example, one paper 
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demonstrated that the ubiquitin ligase inhibitor PYR-41 affected EGFR levels as 
measured by western blotting after only 5 min of 100 ng/mL EGF treatment (211). They 
concluded that PYR-41 inhibited EGFR degradation. However, this treatment condition 
is inconsistent with the EGFR degradation time scale, as described above. Interestingly, 
these data are consistent with the notion that EGFR ubiquitination disrupts EGFR-
antibody binding. Given the importance of accurate quantitative data in studies such as 
those presented in Chapters 2 and 3, this technical issue should be addressed or at least 
considered when interpreting data. 
 
6-6  EGFR INTERNALIZATION AND EGFR-TARGETED THERAPEUTICS 
In addition to the contribution of this thesis to our understanding of the EGFR 
internalization mechanism and its regulation by PTPs in the studies in Chapters 2 and 3, 
we also participated in a collaboration that elucidated a novel therapeutic resistance 
mechanism involving disregulated EGFR internalization (145). Previously, PC9 cells, 
which express the activated EGFR mutant EGFR
DelE746A750
 and are sensitive to treatment 
with gefitinib, were made gefinitib-resistant through long-term culture in the presence of 
gefitinib (212). The resulting cell line (referred to as PC9 GR) was shown to be sensitive 
to the novel, irreversible EGFR tyrosine kinase inhibitor WZ4002 (212). Our 
collaborative effort involved rendering PC9 GR cells resistant to WZ4002 through the 
same long-term culturing approach and analyzing the mechanism through which 
resistance to WZ4002 was conferred (145). The study found that PC9 GR cells rendered 
resistant to WZ4002 (PC9 WZR) were characterized by amplification of ERK2, a protein 
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involved in pro-survival cellular signaling. Consistent with this, inhibiting MEK, a kinase 
upstream of ERK, restored sensitivity of the PC9 WZR cells to WZ4002. Additionally, 
introduction of an activated MEK1 allele into the WZ4002-sensitivite PC9 GR cells 
conferred WZ4002 resistance. In addition to other functions, ERK can phosphorylate 
EGFR at T669 in a process that may affect EGFR turnover (213-215). Consistent with 
this, PC9 WZR cells, which are characterized by amplification of ERK2, were 
characterized by hyperphosphorylation of EGFR T669. Interestingly, we showed that the 
EGF-mediated EGFR internalization rate constant (ke) was elevated in the PC9 WZR 
cells compared to control (PC9 GR) cells. This increase in ke was partially rescued by 
inhibiting MEK, suggesting that feedback through the ERK pathway is able to increase 
EGF-mediated EGFR internalization rates. Previous studies have identified EGFR 
internalization as an important controller of EGF-mediated activation of the ERK 
signaling pathway (46). Thus, our study identified a novel EGFR kinase inhibitor 
resistance mechanism and strengthens the hypothesis that EGFR internalization is an 
important controller of the cellular response to EGFR inhibitor treatment.  
 
6-7  EGFR-TARGETED THERAPEUTICS  
Therapeutic-mediated reduction of phosphorylated EGFR is a treatment strategy 
for some cancers characterized by upregulation of EGFR-mediated signaling (e.g., some 
lung cancers (13, 216)). Our findings in Chapter 4 identify EGFR dephosphorylation as a 
key process in some contexts for therapeutic-mediated reduction in phosphorylated 
EGFR. Furthermore, a previous study by Sharma and coworkers (154) suggests that in 
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some cellular contexts, therapeutics trigger cell death by mediating a more rapid 
reduction in pro-survival signaling compared to pro-apoptotic signaling, triggering 
apoptosis (154, 155). Thus, the time scale with which therapeutics mediate a reduction in 
phosphorylated EGFR, which is controlled by PTPs (Chapter 4), may also be an 
important determinant of the ability of therapeutics to induce cell death. Sharma and 
coworkers partially explore this possibility by treating cells with the general phosphatase 
inhibitor okadaic acid (OA), which led to EGFR ligand independent phosphorylation of 
AKT, ERK and p38, which are each proteins involved in EGFR-mediated signaling. Co-
treatment of cells with gefitinib and OA eliminated phosphorylation of these proteins, 
suggesting that EGFR kinase activity is required for OA-mediated AKT, ERK, and p38 
phosphorylation. These data support an important role for phosphatases in regulating 
proteins that are downstream of EGFR.  
Consistent with this, a study by Morris and coworkers (82) involving the PTP 
PTPRS observed that PTPRS was deleted in 26% of patient tumor samples from a cohort 
of HNSCC patients. Compared to normal tissue, tumors with PTPRS deletion were 
characterized by elevated EGFR and AKT phosphorylation. In the same study, siRNA-
mediated knockdown of PTPRS promoted ligand-independent EGFR phosphorylation in 
MDA-584 and FaDu cells (HNSCC cell lines). PTPRS knockdown also increased cellular 
resistance to erlotinib (EGFR TKI) in HCC827 and H3255 cells (HNSCC and NSCLC 
cell lines, respectively). Lastly, cellular resistance of HNSCC cell lines to treatment with 
the EGFR antibody cetuximab and poor prognosis in lung adenocarcinoma patients with 
TKI-sensitizing EGFR mutations was predicted by low PTPRS expression. The findings 
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by Morris and coworkers are consistent with our findings in Chapter 2 and 4 for an 
important role of receptor dephosphorylation in EGFR-targeted therapeutic efficacy. 
Importantly, at least one previous study supports regulation of EGFR phosphorylation by 
PTPRS by demonstrating that overexpression of PTPRS in A431 cells reduced EGFR 
phosphorylation (62).  
Together the studies by Sharma and coworkers and Morris and coworkers support 
our prediction of an important role for PTPs in therapeutic efficacy. However, further 
work is required to determine if the effect of PTPs in these contexts occurs via 
dephosphorylation of EGFR or through direct dephosphorylation of proteins downstream 
of EGFR. We propose a study that directly addresses this question by focusing on 
PTPRS. Firstly, the proposed study should show that overexpression or knockdown of 
PTPRS shifts EGFR-targeted therapeutic dose-response curves for therapeutic-mediated 
reduction in EGFR phosphorylation and therapeutic-mediated cell death. If PTPRS-
mediated dephosphorylation of EGFR affects cellular sensitivity to EGFR-targeted 
therapeutics by reducing EGFR-mediated signaling through the AKT pathway, as the 
previous studies implies (82), expression of constitutively active PI3K, which is upstream 
of AKT, should rescue an increase in sensitivity of cells to therapeutic with PTPRS 
overexpression. The study by Morris and coworkers suggests that the EGFR-targeted 
therapeutics gefitinib, erlotinib and cetuximab could all be used to test these hypotheses 
(82). It would also be interesting to determine if expression of another receptor-like PTP 
that has been shown to regulate EGFR phosphorylation (e.g., DEP1 (51, 71)) has the 
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same qualitative effect on therapeutic-mediated cell death and reduction in 
phosphorylated EGFR.   
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